{"docstore/data": {"7b7551af-91b8-4d42-a2c7-9b84f4905a6f": {"__data__": {"id_": "7b7551af-91b8-4d42-a2c7-9b84f4905a6f", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter. ", "original_text": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d280ea9-3867-4b39-a95c-f1eea85593d8", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n", "original_text": "(NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion. "}, "hash": "23a8d19686c8d3483bf9e45d06e86e75ffbfcb94e8b4d364f430466310e27b61", "class_name": "RelatedNodeInfo"}}, "text": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "start_char_idx": 0, "end_char_idx": 356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d280ea9-3867-4b39-a95c-f1eea85593d8": {"__data__": {"id_": "7d280ea9-3867-4b39-a95c-f1eea85593d8", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n", "original_text": "(NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b7551af-91b8-4d42-a2c7-9b84f4905a6f", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter. ", "original_text": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52de1557888afce4318a1665ab0d86af6870c32f1b88b2f4daa32568123624fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f076b99-e4d1-4b13-b2e4-c0ec435fd3aa", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024. ", "original_text": "On the basis of U.S. "}, "hash": "a3843ef39acc504da8c10810746a1a43eb254b3189197a9c6f25bbcb90f20d45", "class_name": "RelatedNodeInfo"}}, "text": "(NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion. ", "start_char_idx": 356, "end_char_idx": 515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f076b99-e4d1-4b13-b2e4-c0ec435fd3aa": {"__data__": {"id_": "1f076b99-e4d1-4b13-b2e4-c0ec435fd3aa", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d280ea9-3867-4b39-a95c-f1eea85593d8", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n", "original_text": "(NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64ad28723ddc481065ec31f1b55b9e5263e1d817db5bcaf20b58dcc1a3f40dc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06300998-4d7d-4395-841a-7d2f9e07de86", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter. "}, "hash": "03a080afc1854bad73bfe1c5238c8384a038a20b11c5d9eadbf4b6cf68ce854b", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 515, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06300998-4d7d-4395-841a-7d2f9e07de86": {"__data__": {"id_": "06300998-4d7d-4395-841a-7d2f9e07de86", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f076b99-e4d1-4b13-b2e4-c0ec435fd3aa", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c1c945fee8e05e90f97f51193cb65b60921859096ecd0d62eb89c0445bdc15b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "768b9e47-0c40-4c9a-8b79-2ccaae9de5ce", "node_type": "1", "metadata": {"window": "(NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n"}, "hash": "1aa17e371a407ccb582b001584edbdcc7777452469db99cbf7a5a3b48f213e71", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter. ", "start_char_idx": 536, "end_char_idx": 718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "768b9e47-0c40-4c9a-8b79-2ccaae9de5ce": {"__data__": {"id_": "768b9e47-0c40-4c9a-8b79-2ccaae9de5ce", "embedding": null, "metadata": {"window": "(NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06300998-4d7d-4395-841a-7d2f9e07de86", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0607256699520c094e30b13a5753710b2a99f4337225748aaa86959377d9a90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e01b110-b5a6-4998-81a0-61f1fc6e3b95", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n", "original_text": "Cencora is updating its outlook for fiscal year 2024. "}, "hash": "37e913c7ec408e476ba8db5e7232f3e629572522066fbb1282b87ce1cb5d85da", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n", "start_char_idx": 718, "end_char_idx": 920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e01b110-b5a6-4998-81a0-61f1fc6e3b95": {"__data__": {"id_": "5e01b110-b5a6-4998-81a0-61f1fc6e3b95", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n", "original_text": "Cencora is updating its outlook for fiscal year 2024. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "768b9e47-0c40-4c9a-8b79-2ccaae9de5ce", "node_type": "1", "metadata": {"window": "(NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72f7fa5b838ce6397789d41c4dd2dfb44c6f6f888667391fbdf723b00727ace5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1cc91ab-3d5b-4a1d-bbb6-fb3b074ff279", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. "}, "hash": "77773699357189678982e921e624d953d5f1c125cc1e768e041ab1425a7d7aeb", "class_name": "RelatedNodeInfo"}}, "text": "Cencora is updating its outlook for fiscal year 2024. ", "start_char_idx": 920, "end_char_idx": 974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1cc91ab-3d5b-4a1d-bbb6-fb3b074ff279": {"__data__": {"id_": "d1cc91ab-3d5b-4a1d-bbb6-fb3b074ff279", "embedding": null, "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e01b110-b5a6-4998-81a0-61f1fc6e3b95", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n", "original_text": "Cencora is updating its outlook for fiscal year 2024. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72877cedadd931205bd19cbc2ce07e414995e80edb81c2be2af56c463dcbebba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3204ef13-7d1c-4266-bb07-8b312e8c21cd", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis. ", "original_text": "Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n"}, "hash": "0a113e19ac5bd6b4ab98ba12d00adec66843d52ea2e419d0aec8e206dc9e91e4", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "start_char_idx": 974, "end_char_idx": 1099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3204ef13-7d1c-4266-bb07-8b312e8c21cd": {"__data__": {"id_": "3204ef13-7d1c-4266-bb07-8b312e8c21cd", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis. ", "original_text": "Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1cc91ab-3d5b-4a1d-bbb6-fb3b074ff279", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9034e3228b60e0db9cdd1a234df61ccf5a37cbc05b438f09ddefce27129e76f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e579c2b1-d64c-4cdd-abab-ffd3930fe584", "node_type": "1", "metadata": {"window": "Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n"}, "hash": "8cb65a436fab50cf0ce2bf3a05be5345dae1902526f7ad76ec0524796a9a9b08", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n", "start_char_idx": 1099, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e579c2b1-d64c-4cdd-abab-ffd3930fe584": {"__data__": {"id_": "e579c2b1-d64c-4cdd-abab-ffd3930fe584", "embedding": null, "metadata": {"window": "Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3204ef13-7d1c-4266-bb07-8b312e8c21cd", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,\nincreased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis. ", "original_text": "Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12d80eca75fec35cb65de98528011b33304b9597cc97274fcca3c4f8e7e56a2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b0cbb72-6f74-44f7-950b-7e12f9c8bcb3", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr. "}, "hash": "806691dcfac447ee59cd53bf1e64c89fb4446172a0a8431a77072e5ab0d58f22", "class_name": "RelatedNodeInfo"}}, "text": "\u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n", "start_char_idx": 1238, "end_char_idx": 1581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b0cbb72-6f74-44f7-950b-7e12f9c8bcb3": {"__data__": {"id_": "5b0cbb72-6f74-44f7-950b-7e12f9c8bcb3", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e579c2b1-d64c-4cdd-abab-ffd3930fe584", "node_type": "1", "metadata": {"window": "Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56c9a959b086787db7b2a8637ddfbcfb1b1c8dc6a3df562a4e4c684badf37189", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "714d7593-722a-4dde-8726-8179b5e2a1d7", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "Collis. "}, "hash": "ee4deefdf3ba8a9d7810f71da4db1af861a0f02a5b03042c04ca401b29934215", "class_name": "RelatedNodeInfo"}}, "text": "\u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr. ", "start_char_idx": 1581, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "714d7593-722a-4dde-8726-8179b5e2a1d7": {"__data__": {"id_": "714d7593-722a-4dde-8726-8179b5e2a1d7", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "Collis. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b0cbb72-6f74-44f7-950b-7e12f9c8bcb3", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "201b18fff00d4e8dc9415068dc50e73aeea8a8ed4d20891fde191f9e9faa8aa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1289f16-a84c-490a-a0cf-db9e9e889480", "node_type": "1", "metadata": {"window": "\u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1"}, "hash": "e8eb8816b63a1819ab08e1cc3af44b3f69b0e7199995a2a543dafa65fab685be", "class_name": "RelatedNodeInfo"}}, "text": "Collis. ", "start_char_idx": 1732, "end_char_idx": 1740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1289f16-a84c-490a-a0cf-db9e9e889480": {"__data__": {"id_": "a1289f16-a84c-490a-a0cf-db9e9e889480", "embedding": null, "metadata": {"window": "\u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe3e0ddd2127790f201c469ea940b85c7235d03db72a918f4b491dd545b19fb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "714d7593-722a-4dde-8726-8179b5e2a1d7", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised on the lower end from the previous\nrange of $13.25 to $13.50 to a range of $13.30 to $13.50.\n \u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "Collis. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b0cac0274fdd935034a61c06ee7e5b54bc294f856cd4e7bcb95c2a7665b0875", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ba2d219-11a7-4a7d-b752-0708d15001ce", "node_type": "1", "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "original_text": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc. "}, "hash": "ce877c40ce751710135e9abcd465c29e5fe31e3e028bcd48932a7a05a16d0ece", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "start_char_idx": 1740, "end_char_idx": 2317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ba2d219-11a7-4a7d-b752-0708d15001ce": {"__data__": {"id_": "2ba2d219-11a7-4a7d-b752-0708d15001ce", "embedding": null, "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "original_text": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1289f16-a84c-490a-a0cf-db9e9e889480", "node_type": "1", "metadata": {"window": "\u201cCencora\u2019s critical role at the center of healthcare and the pharmaceutical supply chain was on full display during the quarter as our\npurpose-driven team members\u2019 solutions-oriented mindset helped our customers navigate through complexity and uncertainty,\u201d\nsaid S teven H. Collis, Chairman, President, and Chief Executive Officer of Cencora.\n \u201cOur strong second quarter results and updated full-year guidance, reflect the importance of the value we deliver across our\nfootprint,\u201d continued Mr.  Collis.  \u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "original_text": "\u201cAs we move into the second half of our fiscal year, our focus on creating a best-in-class customer\nexperience, embracing innovation and investing in our infrastructure will allow us to continue to further our pharmaceutical-centric\nstrategy and drive differentiated value for our customers, partners and all our stakeholders.\u201d\nSecond Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.4B $68.4B\nGross Pr ofit $2.5B $2.5B\nOperating Expenses $2.0B $1.5B\nOperating Income $553M $1.0B\nInterest Expense, Net $64M $64M\nEffectiv e Tax Rat e98% 209%\n1", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44ce669279275f56ed94630d78b05310bf6bc2378bfea75346235249f9af5e32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14b0abe4-308b-42e7-9d3f-00add87aea76", "node_type": "1", "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S. ", "original_text": "$421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "8e5dcba3a7e5b7e62307d4103be3d8038100817b50a7fb50d9d2761427a23b5f", "class_name": "RelatedNodeInfo"}}, "text": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc. ", "start_char_idx": 0, "end_char_idx": 54, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14b0abe4-308b-42e7-9d3f-00add87aea76": {"__data__": {"id_": "14b0abe4-308b-42e7-9d3f-00add87aea76", "embedding": null, "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S. ", "original_text": "$421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ba2d219-11a7-4a7d-b752-0708d15001ce", "node_type": "1", "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "original_text": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4be3c2090e4af431c0fd51c3a2903b64f058b0a3bd92ce46d8360989a080001", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9c6385d-b340-4348-97b6-9a1edea7de4c", "node_type": "1", "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "059734b2389887cae6b0cc7a929f5a1db1db2ea305a904e76c31774755444687", "class_name": "RelatedNodeInfo"}}, "text": "$421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 54, "end_char_idx": 261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9c6385d-b340-4348-97b6-9a1edea7de4c": {"__data__": {"id_": "e9c6385d-b340-4348-97b6-9a1edea7de4c", "embedding": null, "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14b0abe4-308b-42e7-9d3f-00add87aea76", "node_type": "1", "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S. ", "original_text": "$421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d1242d8bf07513bd7f57f58045249fa325c687006de447425792296f9f41682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a5c5897-38fd-4b09-afab-ba20ba5c923a", "node_type": "1", "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "original_text": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n"}, "hash": "2016350b104e9697092589cabde18b3bc24593ae23727495643ebe8ce6b5e58e", "class_name": "RelatedNodeInfo"}}, "text": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 261, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a5c5897-38fd-4b09-afab-ba20ba5c923a": {"__data__": {"id_": "8a5c5897-38fd-4b09-afab-ba20ba5c923a", "embedding": null, "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "original_text": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9c6385d-b340-4348-97b6-9a1edea7de4c", "node_type": "1", "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8098babda323c424820bd9c77e65cc2f080c1580b857a17d695fc06e12a37e3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5412e34-7d30-43d2-ae9c-d8353cd9af56", "node_type": "1", "metadata": {"window": "$421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S. "}, "hash": "5e6436a41b7a5a19ca6a5d049e746e76496c59ca996f406bde77033ee132fe87", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "start_char_idx": 353, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5412e34-7d30-43d2-ae9c-d8353cd9af56": {"__data__": {"id_": "f5412e34-7d30-43d2-ae9c-d8353cd9af56", "embedding": null, "metadata": {"window": "$421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a5c5897-38fd-4b09-afab-ba20ba5c923a", "node_type": "1", "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "original_text": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70d3498ab4b9d79d65484dd0ea37212765cf556ea17c19365d3432b31ed24acf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0247707e-ddec-4f29-947d-79f502877126", "node_type": "1", "metadata": {"window": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n", "original_text": "Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n"}, "hash": "5a771bec5fc6b3d9cd10269fbc39f663114083bb24a42ca530a4cdc0d639beca", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S. ", "start_char_idx": 576, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0247707e-ddec-4f29-947d-79f502877126": {"__data__": {"id_": "0247707e-ddec-4f29-947d-79f502877126", "embedding": null, "metadata": {"window": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n", "original_text": "Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5412e34-7d30-43d2-ae9c-d8353cd9af56", "node_type": "1", "metadata": {"window": "$421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb9e132ce14227f87b332123f05ca4319ec46bc149a3c3fa000e1fec75bbcc00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ebbeefc-b54a-4c97-89de-b947fb06cb14", "node_type": "1", "metadata": {"window": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit. ", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. "}, "hash": "d15ffab087fc7acbf0632ffb58995c28ee2dc533a4ba3ae23dc22af663d091b4", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n", "start_char_idx": 812, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ebbeefc-b54a-4c97-89de-b947fb06cb14": {"__data__": {"id_": "2ebbeefc-b54a-4c97-89de-b947fb06cb14", "embedding": null, "metadata": {"window": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit. ", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0247707e-ddec-4f29-947d-79f502877126", "node_type": "1", "metadata": {"window": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n", "original_text": "Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9784a8a2ece3774ca74cb47a707e9a4be5607106f573a65fe60753cbc75aa8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db7ff35-eb42-4d07-bc71-25abd39af2d1", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n", "original_text": "Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n"}, "hash": "8c5afca2db629a02cd82094e5ad772daa5f783b8eac454a308a8518c98798c4d", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "start_char_idx": 914, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db7ff35-eb42-4d07-bc71-25abd39af2d1": {"__data__": {"id_": "9db7ff35-eb42-4d07-bc71-25abd39af2d1", "embedding": null, "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n", "original_text": "Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ebbeefc-b54a-4c97-89de-b947fb06cb14", "node_type": "1", "metadata": {"window": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit. ", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fae71e07564491f8edd6080139e9fd88c301637994aa21931c220ec9ced3d3e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0037dc5f-080e-4d22-80f9-93725b240343", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n"}, "hash": "1220a45c7b024ad6190ff17a31dd1ba07166c4aca9582dcd1f4a7d4494e323c3", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n", "start_char_idx": 1252, "end_char_idx": 1369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0037dc5f-080e-4d22-80f9-93725b240343": {"__data__": {"id_": "0037dc5f-080e-4d22-80f9-93725b240343", "embedding": null, "metadata": {"window": "Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db7ff35-eb42-4d07-bc71-25abd39af2d1", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2024, revenue was $68.4 billion, up 7.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.1 percent increase in revenue within U.S.  Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n", "original_text": "Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eaa5533438e83bb5004bba53fa84225abb079382828ed5208c0ed86605d655c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f34a3c0-5d03-4802-ab95-7e79a9bf2377", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "original_text": "Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit. "}, "hash": "220c38fd35601f435abcdadec2b43797a093bf32e013102c219a3a4e7879c906", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n", "start_char_idx": 1369, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f34a3c0-5d03-4802-ab95-7e79a9bf2377": {"__data__": {"id_": "9f34a3c0-5d03-4802-ab95-7e79a9bf2377", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "original_text": "Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0037dc5f-080e-4d22-80f9-93725b240343", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 5.3 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "127c07f2ec2466d8d9e05ec1cae80eea07f265347676f71e0e35afde4ce445c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e9e4b08-d526-4673-b66d-44e0a5c77a3e", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n", "original_text": "Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n"}, "hash": "a12845aea70d844e626a558e1ffc5ef6f6445367a751b1cf313b7429b0326d7d", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit. ", "start_char_idx": 1716, "end_char_idx": 2042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e9e4b08-d526-4673-b66d-44e0a5c77a3e": {"__data__": {"id_": "4e9e4b08-d526-4673-b66d-44e0a5c77a3e", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n", "original_text": "Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f34a3c0-5d03-4802-ab95-7e79a9bf2377", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 10.6 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "original_text": "Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b510d9f95e238eacb26a5d7fc5c32df412c5690d39451c291fc9a1628c08f2cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "315c9616-8c4e-485b-b0b3-c39fee77fda1", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment. ", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter. "}, "hash": "b5baec28320257a300a28c28cac70f3064fa9c9ac35055aa8c5195e7136823a0", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n", "start_char_idx": 2042, "end_char_idx": 2211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "315c9616-8c4e-485b-b0b3-c39fee77fda1": {"__data__": {"id_": "315c9616-8c4e-485b-b0b3-c39fee77fda1", "embedding": null, "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment. ", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e9e4b08-d526-4673-b66d-44e0a5c77a3e", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was\n3.71 percent, an increase of 9 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n", "original_text": "Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bb17eeca5d183c9d10c0c5e0b3dd2ff3ce15f5d2050112cac1076cc022e2794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e830766-fa2d-4867-84c2-b3301147a455", "node_type": "1", "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n", "original_text": "Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. "}, "hash": "c7fca746d5f29a49b93774161f0c90d324b04d54218303454a77947d1e31fd28", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter. ", "start_char_idx": 2211, "end_char_idx": 2356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e830766-fa2d-4867-84c2-b3301147a455": {"__data__": {"id_": "5e830766-fa2d-4867-84c2-b3301147a455", "embedding": null, "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n", "original_text": "Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "315c9616-8c4e-485b-b0b3-c39fee77fda1", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2024, operating expenses were $2.0 billion, a 14.4 percent increase\ncompared to the same period in the previous fiscal year, primarily due to higher litigation and opioid-related expenses and an\nincrease in distribution, selling, and administrative expenses compared to the prior year quarter.\n Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment. ", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72238d74ab4d276230c84c303a9487133896a422713e1200aee88bcc488f7710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76c01d6f-7f8d-4085-bae0-a33ecc5f52d8", "node_type": "1", "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n", "original_text": "The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n"}, "hash": "89dff2b09fde19007b6b94c294d9735ce58803dbade8d31a57e15a7a0792bcce", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "start_char_idx": 2356, "end_char_idx": 2582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76c01d6f-7f8d-4085-bae0-a33ecc5f52d8": {"__data__": {"id_": "76c01d6f-7f8d-4085-bae0-a33ecc5f52d8", "embedding": null, "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n", "original_text": "The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e830766-fa2d-4867-84c2-b3301147a455", "node_type": "1", "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2024, operating income was $553.3 million, a 1.3 percent decrease\ncompared to the same period in the previous fiscal year as the increases in litigation and opioid-related expenses and\ndistribution, selling, and administrative expenses exceeded the increase in gross profit.  Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n", "original_text": "Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdcfe1ce49536af01036fa5804db74f378387c81d866bc43cb0aa020d0282497", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82438e8f-f731-464f-97da-04b34db40f0c", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment. "}, "hash": "33f3e5e84cdfd6d58981866b9a6eb23ed35236c7291f435ebd0f82a2ca9a5486", "class_name": "RelatedNodeInfo"}}, "text": "The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n", "start_char_idx": 2582, "end_char_idx": 2702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82438e8f-f731-464f-97da-04b34db40f0c": {"__data__": {"id_": "82438e8f-f731-464f-97da-04b34db40f0c", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76c01d6f-7f8d-4085-bae0-a33ecc5f52d8", "node_type": "1", "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.81 percent in the second quarter of fiscal 2024, a decrease of 7 basis points when compared to the prior year\nquarter.\n Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n", "original_text": "The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2408227329b1b3b0590d989ad160cb894aca7e8f40780d0f843dca91d9ee1945", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e807cde0-587f-43cd-93d9-6423561b050a", "node_type": "1", "metadata": {"window": "Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "The effective tax rate was 16.4 percent in the prior year quarter.\n"}, "hash": "3dda34dd1c558fdea94ed5cae181eb2ee027d26ccae30a308023ac4705d3e727", "class_name": "RelatedNodeInfo"}}, "text": "Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment. ", "start_char_idx": 2702, "end_char_idx": 2888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e807cde0-587f-43cd-93d9-6423561b050a": {"__data__": {"id_": "e807cde0-587f-43cd-93d9-6423561b050a", "embedding": null, "metadata": {"window": "Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "The effective tax rate was 16.4 percent in the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82438e8f-f731-464f-97da-04b34db40f0c", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2024, net interest expense of $64.1 million was flat compared to the prior\nyear quarter.  Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1871443f232b7085f0779f898638e88e19990091003ab160c2045ab11ae117c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bea75ad4-7693-47f4-936d-32ba612a5429", "node_type": "1", "metadata": {"window": "The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n"}, "hash": "65c73cb8cbeb5bd7ce61a7859dab8020d9634cd0735c0bb44c1d4addcb2ea809", "class_name": "RelatedNodeInfo"}}, "text": "The effective tax rate was 16.4 percent in the prior year quarter.\n", "start_char_idx": 2888, "end_char_idx": 2955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bea75ad4-7693-47f4-936d-32ba612a5429": {"__data__": {"id_": "bea75ad4-7693-47f4-936d-32ba612a5429", "embedding": null, "metadata": {"window": "The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e807cde0-587f-43cd-93d9-6423561b050a", "node_type": "1", "metadata": {"window": "Interest expense increased as a result of increases in borrowings and interest rates associated with variable-rate\ndebt offset, in part, by the September 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "The effective tax rate was 16.4 percent in the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "474bd07c6ca56a0d4d95b9f5ee03d456c0b11b1fbe5b4f7c85c0688f8ab6db8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d06e57f1-9173-48a5-bd82-26e44da47c3e", "node_type": "1", "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n"}, "hash": "dcc8592d6d98925759d33c88fc427d4897684df1706f2f2fc63e75fce4f23d34", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n", "start_char_idx": 2955, "end_char_idx": 3147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d06e57f1-9173-48a5-bd82-26e44da47c3e": {"__data__": {"id_": "d06e57f1-9173-48a5-bd82-26e44da47c3e", "embedding": null, "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bea75ad4-7693-47f4-936d-32ba612a5429", "node_type": "1", "metadata": {"window": "The increase in\ninterest expense was offset by the increase in interest income due to higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f85ca13851c53ac550077bcb9f0aeec5b32681d750648f5f6bbe6510e997534", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a007954-3f9a-41ed-8c7e-218abb909868", "node_type": "1", "metadata": {"window": "The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "2797c46ad59ae8108a9bb903e4e22e9d5235b1263c61d73f3b115ce26c11572b", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "start_char_idx": 3147, "end_char_idx": 3392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a007954-3f9a-41ed-8c7e-218abb909868": {"__data__": {"id_": "8a007954-3f9a-41ed-8c7e-218abb909868", "embedding": null, "metadata": {"window": "The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d06e57f1-9173-48a5-bd82-26e44da47c3e", "node_type": "1", "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 9.8 percent for the second quarter of fiscal 2024 due to discrete tax benefits\nassociated with a foreign valuation allowance adjustment.  The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4fca668701bca69d044adc9cfa922d3b1d8ee54154dd48a859add556e21ac4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46f512a4-624d-4f9c-9be1-6db34f99f8ad", "node_type": "1", "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n", "original_text": "In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S. "}, "hash": "38418e6d7b4bfe21ec0d0fca7dd725dcb220d17a2b94400f02075e6e5e64f210", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3392, "end_char_idx": 3510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46f512a4-624d-4f9c-9be1-6db34f99f8ad": {"__data__": {"id_": "46f512a4-624d-4f9c-9be1-6db34f99f8ad", "embedding": null, "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n", "original_text": "In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a007954-3f9a-41ed-8c7e-218abb909868", "node_type": "1", "metadata": {"window": "The effective tax rate was 16.4 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abb912c36e18a1a787424dcfcebfb512316285795c99ebfc83a7d5aa9f6dc01c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f21d4ea-63c8-4a96-8538-cb0344237724", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n", "original_text": "Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n"}, "hash": "f20492ce851bfcf0d5455ae8ec9c511c61ff13304ce43a620e239c27e064c7bd", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S. ", "start_char_idx": 3510, "end_char_idx": 3706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f21d4ea-63c8-4a96-8538-cb0344237724": {"__data__": {"id_": "4f21d4ea-63c8-4a96-8538-cb0344237724", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n", "original_text": "Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46f512a4-624d-4f9c-9be1-6db34f99f8ad", "node_type": "1", "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease\ncompared to $2.13 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n", "original_text": "In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdb1855aef0531ba6c6464b166c712d45558abdda1d6115d1bd0309c20ea9db6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c58cafe6-aba2-4389-805a-e24bb440f93c", "node_type": "1", "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n"}, "hash": "06d064b6583f65acf885ee58d095b60560fe7c130dc6818fa5ea9661b1ca812a", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n", "start_char_idx": 3706, "end_char_idx": 3808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c58cafe6-aba2-4389-805a-e24bb440f93c": {"__data__": {"id_": "c58cafe6-aba2-4389-805a-e24bb440f93c", "embedding": null, "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f21d4ea-63c8-4a96-8538-cb0344237724", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2\nmillion, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n", "original_text": "Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cfcc4eeda299eb2dc8e0d35650d90b78f96e5039f825f010bdfc0e89ecb45a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12bcb8d1-148a-4d2e-a976-f12ecea846ab", "node_type": "1", "metadata": {"window": "In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n"}, "hash": "5e6eea5e2dc39539912642140b727209cb35103db992e627cf4dad65067e8236", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "start_char_idx": 3808, "end_char_idx": 4050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12bcb8d1-148a-4d2e-a976-f12ecea846ab": {"__data__": {"id_": "12bcb8d1-148a-4d2e-a976-f12ecea846ab", "embedding": null, "metadata": {"window": "In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c58cafe6-aba2-4389-805a-e24bb440f93c", "node_type": "1", "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e18fa60bf3b34980f5a1176c081b9f227e93b7c88dc07312743bd2d26c5497e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "311f9fca-1f75-4ccf-a6a1-152beafbb075", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n"}, "hash": "fbd8971618896e530d620b08bd2b60315be357327060addbce1fb0b8e7a2d719", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n", "start_char_idx": 4050, "end_char_idx": 4208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "311f9fca-1f75-4ccf-a6a1-152beafbb075": {"__data__": {"id_": "311f9fca-1f75-4ccf-a6a1-152beafbb075", "embedding": null, "metadata": {"window": "Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12bcb8d1-148a-4d2e-a976-f12ecea846ab", "node_type": "1", "metadata": {"window": "In the second quarter of fiscal 2024, revenue was\n$68.4 billion, up 7.8 percent compared to the same quarter in the previous fiscal year, reflecting an 8.1 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57560ce8c08392595e45fe54439e2d28ba9c77fbd2580ba591ddc157b46ccd7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61f9ff46-2777-4524-91f5-906fbe69bdad", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2"}, "hash": "88aafad76a6a68ec418568961d446a3566877efda9f03553a2f7bcbad3574a4f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n", "start_char_idx": 4208, "end_char_idx": 4530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61f9ff46-2777-4524-91f5-906fbe69bdad": {"__data__": {"id_": "61f9ff46-2777-4524-91f5-906fbe69bdad", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c885c4eb75793ae3954275e36d213023e653ecca459654eff88856c0a1944d51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "311f9fca-1f75-4ccf-a6a1-152beafbb075", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 5.3 percent increase in revenue within International Healthcare Solutions.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0493220d6efb79d54db8f94152d0825b5fb47f47f899cf009ba7eff94c8a1405", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fa97b84-1841-4eaa-adc7-79520412a51e", "node_type": "1", "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S. "}, "hash": "adfce4778dc3fc50cc965b3cb076202d8dae4c737efcc248db49e8394ef4c043", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "start_char_idx": 4530, "end_char_idx": 4656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fa97b84-1841-4eaa-adc7-79520412a51e": {"__data__": {"id_": "5fa97b84-1841-4eaa-adc7-79520412a51e", "embedding": null, "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61f9ff46-2777-4524-91f5-906fbe69bdad", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2024 was $2.5 billion, a 7.4 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.70 percent in the fiscal 2024 second quarter, a decrease of 1 basis\npoint from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, a 5.2\npercent increase compared to the same period in the previous fiscal year, primarily driven by an increase in distribution,\nselling, and administrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2024, adjusted operating income was $1.0 billion, a 10.9 percent\n2", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ae0e6f46a81e22c1667928f0ec1a282827565be61ba61c27c9eee661cad91d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "225de017-22a1-40ee-8e39-c966d626403a", "node_type": "1", "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter. ", "original_text": "Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions. "}, "hash": "ca49275628274333ed96c28fddeac78ac547b12920f42d39839c6a2b4a37c0db", "class_name": "RelatedNodeInfo"}}, "text": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S. ", "start_char_idx": 0, "end_char_idx": 106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "225de017-22a1-40ee-8e39-c966d626403a": {"__data__": {"id_": "225de017-22a1-40ee-8e39-c966d626403a", "embedding": null, "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter. ", "original_text": "Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fa97b84-1841-4eaa-adc7-79520412a51e", "node_type": "1", "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4515a7d529df76e7e57f8da998a899b389f06ce2d8b90ba607b95fb38097fa21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cb1e7c1-8ada-4b42-a1f6-060a3b01808f", "node_type": "1", "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "original_text": "Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n"}, "hash": "f03fab2d765bcdc997be3d91e2f6b8373fe967a462858edd45a674f1d621fa48", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions. ", "start_char_idx": 106, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cb1e7c1-8ada-4b42-a1f6-060a3b01808f": {"__data__": {"id_": "4cb1e7c1-8ada-4b42-a1f6-060a3b01808f", "embedding": null, "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "original_text": "Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "225de017-22a1-40ee-8e39-c966d626403a", "node_type": "1", "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter. ", "original_text": "Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fdac77734ba5f64c942ade591cbd299edefb90b4d0025d83c3a73c8563b87ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df4e884c-05ae-4e84-abc9-0af5328d6436", "node_type": "1", "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "d3de99e9a060dcf7ffa99a8942f9b8fff807a82019a5ed0d86d79ffc6a6a5814", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n", "start_char_idx": 193, "end_char_idx": 369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df4e884c-05ae-4e84-abc9-0af5328d6436": {"__data__": {"id_": "df4e884c-05ae-4e84-abc9-0af5328d6436", "embedding": null, "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cb1e7c1-8ada-4b42-a1f6-060a3b01808f", "node_type": "1", "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "original_text": "Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d11004567c4f0c93f848d2b9adc91d0433a3543728e8deb8097922476561e47b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1813be28-c698-46d7-ae4b-802fda2c40f5", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n", "original_text": "In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter. "}, "hash": "04ff04f70b85cfed16ffea322de0f0b64642553399417581fa98ded9b7e02a16", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 369, "end_char_idx": 468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1813be28-c698-46d7-ae4b-802fda2c40f5": {"__data__": {"id_": "1813be28-c698-46d7-ae4b-802fda2c40f5", "embedding": null, "metadata": {"window": "Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n", "original_text": "In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df4e884c-05ae-4e84-abc9-0af5328d6436", "node_type": "1", "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4491def979052f062c67454eafe051e96aab69ca7279fb41e61255bd0e69c1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75990a33-f217-4fc6-a1b0-daa83d94af53", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. "}, "hash": "86a109c531874cdecca7387b3f73ba24f4f412830d058680ae950271abc087d0", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter. ", "start_char_idx": 468, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75990a33-f217-4fc6-a1b0-daa83d94af53": {"__data__": {"id_": "75990a33-f217-4fc6-a1b0-daa83d94af53", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1813be28-c698-46d7-ae4b-802fda2c40f5", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n", "original_text": "In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d51e68f1b1335e4f75fba20d7914e297b0a8e78cc0b70cb9f2b36fdd7973650a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40a0d820-1fc7-432d-8f88-51340b1a9290", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n"}, "hash": "161e1316e76ee5c925459c27fe01540e7b76d2a6f25612f02fa4a410547940c0", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "start_char_idx": 589, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40a0d820-1fc7-432d-8f88-51340b1a9290": {"__data__": {"id_": "40a0d820-1fc7-432d-8f88-51340b1a9290", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75990a33-f217-4fc6-a1b0-daa83d94af53", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21ed85f4a6bd048aceae8bdf27d369643face750454a8b48035a9c12670402a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2866b945-9986-4290-a209-1ce9875ddb07", "node_type": "1", "metadata": {"window": "In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n"}, "hash": "1404c0b44ee3b1725d115655e6da591bd6726d0ec82d639eae01ede78608f915", "class_name": "RelatedNodeInfo"}}, "text": "The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n", "start_char_idx": 815, "end_char_idx": 935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2866b945-9986-4290-a209-1ce9875ddb07": {"__data__": {"id_": "2866b945-9986-4290-a209-1ce9875ddb07", "embedding": null, "metadata": {"window": "In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40a0d820-1fc7-432d-8f88-51340b1a9290", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3511ee488a84b9a94dcc30f86ec8daedb437b49960d18641ebb997b9a43140cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e110028b-1c06-4f6c-ab1a-52d1e26a4079", "node_type": "1", "metadata": {"window": "Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n"}, "hash": "b1061040aeac876987f7f01b7b3ad3aea849d7d055934d87e582a751d508e00d", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n", "start_char_idx": 935, "end_char_idx": 1105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e110028b-1c06-4f6c-ab1a-52d1e26a4079": {"__data__": {"id_": "e110028b-1c06-4f6c-ab1a-52d1e26a4079", "embedding": null, "metadata": {"window": "Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2866b945-9986-4290-a209-1ce9875ddb07", "node_type": "1", "metadata": {"window": "In the second quarter of\nfiscal 2024, net interest expense of $64.1 million was flat compared to the prior year quarter.  Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24321c055a7ae0764d820855f2006d220f6846d5b783e3bf70f4a4ef43d08c75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9991ff59-fbf0-4934-ac33-49713cd98796", "node_type": "1", "metadata": {"window": "The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "1c74ed8d16942bbc2bd9a3b9d6263779b0c44f645b9bfb8b6e8ff6828daff2db", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n", "start_char_idx": 1105, "end_char_idx": 1316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9991ff59-fbf0-4934-ac33-49713cd98796": {"__data__": {"id_": "9991ff59-fbf0-4934-ac33-49713cd98796", "embedding": null, "metadata": {"window": "The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e110028b-1c06-4f6c-ab1a-52d1e26a4079", "node_type": "1", "metadata": {"window": "Interest expense increased as a\nresult of increases in borrowings and interest rates associated with variable-rate debt offset, in part, by the September 30,\n2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.  The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c68f3f58db2dcc699447dc2d1ea00e1d84c9cbe720d17d094c7572504f99e05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f377518b-8ec0-4e8b-bcec-bb2aecc44bc8", "node_type": "1", "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n"}, "hash": "1bfd8bc237ac3985e113cf095b961a1a0123dfc5cf48dfa36f5435f3bb466d6f", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 1316, "end_char_idx": 1426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f377518b-8ec0-4e8b-bcec-bb2aecc44bc8": {"__data__": {"id_": "f377518b-8ec0-4e8b-bcec-bb2aecc44bc8", "embedding": null, "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9991ff59-fbf0-4934-ac33-49713cd98796", "node_type": "1", "metadata": {"window": "The increase in interest expense was offset by the\nincrease in interest income due to higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81cac6a603502181f8f71be35d44f023520c895b3729cbdf611a4e40436061ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8ead5d9-6011-4dfd-9f88-12a67f4996ae", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. "}, "hash": "1ea6d51115fa2f0de63e0c2516ccaadbc99a6c66d938504fd33541ff015937d1", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "start_char_idx": 1426, "end_char_idx": 1642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8ead5d9-6011-4dfd-9f88-12a67f4996ae": {"__data__": {"id_": "c8ead5d9-6011-4dfd-9f88-12a67f4996ae", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f377518b-8ec0-4e8b-bcec-bb2aecc44bc8", "node_type": "1", "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 20.9 percent for the second quarter of fiscal 2024 compared to\n19.0 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1775d3d59abc80354273cb47ca9e59400a078ecdd262fb9c7d2c3451212f4c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1af0fb9-7590-42e1-bd65-ca5b5211e1fd", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n"}, "hash": "b5646ce76f0050370339335480a09c03af7d670c5898c8fd3dc7624dea0c3952", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "start_char_idx": 1642, "end_char_idx": 1803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1af0fb9-7590-42e1-bd65-ca5b5211e1fd": {"__data__": {"id_": "c1af0fb9-7590-42e1-bd65-ca5b5211e1fd", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8ead5d9-6011-4dfd-9f88-12a67f4996ae", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an\n8.6 percent increase compared to $3.50 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4384c48a630d846ce439997f18a21450ac3c8e3960a0d2a4312221beb815dbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3903d68-8a8d-4daf-a417-7f53fbb1d488", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n", "original_text": "U.S. "}, "hash": "00d81e0460ae8ce995d232f98e680fa5b9d37e1b056c9312ef35a7bf8e903a65", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and International Healthcare Solutions.\n", "start_char_idx": 1803, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3903d68-8a8d-4daf-a417-7f53fbb1d488": {"__data__": {"id_": "a3903d68-8a8d-4daf-a417-7f53fbb1d488", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1af0fb9-7590-42e1-bd65-ca5b5211e1fd", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73ed5f7802c219baca4111e8b10c43bcb78ed012ff984df341ca7c3b08823a7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5c9ebc3-1a12-4978-a3ec-520550817f4b", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business. ", "original_text": "Healthcare Solutions\nU.S. "}, "hash": "bcaaa6d2514c049e36951e73bcc6075a09a96346c012a13fe2f1f3f07b936e6f", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 101, "end_char_idx": 106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5c9ebc3-1a12-4978-a3ec-520550817f4b": {"__data__": {"id_": "e5c9ebc3-1a12-4978-a3ec-520550817f4b", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business. ", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3903d68-8a8d-4daf-a417-7f53fbb1d488", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent\nversus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b4fcba21da176e7902a0ef534a089b7ddd689371da166f8c4d7a2961191a6c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c21d133-dcf4-4b57-9933-5a3540634691", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business. ", "original_text": "Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems. "}, "hash": "4130e08b64d06189c80fceba8f12466d2445fa34ab93ffe6e48af6e19da3f80d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nU.S. ", "start_char_idx": 1869, "end_char_idx": 1895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c21d133-dcf4-4b57-9933-5a3540634691": {"__data__": {"id_": "4c21d133-dcf4-4b57-9933-5a3540634691", "embedding": null, "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business. ", "original_text": "Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5c9ebc3-1a12-4978-a3ec-520550817f4b", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business. ", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1b2b4cf648d1476657847b2ad4358601e2204fd091508255cd4455f771907da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a3a6e9f-96d5-4be9-a2d1-2d00c654ee19", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n", "original_text": "Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n"}, "hash": "bd13f53721768b6002fc4d7c825d3be7b56d2dcf408f7d061afe3f5c970b30cb", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems. ", "start_char_idx": 1895, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a3a6e9f-96d5-4be9-a2d1-2d00c654ee19": {"__data__": {"id_": "2a3a6e9f-96d5-4be9-a2d1-2d00c654ee19", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n", "original_text": "Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c21d133-dcf4-4b57-9933-5a3540634691", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business. ", "original_text": "Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63f78db06330081e5ce3c17dc973c170ab14d7a6cbfe08a016d7d33a7e24110b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7009740-e4e7-46cf-b3ba-4bcce68b05cc", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024. ", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business. "}, "hash": "9341f6ec16594608b1509e42f6f5942e3e21b6f8994d067b608a7ee65945c413", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n", "start_char_idx": 2315, "end_char_idx": 2566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7009740-e4e7-46cf-b3ba-4bcce68b05cc": {"__data__": {"id_": "d7009740-e4e7-46cf-b3ba-4bcce68b05cc", "embedding": null, "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024. ", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a3a6e9f-96d5-4be9-a2d1-2d00c654ee19", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n", "original_text": "Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e81e3c783886d086b66af22d0b1279c8011c65e01a6f79fa5bcec5ffc6e2da7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac55e06-8cb8-4d4c-a569-b1cb0f04aabe", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024. ", "original_text": "Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business. "}, "hash": "0212fb975157574837ee9c60a068c139f9897b0c3f8dd13ca710549a8bbdcbb8", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business. ", "start_char_idx": 2566, "end_char_idx": 2970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac55e06-8cb8-4d4c-a569-b1cb0f04aabe": {"__data__": {"id_": "6ac55e06-8cb8-4d4c-a569-b1cb0f04aabe", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024. ", "original_text": "Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7009740-e4e7-46cf-b3ba-4bcce68b05cc", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024. ", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87ff79e4115f84e660dfeeeb80320ac4f4c957b15d657a0a7fc567038e9f3664", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1578410e-4cce-48e4-9d40-7af66c38ca76", "node_type": "1", "metadata": {"window": "Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n"}, "hash": "5e2fb868250fd747c0c5ac0cde0a7cfd69436adf204253dde1d5d89dfa994acf", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business. ", "start_char_idx": 2970, "end_char_idx": 3217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1578410e-4cce-48e4-9d40-7af66c38ca76": {"__data__": {"id_": "1578410e-4cce-48e4-9d40-7af66c38ca76", "embedding": null, "metadata": {"window": "Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac55e06-8cb8-4d4c-a569-b1cb0f04aabe", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $61.3 billion in the second quarter of fiscal 2024, an increase of 8.1 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician\npractices and health systems.  Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024. ", "original_text": "Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0a239b54fbab860c2630da7e5825398706cd7a0bbdc84fccd70836ed54641d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f01daddc-8898-46a7-b22d-3aad5f21f574", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n", "original_text": "Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024. "}, "hash": "28df2eca37676a14fcc799f59c193351e53b73a4a91fccfa3975cbc134a5ac0c", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n", "start_char_idx": 3217, "end_char_idx": 3368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f01daddc-8898-46a7-b22d-3aad5f21f574": {"__data__": {"id_": "f01daddc-8898-46a7-b22d-3aad5f21f574", "embedding": null, "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n", "original_text": "Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1578410e-4cce-48e4-9d40-7af66c38ca76", "node_type": "1", "metadata": {"window": "Segment operating income of $841.1 million in the second quarter of fiscal 2024 was up 11.2 percent\ncompared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in\noperating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7897accd9ccca9369b8845083c875c9e3fad1100a7f40c9c57fd46d9a37e42e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9adb94ce-087e-4938-a10e-468ab3b3b61c", "node_type": "1", "metadata": {"window": "Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n", "original_text": "S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024. "}, "hash": "c1827373424c2d5f2745ef9d73dc0efb8a9bc2692c8df51c000e29577e0f532a", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024. ", "start_char_idx": 3368, "end_char_idx": 3477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9adb94ce-087e-4938-a10e-468ab3b3b61c": {"__data__": {"id_": "9adb94ce-087e-4938-a10e-468ab3b3b61c", "embedding": null, "metadata": {"window": "Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n", "original_text": "S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f01daddc-8898-46a7-b22d-3aad5f21f574", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the second quarter of fiscal 2024, an increase of 5.3 percent from\nthe previous fiscal year\u2019s second quarter due to increased sales in our European distribution business, increased sales in our\nCanadian business, and increased sales at our less-than-wholly-owned Brazil full-line distribution business.  Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n", "original_text": "Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8910e9f26726e1cee4baf94ad21131a9f9edb2084cd6a96d0c8f99588dfca556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf380379-48d2-4964-90e8-bcda96d7bf0d", "node_type": "1", "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n", "original_text": "R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n"}, "hash": "69746bf03bb2bca101110a0555cb83eee21c127dcdaceda905b7856920f670ac", "class_name": "RelatedNodeInfo"}}, "text": "S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024. ", "start_char_idx": 3477, "end_char_idx": 3648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf380379-48d2-4964-90e8-bcda96d7bf0d": {"__data__": {"id_": "bf380379-48d2-4964-90e8-bcda96d7bf0d", "embedding": null, "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n", "original_text": "R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9adb94ce-087e-4938-a10e-468ab3b3b61c", "node_type": "1", "metadata": {"window": "Segment operating\nincome in the second quarter of fiscal 2024 was $192.7 million, an increase of 9.5 percent, primarily due to higher operating income\nat our less-than-wholly-owned Brazil full-line distribution business and our Canadian business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n", "original_text": "S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "194036af28067358fb9b7993484eeb0a730f74a4338f8a599a9d1f70469e93dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a30bea5-56f8-4fbe-8d7b-e830b9f82c96", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n"}, "hash": "e03fb2f175792a401d1cdbfc791fc5160a839eafc03835912e0e8d3d1b8c74ea", "class_name": "RelatedNodeInfo"}}, "text": "R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n", "start_char_idx": 3648, "end_char_idx": 3831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a30bea5-56f8-4fbe-8d7b-e830b9f82c96": {"__data__": {"id_": "7a30bea5-56f8-4fbe-8d7b-e830b9f82c96", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf380379-48d2-4964-90e8-bcda96d7bf0d", "node_type": "1", "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 9.8 percent and 22.1 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n", "original_text": "R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98aff4a04d0a3df10b727ed8904c49643a03bcb8591540b03f1801223718141d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43c670a2-0fde-462c-a0f8-0c9447e93496", "node_type": "1", "metadata": {"window": "S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n"}, "hash": "f7b01c42711393db1d370f629191c3cccf9723c5b16a31548a400c1927ab687c", "class_name": "RelatedNodeInfo"}}, "text": "Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n", "start_char_idx": 3831, "end_char_idx": 3995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43c670a2-0fde-462c-a0f8-0c9447e93496": {"__data__": {"id_": "43c670a2-0fde-462c-a0f8-0c9447e93496", "embedding": null, "metadata": {"window": "S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a30bea5-56f8-4fbe-8d7b-e830b9f82c96", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nCencora announced its leadership succession plan on March 12, 2024.  S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "617123a001209899b496f2537ac3a67ba3cc9dc15021a814ec3ae92018e05a3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2adab6de-f6b8-4505-9efa-0cccf7930d2e", "node_type": "1", "metadata": {"window": "R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n"}, "hash": "4b3cf977e6cab0fc12881df67fe41770dc1aa3bbfa2b794dd18abe968a7f11a4", "class_name": "RelatedNodeInfo"}}, "text": "Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n", "start_char_idx": 3995, "end_char_idx": 4240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2adab6de-f6b8-4505-9efa-0cccf7930d2e": {"__data__": {"id_": "2adab6de-f6b8-4505-9efa-0cccf7930d2e", "embedding": null, "metadata": {"window": "R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43c670a2-0fde-462c-a0f8-0c9447e93496", "node_type": "1", "metadata": {"window": "S teven H. Collis will retire as President and Chief\nExecutive Officer and transition to the role of Executive Chair of the Board of Directors, effective October 1, 2024.  R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a09792d15144b97fb919ddbcdc5ea89349bd89bb8d4c29958d377ad12c41947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e131dbbf-0a0d-435e-a2d2-c6a0498e1d1c", "node_type": "1", "metadata": {"window": "Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Fiscal Y ear 2024 Expectations\n3"}, "hash": "c4f8ee11e6640283ca4497a5a4f6c112ca8d22fd27719e217e3fb62fd8089390", "class_name": "RelatedNodeInfo"}}, "text": "Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n", "start_char_idx": 4240, "end_char_idx": 4424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e131dbbf-0a0d-435e-a2d2-c6a0498e1d1c": {"__data__": {"id_": "e131dbbf-0a0d-435e-a2d2-c6a0498e1d1c", "embedding": null, "metadata": {"window": "Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Fiscal Y ear 2024 Expectations\n3", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c327cebeaf99ffcb0bcb789b7ce5da84c255ed67b9bd22700f3e1ab4da727fcb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2adab6de-f6b8-4505-9efa-0cccf7930d2e", "node_type": "1", "metadata": {"window": "R obert P.\nMauch, PharmD, PhD, current Chief Operating Officer, will succeed Collis as President and CEO, and will also be appointed as\na member of the Board effective the same date.\n Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d5cd5afc35922988698b8849c385639eab39965fe665661dbea32243d03f681", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "328af804-ad17-4e02-9c1a-c4bf2a7880a7", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "bb4504461a35c449b956d20c5367f7b6dcd8cbc0efd4002b5b8e3cdaf59557ae", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2024 Expectations\n3", "start_char_idx": 4424, "end_char_idx": 4456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "328af804-ad17-4e02-9c1a-c4bf2a7880a7": {"__data__": {"id_": "328af804-ad17-4e02-9c1a-c4bf2a7880a7", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e131dbbf-0a0d-435e-a2d2-c6a0498e1d1c", "node_type": "1", "metadata": {"window": "Gina Clark, EVP and Chief Communications & Administration Officer, informed the Company that she intends to retire from\nher position, effective September 30, 2024.\n Cencora was recognized by Newsweek on its inaugural list of \u201cAmerica\u2019s Greenest Companies,\" which is a list that recognizes\nthe top 300 companies in the United S tates who are making progress to positively change their sustainability footprint.\n Cencora released its 2023 DEI Progress R eport and microsite, detailing Cencora\u2019s commitment to DEI, company progress, and\nthe impact for our people, our culture, and our communities.\n Fiscal Y ear 2024 Expectations\n3", "original_text": "Fiscal Y ear 2024 Expectations\n3", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bde1e7324d587a80b5502a20f7a398d598334ff9dff8a9d8577244f628d3695", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53eb4c08-ea28-41eb-98bb-c283fdcd4696", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "e61b26752357049c5f441acdfc8425f75c8dcbf00ba2a2ee36fe4c8733fe5110", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 0, "end_char_idx": 213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53eb4c08-ea28-41eb-98bb-c283fdcd4696": {"__data__": {"id_": "53eb4c08-ea28-41eb-98bb-c283fdcd4696", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "328af804-ad17-4e02-9c1a-c4bf2a7880a7", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8526257032213294195d108079351e51126efd351f3f75ce0197999836479161", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ba83c3e-2920-40c9-94db-9f7dff3e6f89", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S. ", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count. "}, "hash": "8e45cc1238a7c54c2fb3a1c229859e61f99963cd10b536686c379f0fb60eb09f", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 213, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ba83c3e-2920-40c9-94db-9f7dff3e6f89": {"__data__": {"id_": "3ba83c3e-2920-40c9-94db-9f7dff3e6f89", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S. ", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53eb4c08-ea28-41eb-98bb-c283fdcd4696", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db5a968c9a611519b983f176adb5d2b6741cc6e2f3a42b18250b6e1497f785e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbf58b1b-3c9b-4825-8c2e-19e698d9927d", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter. ", "original_text": "The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n"}, "hash": "98ff18fbed9d008e392b831df0778a796a2e68029e27c383094e27f45faa47b7", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count. ", "start_char_idx": 346, "end_char_idx": 603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbf58b1b-3c9b-4825-8c2e-19e698d9927d": {"__data__": {"id_": "fbf58b1b-3c9b-4825-8c2e-19e698d9927d", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter. ", "original_text": "The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ba83c3e-2920-40c9-94db-9f7dff3e6f89", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S. ", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5e152de955320ec126b5e99e0aefd8e96b99e5118c3cbf6ddef8da7a53dd3fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d30a103-9b83-4449-aa78-db791f62cb5f", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S. ", "original_text": "Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S. "}, "hash": "a1057bf0f09b395d86a66c30f43f283b2813ca9ab45094d3ceec75b5ca445080", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n", "start_char_idx": 603, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d30a103-9b83-4449-aa78-db791f62cb5f": {"__data__": {"id_": "5d30a103-9b83-4449-aa78-db791f62cb5f", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S. ", "original_text": "Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbf58b1b-3c9b-4825-8c2e-19e698d9927d", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter. ", "original_text": "The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c07b8ed883977ee09f8f8db17a5b9c0a97481845eaeb69317ecdf0f10b64419c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05d1321a-73ba-49a7-b2a6-68c950236fe1", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S. "}, "hash": "50b92443c6210892674515b84e34d849e34971f015039c528478655e8d1b4bfb", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S. ", "start_char_idx": 749, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05d1321a-73ba-49a7-b2a6-68c950236fe1": {"__data__": {"id_": "05d1321a-73ba-49a7-b2a6-68c950236fe1", "embedding": null, "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d30a103-9b83-4449-aa78-db791f62cb5f", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S. ", "original_text": "Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "067a0a795f364d080ef7f2dff4c83cee9b8a49239faa5ba38b3b1374979c2e17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4b10982-24cc-4335-b5c6-e6807a1d5029", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n", "original_text": "Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter. "}, "hash": "d9be72a639dd73dc982c988fbcb0b2539d27eb283470e4bf13900228fce0f281", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S. ", "start_char_idx": 1071, "end_char_idx": 1458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4b10982-24cc-4335-b5c6-e6807a1d5029": {"__data__": {"id_": "c4b10982-24cc-4335-b5c6-e6807a1d5029", "embedding": null, "metadata": {"window": "The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n", "original_text": "Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05d1321a-73ba-49a7-b2a6-68c950236fe1", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "975b8422a5ad0b4a25566660aae8f5f3e886e3cd9e797cff60a15fb24c68489d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0785fca2-84ae-45df-aa22-6e6e9725a04d", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n", "original_text": "Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S. "}, "hash": "26357d83cada65bc7b393a559c4e957b17d830e5317fdf9c505f9e46c22e8602", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter. ", "start_char_idx": 1458, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0785fca2-84ae-45df-aa22-6e6e9725a04d": {"__data__": {"id_": "0785fca2-84ae-45df-aa22-6e6e9725a04d", "embedding": null, "metadata": {"window": "Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n", "original_text": "Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4b10982-24cc-4335-b5c6-e6807a1d5029", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n", "original_text": "Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2823c436dd6e2755dff6ad199dba3a963748aec8ff09ea87612273f7df613ce3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57342f3b-c7d4-456b-bf6a-43b082c9f353", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n", "original_text": "Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n"}, "hash": "d7113fc113e83ebcdc49f455908e83e0d3ca1707dd5d68ea541e9044c4933f57", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S. ", "start_char_idx": 1548, "end_char_idx": 1648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57342f3b-c7d4-456b-bf6a-43b082c9f353": {"__data__": {"id_": "57342f3b-c7d4-456b-bf6a-43b082c9f353", "embedding": null, "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n", "original_text": "Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0785fca2-84ae-45df-aa22-6e6e9725a04d", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nInternational Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent, narrowed from the previous\nrange of 4 to 8 percent;\nAdjusted consolidated operating income growth to be in the range of 9 to 11 percent, up from the previous range of 8 to 10\npercent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n", "original_text": "Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5cbce17df7921836751f07ec005308192a5b5e0585b68d487ba780a4b3af196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74b229fd-c6d5-4a8c-b5b3-07b8c018d14f", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m. ", "original_text": "For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n"}, "hash": "a2b6b69288dc7a83e457a6c978956d08f634402f01885622f2e7c2a8031675a8", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n", "start_char_idx": 1648, "end_char_idx": 1953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74b229fd-c6d5-4a8c-b5b3-07b8c018d14f": {"__data__": {"id_": "74b229fd-c6d5-4a8c-b5b3-07b8c018d14f", "embedding": null, "metadata": {"window": "Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m. ", "original_text": "For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57342f3b-c7d4-456b-bf6a-43b082c9f353", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent, up from the\nprevious range of 9 to 11 percent;\nThe Company does not expect exclusive C OVID-19 therapy contributions for the balance of fiscal 2024 and no longer expects\nto guide to ex-C OVID growth rates;\nThe fiscal year to date EPS contribution from exclusive C OVID-19 therapies in the U.S.  Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n", "original_text": "Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb77690e68ebba3e672a22d033f6ba2143ed3463bff791a780cda775a5fc451a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "025e83c7-8a32-4a73-ab5c-2ca570f5982d", "node_type": "1", "metadata": {"window": "Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n"}, "hash": "9e3d04bcee589e4336f68baec28ea3c7c57e68743e4d6b0a0f0568f2a602b434", "class_name": "RelatedNodeInfo"}}, "text": "For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n", "start_char_idx": 1953, "end_char_idx": 2100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "025e83c7-8a32-4a73-ab5c-2ca570f5982d": {"__data__": {"id_": "025e83c7-8a32-4a73-ab5c-2ca570f5982d", "embedding": null, "metadata": {"window": "Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74b229fd-c6d5-4a8c-b5b3-07b8c018d14f", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment\nwas $0.06, all of which was recognized in the first quarter.  Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m. ", "original_text": "For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b65e32fb4d045167f494cd7adaeaa8df3a814c7cc352cbf7c2ec4316d0b6af2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52b8526c-1d33-461d-b0d7-7e8e127dd513", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com. ", "original_text": "New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n"}, "hash": "8a2941365b8111ab95b8b3b6f55ce73e276dc7a36aba312d45814a72757febb0", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n", "start_char_idx": 2100, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52b8526c-1d33-461d-b0d7-7e8e127dd513": {"__data__": {"id_": "52b8526c-1d33-461d-b0d7-7e8e127dd513", "embedding": null, "metadata": {"window": "Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com. ", "original_text": "New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "025e83c7-8a32-4a73-ab5c-2ca570f5982d", "node_type": "1", "metadata": {"window": "Fiscal 2023 included $0.38 of consolidated exclusive C OVID-\n19 contribution with $0.31 in the U.S.  Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "574b03d649d20109e05bb45149880af4ecd186b1d0c87170c866dac0fb2ec571", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ebed0e8-b156-4c30-87a9-979dfab11391", "node_type": "1", "metadata": {"window": "For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m. "}, "hash": "54dcaa27f215437c0b707a480a6338fcd7d1372dd19a16efaae3c2927e464401", "class_name": "RelatedNodeInfo"}}, "text": "New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n", "start_char_idx": 2306, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ebed0e8-b156-4c30-87a9-979dfab11391": {"__data__": {"id_": "2ebed0e8-b156-4c30-87a9-979dfab11391", "embedding": null, "metadata": {"window": "For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52b8526c-1d33-461d-b0d7-7e8e127dd513", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment;\nAdjusted effective tax rate to be approximately 21 percent, from the previous range of 20 percent to 21 percent; and\nWeighted average diluted shares outstanding are expected to be approximately 201 to 202 million, from the previous range\nof approximately 200 to 202 million.\n For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com. ", "original_text": "New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7212bfcb05c4d5e981aca15b7d1014b1cf8615c0effda6a3ec6d4de5074e8a29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "713b037c-5e3c-419e-9441-a1b86e46fe02", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "ET on May 1, 2024. "}, "hash": "2acd695a4f2e6d3a18ae2af68d73d6aee5058d24ec915f79b90143a145e37d4e", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m. ", "start_char_idx": 2543, "end_char_idx": 2668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "713b037c-5e3c-419e-9441-a1b86e46fe02": {"__data__": {"id_": "713b037c-5e3c-419e-9441-a1b86e46fe02", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "ET on May 1, 2024. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ebed0e8-b156-4c30-87a9-979dfab11391", "node_type": "1", "metadata": {"window": "For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation\nfor investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7f82482966e5349053531d33344b0a4e2e5f016d82eb646470799db67a6ff2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8dfce02-ecae-47d5-aeb0-c1f7cf8915de", "node_type": "1", "metadata": {"window": "New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com. "}, "hash": "1ded486cb05e2caae18f3adb785f201e9d3c00a603f4343a88080dcdd443c588", "class_name": "RelatedNodeInfo"}}, "text": "ET on May 1, 2024. ", "start_char_idx": 2668, "end_char_idx": 2687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8dfce02-ecae-47d5-aeb0-c1f7cf8915de": {"__data__": {"id_": "f8dfce02-ecae-47d5-aeb0-c1f7cf8915de", "embedding": null, "metadata": {"window": "New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "713b037c-5e3c-419e-9441-a1b86e46fe02", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable May 24, 2024, to\nstockholders of record at the close of business on May 10, 2024.\n New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "ET on May 1, 2024. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3b8e54da53e1108ead6a7405e78f1423c7c2abb977148a2037d05b93a92a9fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5a59f1d-fe2e-419a-8f4a-e83c5741a535", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4"}, "hash": "86e62367330a47b1cc99234f33bd523e12b1babf8e3ea8116befca7452d3c499", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com. ", "start_char_idx": 2687, "end_char_idx": 2793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5a59f1d-fe2e-419a-8f4a-e83c5741a535": {"__data__": {"id_": "c5a59f1d-fe2e-419a-8f4a-e83c5741a535", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10a262ac6d304160e5688131649165647993dc635e0756c6177c45807cff4c33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8dfce02-ecae-47d5-aeb0-c1f7cf8915de", "node_type": "1", "metadata": {"window": "New Shar e Repur chase Pr ogram\nIn March 2024, the Company\u2019s Board of Directors authorized a new share repurchase program allowing the Company to purchase\nup to $2.0 billion of its outstanding common stock, subject to market conditions.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "054b209eace99a079720f7c47e76304088558562c2d04f110814f159cc371d43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9cdd5da-f2c4-43c2-97fe-6d864ff05352", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "original_text": "The dial-in number for the live call will be (833) 470-1428. "}, "hash": "9827689d0a64d193831e0ea39dfa80334c5ccd12f67baa47ad1dcf83f59f74ed", "class_name": "RelatedNodeInfo"}}, "text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "start_char_idx": 2793, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9cdd5da-f2c4-43c2-97fe-6d864ff05352": {"__data__": {"id_": "e9cdd5da-f2c4-43c2-97fe-6d864ff05352", "embedding": null, "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "original_text": "The dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5a59f1d-fe2e-419a-8f4a-e83c5741a535", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss its operating results at 8:30 a.m.  ET on May 1, 2024.  A slide presentation for\ninvestors has also been posted on the Company\u2019s website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nRobert P. Mauch, Executive Vice President & Chief Operating Officer\n4", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "338e7f623cd748233d391ef19013bae9ac1be55a69ade78592490bd0b27e7524", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db97e0cc-0907-49b2-bd50-f71195fdcee1", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. "}, "hash": "9d1be8689db8b0ef82584d51f0e3c9881b6181910048ee37762d8ef6fe706d13", "class_name": "RelatedNodeInfo"}}, "text": "The dial-in number for the live call will be (833) 470-1428. ", "start_char_idx": 0, "end_char_idx": 61, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db97e0cc-0907-49b2-bd50-f71195fdcee1": {"__data__": {"id_": "db97e0cc-0907-49b2-bd50-f71195fdcee1", "embedding": null, "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9cdd5da-f2c4-43c2-97fe-6d864ff05352", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "original_text": "The dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb02ceac12a7d5ff4d0ad4b3091257f3b1779db46a4e75341cbbed70a34f4b14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee231c5f-0133-4a83-a31c-92aa0f877325", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 161532. "}, "hash": "6a85d0d1e677d0a05f5cf8907cd0fdf462e4f730bae986ed4c17646ec84e526e", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "start_char_idx": 61, "end_char_idx": 129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee231c5f-0133-4a83-a31c-92aa0f877325": {"__data__": {"id_": "ee231c5f-0133-4a83-a31c-92aa0f877325", "embedding": null, "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 161532. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db97e0cc-0907-49b2-bd50-f71195fdcee1", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f179171f72975c79d32221cac2caa236fff7bb3547e7ea120dd2a0b1c8ae5fd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5f050c2-9184-4dac-ab72-469afc02a491", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com. "}, "hash": "f7fe91fe40c26a20986a0fc947792067a62117c7c9856cfa7d3e9d09e0ee5a08", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 161532. ", "start_char_idx": 129, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5f050c2-9184-4dac-ab72-469afc02a491": {"__data__": {"id_": "c5f050c2-9184-4dac-ab72-469afc02a491", "embedding": null, "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee231c5f-0133-4a83-a31c-92aa0f877325", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 161532. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5315140f7b9c44c48b3fb7a68a0ea47201f004febd9d94ae0d9f9c010adfdbce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b86a53c-f919-4f93-899b-1a81a207ed7d", "node_type": "1", "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "0d499d722bbd96c852184cac754401fb6204f7b2feb37f52e41ba13fc7053a56", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "start_char_idx": 174, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b86a53c-f919-4f93-899b-1a81a207ed7d": {"__data__": {"id_": "5b86a53c-f919-4f93-899b-1a81a207ed7d", "embedding": null, "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5f050c2-9184-4dac-ab72-469afc02a491", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "592c086f06e36b241c6654a904ada6d1481c11580b140781fe02047e437d996d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a60c433-1b63-4637-9534-0934aa8237fd", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "2085f6b44e03dc4bb96daf4219fcaac15a29dcc2fb4cf31b58d3f024bea22b1d", "class_name": "RelatedNodeInfo"}}, "text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 260, "end_char_idx": 383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a60c433-1b63-4637-9534-0934aa8237fd": {"__data__": {"id_": "8a60c433-1b63-4637-9534-0934aa8237fd", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b86a53c-f919-4f93-899b-1a81a207ed7d", "node_type": "1", "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "439e75b4f987394edeb76c698eef558c9379e79d3136717e445645109fd49311", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07340f46-c907-46cc-a472-29ccc9633fe5", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. "}, "hash": "14b6a35172d25bc1bee11031e6c7c281c41c0ed6dac049807095184d0e5d89c4", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 383, "end_char_idx": 453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07340f46-c907-46cc-a472-29ccc9633fe5": {"__data__": {"id_": "07340f46-c907-46cc-a472-29ccc9633fe5", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a60c433-1b63-4637-9534-0934aa8237fd", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b9b6ba0e5838e0fc987486b70ff5e872714116979e4a30b71ded8eed96b4829", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d90a6932-a376-4dd4-a667-0196a1f84280", "node_type": "1", "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. "}, "hash": "280f25b81fba3300f7f7447596821e1433f7a612add9050dfa6bebe6a693c943", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 453, "end_char_idx": 612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d90a6932-a376-4dd4-a667-0196a1f84280": {"__data__": {"id_": "d90a6932-a376-4dd4-a667-0196a1f84280", "embedding": null, "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07340f46-c907-46cc-a472-29ccc9633fe5", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bddc5369ddb682194225877ec3258f14778457dfa4e64de762a2c5dab8b0659c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40d55e68-bbb2-42bc-b103-4302cde4fb49", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n", "original_text": "T o access the telephone\nreplay from within the U.S. "}, "hash": "ec9a11f1a188ebe273d1598dca61832deadc994a43d7b7e9e256418e84b25c5b", "class_name": "RelatedNodeInfo"}}, "text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "start_char_idx": 612, "end_char_idx": 754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40d55e68-bbb2-42bc-b103-4302cde4fb49": {"__data__": {"id_": "40d55e68-bbb2-42bc-b103-4302cde4fb49", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n", "original_text": "T o access the telephone\nreplay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d90a6932-a376-4dd4-a667-0196a1f84280", "node_type": "1", "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c22d59ad8505736786e79660b525cf55fcef2d14a7f20bc96c595eb79a63775", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7526e408-4778-4e05-bd77-ecba90053fa2", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "1d394fc4c02e3d38ebaf2bc681cd07f3f2eea0b5447f0c677959796c3e6a77cc", "class_name": "RelatedNodeInfo"}}, "text": "T o access the telephone\nreplay from within the U.S. ", "start_char_idx": 754, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7526e408-4778-4e05-bd77-ecba90053fa2": {"__data__": {"id_": "7526e408-4778-4e05-bd77-ecba90053fa2", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40d55e68-bbb2-42bc-b103-4302cde4fb49", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n", "original_text": "T o access the telephone\nreplay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e236838cffabcb66e7c47a467686577cb4e57521c647e69e670b5434f46d8035", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e96f8a8-59d9-4643-bb95-4c2061d630de", "node_type": "1", "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United S tates, dial +1 (929) 458-6194. "}, "hash": "476a545d6b4312ba7d03896dac8f6d9899f3494750d1995c07e3c26108d2038c", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 807, "end_char_idx": 840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e96f8a8-59d9-4643-bb95-4c2061d630de": {"__data__": {"id_": "9e96f8a8-59d9-4643-bb95-4c2061d630de", "embedding": null, "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United S tates, dial +1 (929) 458-6194. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7526e408-4778-4e05-bd77-ecba90053fa2", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c178f9e051492c1efbd9fbbe849dfd6de1a6211c7326ec6fbed62af7f765c04f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "403efabc-4574-476c-b4bf-fce72de65122", "node_type": "1", "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "The access\ncode for the replay is 702498.\n"}, "hash": "67ea589c9cd4d2ff0a12348b5eda1d0ade8a8cc8169764076c5738a678d25107", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United S tates, dial +1 (929) 458-6194. ", "start_char_idx": 840, "end_char_idx": 897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "403efabc-4574-476c-b4bf-fce72de65122": {"__data__": {"id_": "403efabc-4574-476c-b4bf-fce72de65122", "embedding": null, "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "The access\ncode for the replay is 702498.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e96f8a8-59d9-4643-bb95-4c2061d630de", "node_type": "1", "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United S tates, dial +1 (929) 458-6194. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd3af71aaa7a8526699687a08cc9eb5ceb94a76e90e0ba22c01ee97a90a8add0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6b504a2-e20d-4bf9-9299-27d312f0e95f", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n"}, "hash": "28f3c4699efbf4a5f0c33a55e0b9db633b51cf8e342c83170c103db8c6a375ab", "class_name": "RelatedNodeInfo"}}, "text": "The access\ncode for the replay is 702498.\n", "start_char_idx": 897, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6b504a2-e20d-4bf9-9299-27d312f0e95f": {"__data__": {"id_": "a6b504a2-e20d-4bf9-9299-27d312f0e95f", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "403efabc-4574-476c-b4bf-fce72de65122", "node_type": "1", "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "The access\ncode for the replay is 702498.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b6da709cc6297ea9691886fccf786c57f6af5932df4902b0bb0944f73687b58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69a11c44-6cc4-4542-80aa-8518dfb89104", "node_type": "1", "metadata": {"window": "From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "1e42d9a4448678cc83728c13a4b579b0405eef203ca3020849a8d2c5a57efaee", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n", "start_char_idx": 939, "end_char_idx": 1108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69a11c44-6cc4-4542-80aa-8518dfb89104": {"__data__": {"id_": "69a11c44-6cc4-4542-80aa-8518dfb89104", "embedding": null, "metadata": {"window": "From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6b504a2-e20d-4bf9-9299-27d312f0e95f", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3edca15bc24c4207d5ccd8efadce543f0b9f7bbe4fc1988518a982e1750aeda4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "292e67c5-1a5a-403c-b12d-dcb25030fc03", "node_type": "1", "metadata": {"window": "The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. "}, "hash": "8e0a50314a608e4548bf3ab68d36d85d69f42293be1d4148e063af379488ed81", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 1108, "end_char_idx": 1237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "292e67c5-1a5a-403c-b12d-dcb25030fc03": {"__data__": {"id_": "292e67c5-1a5a-403c-b12d-dcb25030fc03", "embedding": null, "metadata": {"window": "The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69a11c44-6cc4-4542-80aa-8518dfb89104", "node_type": "1", "metadata": {"window": "From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c015564a3d468af77b5a461823687ac171dfc88f98ffcc3835e0c9c784e7bf2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c851b4fe-b7bc-45cf-adc7-94e6c6fe20b3", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n"}, "hash": "02c9d3fdd39f6d76cdb453495cb530434625f971eada7fe27a87469f9627c8eb", "class_name": "RelatedNodeInfo"}}, "text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "start_char_idx": 1237, "end_char_idx": 1389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c851b4fe-b7bc-45cf-adc7-94e6c6fe20b3": {"__data__": {"id_": "c851b4fe-b7bc-45cf-adc7-94e6c6fe20b3", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "292e67c5-1a5a-403c-b12d-dcb25030fc03", "node_type": "1", "metadata": {"window": "The access\ncode for the replay is 702498.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73ad269e0da2a837b144fed22e005c82bd25fb4ee3e903e326a7577f40c3a717", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d6fd5c1-5a17-4da9-b639-440e5e1193cd", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. "}, "hash": "4a25185a75d4b3af413da6a71b8e01ac980a9e5efc53ce4dead13d4969136070", "class_name": "RelatedNodeInfo"}}, "text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "start_char_idx": 1389, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d6fd5c1-5a17-4da9-b639-440e5e1193cd": {"__data__": {"id_": "5d6fd5c1-5a17-4da9-b639-440e5e1193cd", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c851b4fe-b7bc-45cf-adc7-94e6c6fe20b3", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nLeerink Healthcare Crossroads Conference May 30, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f853e78c35bfe5a6c6ac791eff723846dd6422f846e5bb54ca4e32cb424dcbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0872f7c-2fe8-4bf2-ad33-26a316747698", "node_type": "1", "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. "}, "hash": "ce0d6f5a21e058edaf7fcceaec4e1c2f20aacaec29289ee298832dd911e99742", "class_name": "RelatedNodeInfo"}}, "text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "start_char_idx": 1510, "end_char_idx": 1628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0872f7c-2fe8-4bf2-ad33-26a316747698": {"__data__": {"id_": "f0872f7c-2fe8-4bf2-ad33-26a316747698", "embedding": null, "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d6fd5c1-5a17-4da9-b639-440e5e1193cd", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cde942138354c4be7c911fdf64c44978d82b79d79bc42738f9ea9fa38cf2bb23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3fdc0d8-1222-455b-9299-227b727b74d2", "node_type": "1", "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. "}, "hash": "c1e84bb5f3c06763a7af5eacd8775e7e9d14ae2290c35a3eeae5a53d889b0689", "class_name": "RelatedNodeInfo"}}, "text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 1628, "end_char_idx": 1802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3fdc0d8-1222-455b-9299-227b727b74d2": {"__data__": {"id_": "f3fdc0d8-1222-455b-9299-227b727b74d2", "embedding": null, "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0872f7c-2fe8-4bf2-ad33-26a316747698", "node_type": "1", "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "865b8f3b28bd2a5e4ccaddd8981ac2a023c7bd89539cd1723c3a749e76d3b4a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a5f7bf-f833-42ec-be5a-60f34015cf84", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). "}, "hash": "0dec85da0fa9b184431cf8ce5d1b12f4bb3109aaf7cf7208f93bae37c74b20db", "class_name": "RelatedNodeInfo"}}, "text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "start_char_idx": 1802, "end_char_idx": 1924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43a5f7bf-f833-42ec-be5a-60f34015cf84": {"__data__": {"id_": "43a5f7bf-f833-42ec-be5a-60f34015cf84", "embedding": null, "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3fdc0d8-1222-455b-9299-227b727b74d2", "node_type": "1", "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4490761683bef2971adeb50e12a8795ed227e0c1424ab38513afda53addb8b75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "276a92b0-090e-4fe2-b100-a3410d5f0ef4", "node_type": "1", "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. "}, "hash": "b3ec51a7d2d761e7e83f68fea8216c4ec2dc03ea0caf4007787ea04508f433fc", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "start_char_idx": 1924, "end_char_idx": 2295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "276a92b0-090e-4fe2-b100-a3410d5f0ef4": {"__data__": {"id_": "276a92b0-090e-4fe2-b100-a3410d5f0ef4", "embedding": null, "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43a5f7bf-f833-42ec-be5a-60f34015cf84", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4254ebba377f6da466592c186f97eea96a5b04ce7b66a677b13c85282e4643", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66b939a5-a757-4aa1-b71d-ba0f7c2a1daa", "node_type": "1", "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "5e06346399805fee268ed12bf2a4013f2d82be81894033fa074577cd5e4f7170", "class_name": "RelatedNodeInfo"}}, "text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "start_char_idx": 2295, "end_char_idx": 2740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66b939a5-a757-4aa1-b71d-ba0f7c2a1daa": {"__data__": {"id_": "66b939a5-a757-4aa1-b71d-ba0f7c2a1daa", "embedding": null, "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "276a92b0-090e-4fe2-b100-a3410d5f0ef4", "node_type": "1", "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13a09475376a22f62dd523d7630998d167f8d7e8c1fcd208bed5261493755e4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e42d9434-2b2f-4f03-b5d4-29d862f36f85", "node_type": "1", "metadata": {"window": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. "}, "hash": "19fbeaae32dc6c33e50f5f48d96ad249183301344a61ebe932169a52a78f117e", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 2740, "end_char_idx": 2902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e42d9434-2b2f-4f03-b5d4-29d862f36f85": {"__data__": {"id_": "e42d9434-2b2f-4f03-b5d4-29d862f36f85", "embedding": null, "metadata": {"window": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66b939a5-a757-4aa1-b71d-ba0f7c2a1daa", "node_type": "1", "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcb7cad5ee63e9fb878ed227c51076fc3f3c6b1fb4e74974f9e3079aadb88331", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6803601-6d9f-48ea-8414-5ff00d8dbf68", "node_type": "1", "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. "}, "hash": "04040bff5f9b02a86b0af3e41ed760d171e1eee4e5badf4844004632b48a78e9", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "start_char_idx": 2902, "end_char_idx": 3101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6803601-6d9f-48ea-8414-5ff00d8dbf68": {"__data__": {"id_": "c6803601-6d9f-48ea-8414-5ff00d8dbf68", "embedding": null, "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e42d9434-2b2f-4f03-b5d4-29d862f36f85", "node_type": "1", "metadata": {"window": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c3dd0e16c1dcb73946a8c699fafdb6dd26fd4d7f9f20fb90623e080f56accdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c83fc0a-a96d-4c19-8b22-a14a9ddd59c6", "node_type": "1", "metadata": {"window": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n"}, "hash": "efb8f28c28bd997d0e18c941daefc47bfd24c2a64d405a2b52e91ba6c1e4bd89", "class_name": "RelatedNodeInfo"}}, "text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 3101, "end_char_idx": 3529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c83fc0a-a96d-4c19-8b22-a14a9ddd59c6": {"__data__": {"id_": "4c83fc0a-a96d-4c19-8b22-a14a9ddd59c6", "embedding": null, "metadata": {"window": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6803601-6d9f-48ea-8414-5ff00d8dbf68", "node_type": "1", "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b465da74d0a61f17ea556018d79e33fce1a84bde139fc69543f8d66bce36462c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4eb2b667-d210-45cf-a9e9-fcb4a93508e4", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "CENC ORA, INC.\n"}, "hash": "3962de69b480afd95a781faaa7eb268e5fa9c1c3211ee5414de92e735998372a", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "start_char_idx": 3529, "end_char_idx": 3678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4eb2b667-d210-45cf-a9e9-fcb4a93508e4": {"__data__": {"id_": "4eb2b667-d210-45cf-a9e9-fcb4a93508e4", "embedding": null, "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "CENC ORA, INC.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c83fc0a-a96d-4c19-8b22-a14a9ddd59c6", "node_type": "1", "metadata": {"window": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4da6be068b7e8636935d50564a2e712578f322f5c3c962feaaf3ffee4cfa2e54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52c14d94-0e10-4de0-996c-2c587441bbc4", "node_type": "1", "metadata": {"window": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5"}, "hash": "6746b324f9d362143b81eb3726603adf76ba7fd66ae7b9f002019bceba6c3466", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 3678, "end_char_idx": 3693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52c14d94-0e10-4de0-996c-2c587441bbc4": {"__data__": {"id_": "52c14d94-0e10-4de0-996c-2c587441bbc4", "embedding": null, "metadata": {"window": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355a8930d98c59d99a60d67570099cae684ad51d451bce5ccfbe205f3c89d729", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4eb2b667-d210-45cf-a9e9-fcb4a93508e4", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "CENC ORA, INC.\n", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "970e220223db5c6fadd552fc3d477a5abcb7ecc29c5a88232e60cd5a74ba2fe9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0431000-c468-496f-b273-0a1dd357b18a", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6"}, "hash": "2b70e1b83670b4785cdb418f3a7d5769608dad627b7cba702573b5c37a8bbfc9", "class_name": "RelatedNodeInfo"}}, "text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "start_char_idx": 3693, "end_char_idx": 3751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0431000-c468-496f-b273-0a1dd357b18a": {"__data__": {"id_": "a0431000-c468-496f-b273-0a1dd357b18a", "embedding": null, "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2fbe393-a348-40f2-ad00-b60f8963e0b2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a150fd63251ec2e5d466729edcb784164718ccec0762b09dc03778fb6aaf462", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52c14d94-0e10-4de0-996c-2c587441bbc4", "node_type": "1", "metadata": {"window": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n5", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87c4032b1390a09d45ed76f2d5510de980ff11cd3ad8becef08aace6fd24e2d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "239d6526-250b-4ab5-98f1-c1276c5655aa", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0"}, "hash": "51b6aae4eb1b5202390801e344e3e0245a7d459a4017d52f9a9efcc87abc3444", "class_name": "RelatedNodeInfo"}}, "text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "start_char_idx": 0, "end_char_idx": 1207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "239d6526-250b-4ab5-98f1-c1276c5655aa": {"__data__": {"id_": "239d6526-250b-4ab5-98f1-c1276c5655aa", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86400052-ca68-4aad-b381-1be5923275a2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e4620de4b1356b6d0add5e19e138be979709a9764ca714f1382d7b65411b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0431000-c468-496f-b273-0a1dd357b18a", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5de7d43d27c6e868c1143ebd335336d69bab08460e8238e1325193ee40ff6707", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32b9e30c-fb3f-4f51-aa79-44d4aaaf8c32", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n", "original_text": "$420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024. "}, "hash": "189caaec40c3ad5542fd5c95adc87f75f72dcb36f800f9787a1b1575ffb10e2e", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "start_char_idx": 0, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32b9e30c-fb3f-4f51-aa79-44d4aaaf8c32": {"__data__": {"id_": "32b9e30c-fb3f-4f51-aa79-44d4aaaf8c32", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n", "original_text": "$420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024. ", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86400052-ca68-4aad-b381-1be5923275a2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e4620de4b1356b6d0add5e19e138be979709a9764ca714f1382d7b65411b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "239d6526-250b-4ab5-98f1-c1276c5655aa", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8052a206cef22494947e63d1813aa016e67f0f21f5db7ad7ab71d4c872894bd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35d7bf03-77ef-4feb-b81a-5aa588d9d5f6", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n"}, "hash": "60cef5c43b6ad7d7df5048b8c3ad39040d39886685f780f160577eaedb6422dc", "class_name": "RelatedNodeInfo"}}, "text": "$420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024. ", "start_char_idx": 233, "end_char_idx": 796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35d7bf03-77ef-4feb-b81a-5aa588d9d5f6": {"__data__": {"id_": "35d7bf03-77ef-4feb-b81a-5aa588d9d5f6", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86400052-ca68-4aad-b381-1be5923275a2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e4620de4b1356b6d0add5e19e138be979709a9764ca714f1382d7b65411b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32b9e30c-fb3f-4f51-aa79-44d4aaaf8c32", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n", "original_text": "$420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024. ", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "777fcf4ef1261241c80b09c281511f8b9519decaff78769d1aad435648bab1ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72cadb08-a6c2-4ca9-8869-44effa0f12d6", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n"}, "hash": "169511311003926d4cfac1a201dc27a3162e4d23b371d37c409aeebc5d97806a", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n", "start_char_idx": 796, "end_char_idx": 942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72cadb08-a6c2-4ca9-8869-44effa0f12d6": {"__data__": {"id_": "72cadb08-a6c2-4ca9-8869-44effa0f12d6", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86400052-ca68-4aad-b381-1be5923275a2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e4620de4b1356b6d0add5e19e138be979709a9764ca714f1382d7b65411b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35d7bf03-77ef-4feb-b81a-5aa588d9d5f6", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3cae02e625c1b2793924909e902ec135e8a3a97bcd11bcfc4281b344b2fbc3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c42d7d65-301d-4197-b22a-70fadf588145", "node_type": "1", "metadata": {"window": "$420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "CENC ORA, INC.\n"}, "hash": "7751198ca50fdfe5fe4708cfeab40182f4bd5cd6e06131e2cef7c02a9a2d026a", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n", "start_char_idx": 942, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c42d7d65-301d-4197-b22a-70fadf588145": {"__data__": {"id_": "c42d7d65-301d-4197-b22a-70fadf588145", "embedding": null, "metadata": {"window": "$420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "CENC ORA, INC.\n", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86400052-ca68-4aad-b381-1be5923275a2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e4620de4b1356b6d0add5e19e138be979709a9764ca714f1382d7b65411b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72cadb08-a6c2-4ca9-8869-44effa0f12d6", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2df6108fc1a1bce16307e417136e92975f60abcc8569f0c360050170e8a2539c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f5c7b00-3249-40ec-b4ff-84a66d15f729", "node_type": "1", "metadata": {"window": "Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7"}, "hash": "4b3599382e978f5737cfe5174244f8aa19512a3b9995118c68d432416aaf0c47", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 1037, "end_char_idx": 1052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f5c7b00-3249-40ec-b4ff-84a66d15f729": {"__data__": {"id_": "7f5c7b00-3249-40ec-b4ff-84a66d15f729", "embedding": null, "metadata": {"window": "Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86400052-ca68-4aad-b381-1be5923275a2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e4620de4b1356b6d0add5e19e138be979709a9764ca714f1382d7b65411b9d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c42d7d65-301d-4197-b22a-70fadf588145", "node_type": "1", "metadata": {"window": "$420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "CENC ORA, INC.\n", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b20df28c48575f539a0c1241a07e99b58702c648c01ab38277ff530bb525513", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3827c93-79b6-422d-a3ea-f4390d8e40b1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8"}, "hash": "931be0768dd815d7cc5fa05fbcef7fe3b9e7e0384e939de68103f07c6abdee1c", "class_name": "RelatedNodeInfo"}}, "text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "start_char_idx": 1052, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3827c93-79b6-422d-a3ea-f4390d8e40b1": {"__data__": {"id_": "a3827c93-79b6-422d-a3ea-f4390d8e40b1", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e20bd6c-b0bd-4425-ba28-47e289fb62e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a12ed1b1b3e90ade9fcf3c2b7e908ee5155cc962b3253df35cd748dd60d7df9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f5c7b00-3249-40ec-b4ff-84a66d15f729", "node_type": "1", "metadata": {"window": "Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\nSix Months Six Months \n7", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54106737effc2f8168b4891f6f50110c1d38e0c58c6ea63a97cfb2ad93d0e3e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dc2ecba-748d-48cf-8be8-e580cef4b8e2", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n", "original_text": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0"}, "hash": "58ade35bedd68dc495ba2d46326f96fbfc9777a4e9d69ad35876fd6c5f8c3d59", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "start_char_idx": 0, "end_char_idx": 1281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dc2ecba-748d-48cf-8be8-e580cef4b8e2": {"__data__": {"id_": "2dc2ecba-748d-48cf-8be8-e580cef4b8e2", "embedding": null, "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n", "original_text": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4072ad2fbe6b342f452e170ec34c8201dbf9b15a6fe68cb0e28e196a94610bf8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3827c93-79b6-422d-a3ea-f4390d8e40b1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f45bd2ff7f9fe28151ce3654618de2ea646282cd7cf599d402a299efcbeef495", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a007d0c4-13ca-4eba-8a42-13503980d9a5", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n", "original_text": "$1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024. "}, "hash": "95b66624f32c592a42d98c8d4d29980de7bf515cc732ac641d0582a040367810", "class_name": "RelatedNodeInfo"}}, "text": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "start_char_idx": 0, "end_char_idx": 147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a007d0c4-13ca-4eba-8a42-13503980d9a5": {"__data__": {"id_": "a007d0c4-13ca-4eba-8a42-13503980d9a5", "embedding": null, "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n", "original_text": "$1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024. ", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4072ad2fbe6b342f452e170ec34c8201dbf9b15a6fe68cb0e28e196a94610bf8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dc2ecba-748d-48cf-8be8-e580cef4b8e2", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n", "original_text": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed0fcf83fa6f7349442512f70899a5ab23e3567879b0066240b929bc9b71720c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03456a72-7aa9-4777-886a-7ed15e2a9bb1", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n"}, "hash": "22714330a535e67ff33a3431195aa4ba1b296474f93ce437f65599c740d83594", "class_name": "RelatedNodeInfo"}}, "text": "$1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024. ", "start_char_idx": 147, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03456a72-7aa9-4777-886a-7ed15e2a9bb1": {"__data__": {"id_": "03456a72-7aa9-4777-886a-7ed15e2a9bb1", "embedding": null, "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4072ad2fbe6b342f452e170ec34c8201dbf9b15a6fe68cb0e28e196a94610bf8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a007d0c4-13ca-4eba-8a42-13503980d9a5", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n", "original_text": "$1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024. ", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0a8b5d59eb9c295f95582f0cbb5c091130bbaad81f89665e570b6e2a7f3920", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e807335b-998e-42e0-a1e5-1e8175e78ec4", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n"}, "hash": "823f59f0068dc5a35e249ee0b3ff4ad40da8b70568689988a02b0f4ee787cf7c", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n", "start_char_idx": 707, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e807335b-998e-42e0-a1e5-1e8175e78ec4": {"__data__": {"id_": "e807335b-998e-42e0-a1e5-1e8175e78ec4", "embedding": null, "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4072ad2fbe6b342f452e170ec34c8201dbf9b15a6fe68cb0e28e196a94610bf8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03456a72-7aa9-4777-886a-7ed15e2a9bb1", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e58614783af1f3d8b6535abeaaf5a86d987a87262d37a48f976643980387737", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "639927b8-2190-4eef-9f89-7469c75540ed", "node_type": "1", "metadata": {"window": "$1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "CENC ORA, INC.\n"}, "hash": "6ce9d04b43c0fb9506d7aabb8395057fd2b91d726fb650a17d28872349c34cb6", "class_name": "RelatedNodeInfo"}}, "text": "2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n", "start_char_idx": 912, "end_char_idx": 1223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "639927b8-2190-4eef-9f89-7469c75540ed": {"__data__": {"id_": "639927b8-2190-4eef-9f89-7469c75540ed", "embedding": null, "metadata": {"window": "$1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "CENC ORA, INC.\n", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4072ad2fbe6b342f452e170ec34c8201dbf9b15a6fe68cb0e28e196a94610bf8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e807335b-998e-42e0-a1e5-1e8175e78ec4", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "626568b6c6e45f9f3426655dc0f8a1f695f6a797269e5d1e112fa9b142975832", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "858b26ab-b174-43fd-8281-73d030e311cc", "node_type": "1", "metadata": {"window": "Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9"}, "hash": "7f0e1f4c56237e93c6ed9618813e9fad55c49ea2332a86530a51654185fe2de2", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 1223, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "858b26ab-b174-43fd-8281-73d030e311cc": {"__data__": {"id_": "858b26ab-b174-43fd-8281-73d030e311cc", "embedding": null, "metadata": {"window": "Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4072ad2fbe6b342f452e170ec34c8201dbf9b15a6fe68cb0e28e196a94610bf8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "639927b8-2190-4eef-9f89-7469c75540ed", "node_type": "1", "metadata": {"window": "$1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "CENC ORA, INC.\n", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb86b534896f73628cf911744e78098adbc1fa3388a65006b76667a06c841e20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e5cfa1c-375c-4ea3-9b06-949fdfc98ad9", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10"}, "hash": "d04b2d73f5e1575b72e1928386286ee8ac4421b7f6f1a12f9e508e5c47eb7196", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "start_char_idx": 1238, "end_char_idx": 1474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e5cfa1c-375c-4ea3-9b06-949fdfc98ad9": {"__data__": {"id_": "1e5cfa1c-375c-4ea3-9b06-949fdfc98ad9", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fc4a8f-d731-478a-aa5e-9e1d6a44e640", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44c55738344d5f0fea8faaf2dfd3e4dc74df2c07c847b4718a8134bd3eb58d2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "858b26ab-b174-43fd-8281-73d030e311cc", "node_type": "1", "metadata": {"window": "Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2024 \u00a0\nGrossOperating Operating Income \n  \nBefor e Income T ax Net Income \n  \nAttributable Dilut ed \n  \nEarnings \n9", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "deedac8c4c33e9ff8a05de9836de8e992c9e645e180b1f8618468e583e7d3f7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbf02833-fe40-4860-8460-e53f5df00670", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "Adjusted Non-GAAP % change vs.\n"}, "hash": "e2509c1ade7e9013eac9b54e2ca1b53b1ff760c26237d33955dc1be4a4ec9182", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10", "start_char_idx": 0, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbf02833-fe40-4860-8460-e53f5df00670": {"__data__": {"id_": "bbf02833-fe40-4860-8460-e53f5df00670", "embedding": null, "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "Adjusted Non-GAAP % change vs.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62e75998-5959-41c0-a06a-9bb5eaa87858", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd4f461a02ca2471d67631c34326e8b97a65bd23d281ba061873e0aaddfde3fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e5cfa1c-375c-4ea3-9b06-949fdfc98ad9", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b2872c931fae109724098388130388604ef229794e53cb4b1eaa7f5462c6701", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "761957b0-439b-4652-9171-c3044e52f0b3", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "original_text": "prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n"}, "hash": "5a333d57ef1c8311fd52a47ba8adc9b6ced838a2fe0ac80515514ad5e45884b0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Non-GAAP % change vs.\n", "start_char_idx": 0, "end_char_idx": 31, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "761957b0-439b-4652-9171-c3044e52f0b3": {"__data__": {"id_": "761957b0-439b-4652-9171-c3044e52f0b3", "embedding": null, "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "original_text": "prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62e75998-5959-41c0-a06a-9bb5eaa87858", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd4f461a02ca2471d67631c34326e8b97a65bd23d281ba061873e0aaddfde3fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbf02833-fe40-4860-8460-e53f5df00670", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "Adjusted Non-GAAP % change vs.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73cc66cd3d7780d28f8942c5027b77d9730e3f845474b4a3e8e56da11d006d6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09f08ef6-c5e1-4c95-a38b-eec72bacdff0", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n", "original_text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n"}, "hash": "e57be04d0b2cfbeb747ecc652ef60847006afdaa362c1292a5f8b3336657262f", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n", "start_char_idx": 31, "end_char_idx": 316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09f08ef6-c5e1-4c95-a38b-eec72bacdff0": {"__data__": {"id_": "09f08ef6-c5e1-4c95-a38b-eec72bacdff0", "embedding": null, "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n", "original_text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62e75998-5959-41c0-a06a-9bb5eaa87858", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd4f461a02ca2471d67631c34326e8b97a65bd23d281ba061873e0aaddfde3fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "761957b0-439b-4652-9171-c3044e52f0b3", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "original_text": "prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2d00cd6035cd928af398f91a928e1c0b26a3d9c14cd520e9b95332e1517fdf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab03d49e-aaf6-4d97-b886-082f6ea837e0", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0"}, "hash": "430019f7e1e422747f4e02c9ea4e4806ae9f00772ec4dc0ee0a6d92e516656bd", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n", "start_char_idx": 316, "end_char_idx": 654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab03d49e-aaf6-4d97-b886-082f6ea837e0": {"__data__": {"id_": "ab03d49e-aaf6-4d97-b886-082f6ea837e0", "embedding": null, "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62e75998-5959-41c0-a06a-9bb5eaa87858", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd4f461a02ca2471d67631c34326e8b97a65bd23d281ba061873e0aaddfde3fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09f08ef6-c5e1-4c95-a38b-eec72bacdff0", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n", "original_text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92be177ec67b8f8e8d0bbc0d907e6de346a561952b8699e4abf0e017697a786d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7173bba-f621-4909-aec5-ac7521290be2", "node_type": "1", "metadata": {"window": "prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n"}, "hash": "e6f9622ebd895a5cdcfbaf156a39a5099978de872de58990e38e5e3c11e0e3a1", "class_name": "RelatedNodeInfo"}}, "text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "start_char_idx": 654, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7173bba-f621-4909-aec5-ac7521290be2": {"__data__": {"id_": "c7173bba-f621-4909-aec5-ac7521290be2", "embedding": null, "metadata": {"window": "prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62e75998-5959-41c0-a06a-9bb5eaa87858", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd4f461a02ca2471d67631c34326e8b97a65bd23d281ba061873e0aaddfde3fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab03d49e-aaf6-4d97-b886-082f6ea837e0", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df2237a918c29e1d119c186fd9be5df16bda33441f71408cedae946e2fe55240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd6ab857-e118-457c-9cbd-ba95ac26a1d5", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "CENC ORA, INC.\n"}, "hash": "e2c9c3278922e21b16cf75c1d72e004bfafb05be6374ed4778fa611d77f9dedb", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "start_char_idx": 724, "end_char_idx": 902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd6ab857-e118-457c-9cbd-ba95ac26a1d5": {"__data__": {"id_": "fd6ab857-e118-457c-9cbd-ba95ac26a1d5", "embedding": null, "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "CENC ORA, INC.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62e75998-5959-41c0-a06a-9bb5eaa87858", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd4f461a02ca2471d67631c34326e8b97a65bd23d281ba061873e0aaddfde3fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7173bba-f621-4909-aec5-ac7521290be2", "node_type": "1", "metadata": {"window": "prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9986219f5822284ddb87899c7f7ddabaca0b18c7fb8e10bea31c89d9a13739ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be1bb707-3dbb-4c6c-9772-275a019d46f6", "node_type": "1", "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11"}, "hash": "65374af2cad2b87674b7f3cea9f6b5821ccb56208362d2bf442e15aacf40c4c3", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 902, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be1bb707-3dbb-4c6c-9772-275a019d46f6": {"__data__": {"id_": "be1bb707-3dbb-4c6c-9772-275a019d46f6", "embedding": null, "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62e75998-5959-41c0-a06a-9bb5eaa87858", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd4f461a02ca2471d67631c34326e8b97a65bd23d281ba061873e0aaddfde3fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd6ab857-e118-457c-9cbd-ba95ac26a1d5", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "CENC ORA, INC.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f8d91eab9dad30ff1610a0de8ef9772666206d33b2b0dc45329a92cb26db44a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36abdebd-05c0-4af3-823c-2772d35babde", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12"}, "hash": "bda98d01b0c06ace21244be8a95589253127e6f46eea446073a3bfbebf009670", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "start_char_idx": 917, "end_char_idx": 1353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36abdebd-05c0-4af3-823c-2772d35babde": {"__data__": {"id_": "36abdebd-05c0-4af3-823c-2772d35babde", "embedding": null, "metadata": {"window": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "page_label": "12", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a81bcfaa-f328-44f6-813d-f24531c85447", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aac0108d4e8740aedcdd838c3f7da0d1142f59553e7b490a2cae11f9ff6d7a0d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be1bb707-3dbb-4c6c-9772-275a019d46f6", "node_type": "1", "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0\u00a0$560,519 \u00a0$512,130 \u00a0\u00a0$83,917 \u00a0\u00a0$435,402 \u00a0\u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fad28304eca4ee01249caf76555227fa38e38b91f14d748bfe274eb0e2879884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d63250a0-a804-40f4-a00e-e3b3edc4bbb1", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0"}, "hash": "be828bcbe8bb345156cb7620001d41f2b7ddf3b0793d2e2ffca632af22aa08f7", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "start_char_idx": 0, "end_char_idx": 1233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d63250a0-a804-40f4-a00e-e3b3edc4bbb1": {"__data__": {"id_": "d63250a0-a804-40f4-a00e-e3b3edc4bbb1", "embedding": null, "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a64808f1-ce11-4767-afc4-6e88c2c164b5", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc93b06f797f26d56a749773f34b0c815de15e6f9e99b86a90708fd8c835671c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36abdebd-05c0-4af3-823c-2772d35babde", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "page_label": "12", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dc03bd6ca9686a83c160d5bc8f1fd266107433f5170bc4e651a5812ddf9dd2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de2166dc-cf5e-4f9b-9baf-bc5b71618542", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n"}, "hash": "75f9c4ea0ba3d9044591ec5eca7dede327d74353951ff277d5bb48323133dc6e", "class_name": "RelatedNodeInfo"}}, "text": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0", "start_char_idx": 0, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de2166dc-cf5e-4f9b-9baf-bc5b71618542": {"__data__": {"id_": "de2166dc-cf5e-4f9b-9baf-bc5b71618542", "embedding": null, "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a64808f1-ce11-4767-afc4-6e88c2c164b5", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc93b06f797f26d56a749773f34b0c815de15e6f9e99b86a90708fd8c835671c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d63250a0-a804-40f4-a00e-e3b3edc4bbb1", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a55f3d3c88f8ec4c66f70df6ee63feaec9cff58e0ad7037041770937db7b78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5239d60e-7297-480c-ac45-91427851d131", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "CENC ORA, INC.\n"}, "hash": "47c8cfbfdbb2b9e74dc4d717c1a4fb0864341477764eb3a54f188e3840fd62b6", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "start_char_idx": 240, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5239d60e-7297-480c-ac45-91427851d131": {"__data__": {"id_": "5239d60e-7297-480c-ac45-91427851d131", "embedding": null, "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "CENC ORA, INC.\n", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a64808f1-ce11-4767-afc4-6e88c2c164b5", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc93b06f797f26d56a749773f34b0c815de15e6f9e99b86a90708fd8c835671c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de2166dc-cf5e-4f9b-9baf-bc5b71618542", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77f21207e36e2046c78435341c0fa47088fa171cb88031f9e154fcce0b40e546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e1f72e8-287f-4621-8640-7bcc5a846d21", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13"}, "hash": "588a5e761802641c8b35207ae8df428eb713f667cb10776d5e839511ce5b9d1f", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 418, "end_char_idx": 433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e1f72e8-287f-4621-8640-7bcc5a846d21": {"__data__": {"id_": "5e1f72e8-287f-4621-8640-7bcc5a846d21", "embedding": null, "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a64808f1-ce11-4767-afc4-6e88c2c164b5", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc93b06f797f26d56a749773f34b0c815de15e6f9e99b86a90708fd8c835671c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5239d60e-7297-480c-ac45-91427851d131", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "CENC ORA, INC.\n", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a202b4d514d03b6c872c35c99ff7b4251e4268cc12fed0a83a5c08a7c3f86be7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "344f3c9e-c857-4ca1-af9e-5bb42e9988e1", "node_type": "1", "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n"}, "hash": "3e02ad2e1a0242116d079b2ccdf645542d94bad90bb1f7fa60f5a934974fdb95", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "start_char_idx": 433, "end_char_idx": 1391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "344f3c9e-c857-4ca1-af9e-5bb42e9988e1": {"__data__": {"id_": "344f3c9e-c857-4ca1-af9e-5bb42e9988e1", "embedding": null, "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n", "page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44dcd1ff-0364-46a7-bd0c-532862c300d1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c83e944cdcf5da1a31fba29023f3ec83d4f44e99608767b52a67b40d6bd6c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e1f72e8-287f-4621-8640-7bcc5a846d21", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56ee51f20c2bb30f3540441ae3fc2ad2a8b8d18fb5115e6f0866557dfc441125", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83a5d413-dfb1-4825-a3b4-befd27c3333c", "node_type": "1", "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n"}, "hash": "45e5386faad2643428f85271a6682376b09daca8413e115984ccd8a4f8873ed7", "class_name": "RelatedNodeInfo"}}, "text": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n", "start_char_idx": 0, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83a5d413-dfb1-4825-a3b4-befd27c3333c": {"__data__": {"id_": "83a5d413-dfb1-4825-a3b4-befd27c3333c", "embedding": null, "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n", "page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44dcd1ff-0364-46a7-bd0c-532862c300d1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c83e944cdcf5da1a31fba29023f3ec83d4f44e99608767b52a67b40d6bd6c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "344f3c9e-c857-4ca1-af9e-5bb42e9988e1", "node_type": "1", "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n", "page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e167016aa2d3f3d1f2bdf78b293040ce3d25af01464b31a74346f9c461160e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca1450bb-9c9e-44b6-bd2a-44ca6393b899", "node_type": "1", "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "14"}, "hash": "a98e8b77d10171abb9233e896d6aa37fe635e55c06ab8a4a54ad4fdd4c1b7624", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n", "start_char_idx": 890, "end_char_idx": 1398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca1450bb-9c9e-44b6-bd2a-44ca6393b899": {"__data__": {"id_": "ca1450bb-9c9e-44b6-bd2a-44ca6393b899", "embedding": null, "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "14", "page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44dcd1ff-0364-46a7-bd0c-532862c300d1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c83e944cdcf5da1a31fba29023f3ec83d4f44e99608767b52a67b40d6bd6c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83a5d413-dfb1-4825-a3b4-befd27c3333c", "node_type": "1", "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n", "page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dc59b07973ccbf7be629f32466ad1eaeaac4ba7bb44cba6e8b92aec46da27ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07bfa497-0b82-4bf5-901a-d5ff6134bafd", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n", "original_text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n"}, "hash": "51311cd0c888e501095743c80e63df192a71f45fb8b4f86b3e96e7472cdff2e1", "class_name": "RelatedNodeInfo"}}, "text": "14", "start_char_idx": 54, "end_char_idx": 56, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07bfa497-0b82-4bf5-901a-d5ff6134bafd": {"__data__": {"id_": "07bfa497-0b82-4bf5-901a-d5ff6134bafd", "embedding": null, "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n", "original_text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0574292ee49041e7a582cda4b60844a1afefafeb2300944fee690297f0a77aa0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca1450bb-9c9e-44b6-bd2a-44ca6393b899", "node_type": "1", "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "14", "page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69af90c935332dce13352912010e5c4767f0e08a91158266732e560093551b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fccc8ee0-ab94-4244-8a72-a07038f24310", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0"}, "hash": "8fd3b6c4a498a1fd7313b64e9df87f8cdd98565eb7a08b2dca0d300ff883346e", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n", "start_char_idx": 0, "end_char_idx": 338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fccc8ee0-ab94-4244-8a72-a07038f24310": {"__data__": {"id_": "fccc8ee0-ab94-4244-8a72-a07038f24310", "embedding": null, "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0574292ee49041e7a582cda4b60844a1afefafeb2300944fee690297f0a77aa0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07bfa497-0b82-4bf5-901a-d5ff6134bafd", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n", "original_text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0f0089389f1ca06429286903b44f2fa075ecb4b83a4faf095d0db0d4d38a055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c434626-4aab-46a5-be8e-2d51619ce329", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n"}, "hash": "096c2d533005e65f34e5040b841b8d7cb6616cf666fbcd992fba2619a837bb88", "class_name": "RelatedNodeInfo"}}, "text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "start_char_idx": 338, "end_char_idx": 408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c434626-4aab-46a5-be8e-2d51619ce329": {"__data__": {"id_": "6c434626-4aab-46a5-be8e-2d51619ce329", "embedding": null, "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0574292ee49041e7a582cda4b60844a1afefafeb2300944fee690297f0a77aa0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fccc8ee0-ab94-4244-8a72-a07038f24310", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f070ecd4441e14c6b568566f211b6f3fe33b9c66c746215eb3e9e7e7662da4b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbd1f504-8904-479e-9f43-9317e563c650", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "CENC ORA, INC.\n"}, "hash": "7ed21758f03388b88853a723e9b72654e315391b526e023b9f2c76977882385b", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "start_char_idx": 408, "end_char_idx": 586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbd1f504-8904-479e-9f43-9317e563c650": {"__data__": {"id_": "dbd1f504-8904-479e-9f43-9317e563c650", "embedding": null, "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "CENC ORA, INC.\n", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0574292ee49041e7a582cda4b60844a1afefafeb2300944fee690297f0a77aa0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c434626-4aab-46a5-be8e-2d51619ce329", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04edf3672412a3e232e1d3fe446d365faadd45e1879e179f8f3f422d964a1c62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d24d70b-2911-454c-b568-d2de6b5dfb58", "node_type": "1", "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15"}, "hash": "83f03a2adf988fe3b5f1cd81fb4230856825b660cee62bb2e70416b11f0b314f", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 586, "end_char_idx": 601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d24d70b-2911-454c-b568-d2de6b5dfb58": {"__data__": {"id_": "1d24d70b-2911-454c-b568-d2de6b5dfb58", "embedding": null, "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0574292ee49041e7a582cda4b60844a1afefafeb2300944fee690297f0a77aa0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbd1f504-8904-479e-9f43-9317e563c650", "node_type": "1", "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "CENC ORA, INC.\n", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9c029af587f5ea2744397cc2f6609138e4613491b9e334a26a5a488ee1e66f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "323e347a-14d2-4fb4-885c-864b3222648e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n"}, "hash": "76786f1b8b57ef65904e9bd7dce3b42fe1cd8db22b61e66f632eb1795634b394", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "start_char_idx": 601, "end_char_idx": 1651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "323e347a-14d2-4fb4-885c-864b3222648e": {"__data__": {"id_": "323e347a-14d2-4fb4-885c-864b3222648e", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d424d89-7111-4b99-9ca1-4cedb48c0000", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12bb51529fd9863bd00d4064dadd737cd1584c535afcfd2c54a50b40a55e02b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d24d70b-2911-454c-b568-d2de6b5dfb58", "node_type": "1", "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n \nExpense \u00a0Net Income \n  \nAttributable \n \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$4,441,395 \u00a0\u00a0$3,247,733 \u00a0\u00a0$1,193,662 \u00a0\u00a0$1,105,585 \u00a0\u00a0$201,202 \u00a0\u00a0$915,147 \u00a0\u00a0$4.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,657 )\u00a0\u00a0(38,242 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a079,320 \u00a0\u00a0\u00a018,529 \u00a0\u00a0\u00a060,791 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a08,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,439 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,441 \u00a0\u00a0\u00a00.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles amortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(211,992 )\u00a0\u00a0211,992 \u00a0\u00a0\u00a0211,992 \u00a0\u00a0\u00a049,522 \u00a0\u00a0\u00a0160,328 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(28,519 )\u00a0\u00a028,519 \u00a0\u00a0\u00a028,519 \u00a0\u00a0\u00a06,662 \u00a0\u00a0\u00a021,857 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b49cafc90e285c5ca24e049deba5c560fd0377c139f7a2c1407f378885c39f2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5885b961-6701-4602-9179-c63488e128ad", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "2The sum of the components does not equal the total due to rounding.\n"}, "hash": "d009ae6298df110e81b425f541ed94c4d6ba9e12d3ae3dd28606f555c6e781ee", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n", "start_char_idx": 0, "end_char_idx": 1043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5885b961-6701-4602-9179-c63488e128ad": {"__data__": {"id_": "5885b961-6701-4602-9179-c63488e128ad", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "2The sum of the components does not equal the total due to rounding.\n", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d424d89-7111-4b99-9ca1-4cedb48c0000", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12bb51529fd9863bd00d4064dadd737cd1584c535afcfd2c54a50b40a55e02b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "323e347a-14d2-4fb4-885c-864b3222648e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80b33e580b843072e8b3279df435b5d84fc4669b6e2d78173265aba9df2180f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b52a2e02-9571-400e-b9cf-4ea086eef033", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n"}, "hash": "6a5abf1b0a534f30f3b747ace66f45327bca7a0866861d61703ce442bf2ce9cb", "class_name": "RelatedNodeInfo"}}, "text": "2The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 1043, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b52a2e02-9571-400e-b9cf-4ea086eef033": {"__data__": {"id_": "b52a2e02-9571-400e-b9cf-4ea086eef033", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d424d89-7111-4b99-9ca1-4cedb48c0000", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12bb51529fd9863bd00d4064dadd737cd1584c535afcfd2c54a50b40a55e02b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5885b961-6701-4602-9179-c63488e128ad", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "2The sum of the components does not equal the total due to rounding.\n", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "589d5f2b7e4018e40117c76e0afabdcac93c8a3ba3cab7e7b737b9451fba6a8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb86db53-c9f2-48d3-a099-9179eaf88550", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "16"}, "hash": "fb1c00c4cfca6057f01e2d0633ad5ce046729e72c63145d00fc0813ca98eec39", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "start_char_idx": 1112, "end_char_idx": 1290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb86db53-c9f2-48d3-a099-9179eaf88550": {"__data__": {"id_": "cb86db53-c9f2-48d3-a099-9179eaf88550", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "16", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d424d89-7111-4b99-9ca1-4cedb48c0000", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12bb51529fd9863bd00d4064dadd737cd1584c535afcfd2c54a50b40a55e02b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b52a2e02-9571-400e-b9cf-4ea086eef033", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e62215774ee007ee5f5814d39e877130265dfc020195c2884968311cb8acd610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1248432-5856-4eda-add8-cfc0e1dc19ed", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "CENC ORA, INC.\n"}, "hash": "704a624fa321dac8ed04753bf750ba1f3f5af1bf27cb20e4015d47568148ab97", "class_name": "RelatedNodeInfo"}}, "text": "16", "start_char_idx": 1290, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1248432-5856-4eda-add8-cfc0e1dc19ed": {"__data__": {"id_": "b1248432-5856-4eda-add8-cfc0e1dc19ed", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "CENC ORA, INC.\n", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43aee5d8-c5c7-4b62-a8c8-604ff2579d97", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f64c395453d1f0df0ccbb37c69fcea6a61d69c22d1ba49777258b4009e6239d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb86db53-c9f2-48d3-a099-9179eaf88550", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "16", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ab2f32edb2a54f95f9813206541c20e7e078541a74f0fe6a8251fceb09d08d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49509dfe-ea7f-4ec7-adca-1f7e9514116a", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. "}, "hash": "3d15a96a0643f6e0ac012a0b1589216abe2187b011aa1cae9e888b161ade9f78", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 15, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49509dfe-ea7f-4ec7-adca-1f7e9514116a": {"__data__": {"id_": "49509dfe-ea7f-4ec7-adca-1f7e9514116a", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43aee5d8-c5c7-4b62-a8c8-604ff2579d97", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f64c395453d1f0df0ccbb37c69fcea6a61d69c22d1ba49777258b4009e6239d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1248432-5856-4eda-add8-cfc0e1dc19ed", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "CENC ORA, INC.\n", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01aa20b6916f93325462f8be85e6a00884fd0e24ced91407a287a0089a77495a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8634038e-b6f3-454e-9237-ce0f1a06bb42", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. "}, "hash": "f2b0dfeef973c77f782199c9c14c2cad546ab457ea38cfeff27ba91721f7fd08", "class_name": "RelatedNodeInfo"}}, "text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 15, "end_char_idx": 146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8634038e-b6f3-454e-9237-ce0f1a06bb42": {"__data__": {"id_": "8634038e-b6f3-454e-9237-ce0f1a06bb42", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43aee5d8-c5c7-4b62-a8c8-604ff2579d97", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f64c395453d1f0df0ccbb37c69fcea6a61d69c22d1ba49777258b4009e6239d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49509dfe-ea7f-4ec7-adca-1f7e9514116a", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bef2194c7537efb46ca60281f74f468f429fd658f3787bbea7bdd03aa91f094c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ab4ed94-55ac-465e-816e-a0fa4f05c5bb", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17"}, "hash": "0aedae516315d65fcb5f8198f37e7e0f8a8d23353de64f0ffe0c299ea466d9ac", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 146, "end_char_idx": 451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ab4ed94-55ac-465e-816e-a0fa4f05c5bb": {"__data__": {"id_": "4ab4ed94-55ac-465e-816e-a0fa4f05c5bb", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43aee5d8-c5c7-4b62-a8c8-604ff2579d97", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f64c395453d1f0df0ccbb37c69fcea6a61d69c22d1ba49777258b4009e6239d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8634038e-b6f3-454e-9237-ce0f1a06bb42", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36217b27a2349c5d52f191a9edb2940ce9a06ed21bbbe5912976b2d6391ab99e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13755b78-9a87-4904-a574-70c04906a7f5", "node_type": "1", "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "43238d24c17965dd87ab6c46acbfaf6860b5d72213e8e9ebd386d14109b443da", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "start_char_idx": 451, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13755b78-9a87-4904-a574-70c04906a7f5": {"__data__": {"id_": "13755b78-9a87-4904-a574-70c04906a7f5", "embedding": null, "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c035101ace6c4abfcc3cd4032c01a9a87edbe8f1ecf69cb8cfc15dfaeadb014", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ab4ed94-55ac-465e-816e-a0fa4f05c5bb", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4db21522a25d322aa74206a1989444a3f944df40ba1c8eecb326fac434e2f90c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8abd9258-016c-4ec1-9a9d-7445abfd3ebe", "node_type": "1", "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "cbc6cad4c5c4e6ab016e8838ae589878cfe9909eced5e587055bf5ea6af30887", "class_name": "RelatedNodeInfo"}}, "text": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8abd9258-016c-4ec1-9a9d-7445abfd3ebe": {"__data__": {"id_": "8abd9258-016c-4ec1-9a9d-7445abfd3ebe", "embedding": null, "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c035101ace6c4abfcc3cd4032c01a9a87edbe8f1ecf69cb8cfc15dfaeadb014", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13755b78-9a87-4904-a574-70c04906a7f5", "node_type": "1", "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94c769a6994a8fcc81af6ed39e18c0ebbcef9864c8cfd0d5c00d5046f525af79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c7b3d39-ee49-407a-afa7-c2f1e55f4956", "node_type": "1", "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "19ebf83e21306d5ba4ffb04911b66e8bef209b851e21f40f67eadff2426c9cf2", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 108, "end_char_idx": 432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c7b3d39-ee49-407a-afa7-c2f1e55f4956": {"__data__": {"id_": "6c7b3d39-ee49-407a-afa7-c2f1e55f4956", "embedding": null, "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c035101ace6c4abfcc3cd4032c01a9a87edbe8f1ecf69cb8cfc15dfaeadb014", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8abd9258-016c-4ec1-9a9d-7445abfd3ebe", "node_type": "1", "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9dd0e7b67e8365e09c1d07c9c92d84b70b7a903c06f8249ae719427101a37c50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edd09976-3685-492d-92be-329add1ad645", "node_type": "1", "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "aca5a2a5361f707f7071dabb55f8fe2de46294debd8ae4e5fb15275d5687a3d7", "class_name": "RelatedNodeInfo"}}, "text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 432, "end_char_idx": 579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edd09976-3685-492d-92be-329add1ad645": {"__data__": {"id_": "edd09976-3685-492d-92be-329add1ad645", "embedding": null, "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c035101ace6c4abfcc3cd4032c01a9a87edbe8f1ecf69cb8cfc15dfaeadb014", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c7b3d39-ee49-407a-afa7-c2f1e55f4956", "node_type": "1", "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67364bce7cb7fbf5a6cc014d9ccd7319fb80972a52303a966f829d5b2aad0ddf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b66b757-01b3-4f4e-bdd5-fce7d4b6eab2", "node_type": "1", "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "18"}, "hash": "64052ea2548ad477a43bd6721c90cc1d700a1317002a627ba532f54fae95f4ce", "class_name": "RelatedNodeInfo"}}, "text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 579, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b66b757-01b3-4f4e-bdd5-fce7d4b6eab2": {"__data__": {"id_": "9b66b757-01b3-4f4e-bdd5-fce7d4b6eab2", "embedding": null, "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c035101ace6c4abfcc3cd4032c01a9a87edbe8f1ecf69cb8cfc15dfaeadb014", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edd09976-3685-492d-92be-329add1ad645", "node_type": "1", "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76c665a91714b06edec87c89217da92fc2e758d3d0bfa17b256da3f2b92c4438", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8234117-73cf-4f20-9e15-820e83dad97a", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "CENC ORA, INC.\n"}, "hash": "62abef736d853e66fc19e51a096360b1ce3edd7291afc54a003ebc0a2d97232d", "class_name": "RelatedNodeInfo"}}, "text": "18", "start_char_idx": 909, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8234117-73cf-4f20-9e15-820e83dad97a": {"__data__": {"id_": "d8234117-73cf-4f20-9e15-820e83dad97a", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "CENC ORA, INC.\n", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d75023b3-9659-451e-a937-7277b012911b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2f4f6e8ff09fa481a1809cf76bb88b5f5bf10df8a1ef9a455b8eaa819062f42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b66b757-01b3-4f4e-bdd5-fce7d4b6eab2", "node_type": "1", "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7afc3637ceb96d74d05edac63e5a42d1140d9adee0784d9f1e3fcfcbae18fa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a989f9e9-5479-4b59-b639-5d7495d49766", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. "}, "hash": "5704867c3aa6c228d2af504783e9f570a2cb6201d40d020afff6feccf537e484", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 15, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a989f9e9-5479-4b59-b639-5d7495d49766": {"__data__": {"id_": "a989f9e9-5479-4b59-b639-5d7495d49766", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d75023b3-9659-451e-a937-7277b012911b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2f4f6e8ff09fa481a1809cf76bb88b5f5bf10df8a1ef9a455b8eaa819062f42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8234117-73cf-4f20-9e15-820e83dad97a", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "CENC ORA, INC.\n", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfc05ed32d349a3be8677d9a5c877342a1cd88ad3c53733bb34ef0f260eca1a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f67c9f5-ad18-4ba6-bf90-e459cad69656", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. "}, "hash": "0bec7db8e8094b744abb2fd48480e8f3495313e23fe50d1a1a00d8d7cb0567d2", "class_name": "RelatedNodeInfo"}}, "text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 15, "end_char_idx": 144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f67c9f5-ad18-4ba6-bf90-e459cad69656": {"__data__": {"id_": "5f67c9f5-ad18-4ba6-bf90-e459cad69656", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d75023b3-9659-451e-a937-7277b012911b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2f4f6e8ff09fa481a1809cf76bb88b5f5bf10df8a1ef9a455b8eaa819062f42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a989f9e9-5479-4b59-b639-5d7495d49766", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdb7ffa65512df1e22e86641146c40230be198db5eecd36576b3dc3bc38c0162", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59aae726-591c-4939-b3a6-f027d846dbb8", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19"}, "hash": "38e4561209d5c58e7b2213cdc467003f516beeaa52c7ba8ab2cf9b7eb53c20e0", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 144, "end_char_idx": 455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59aae726-591c-4939-b3a6-f027d846dbb8": {"__data__": {"id_": "59aae726-591c-4939-b3a6-f027d846dbb8", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d75023b3-9659-451e-a937-7277b012911b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2f4f6e8ff09fa481a1809cf76bb88b5f5bf10df8a1ef9a455b8eaa819062f42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f67c9f5-ad18-4ba6-bf90-e459cad69656", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f45517836c355be8d007c8c02ae491f54328bbed0d7f5586764069826fcce33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb88628b-c38a-4a91-81d3-d269d60b5bae", "node_type": "1", "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "fd29f28cc471986fbefe837467a3594ab702f764cdf4bc36e4cd298e2ab82800", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "start_char_idx": 455, "end_char_idx": 1098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb88628b-c38a-4a91-81d3-d269d60b5bae": {"__data__": {"id_": "fb88628b-c38a-4a91-81d3-d269d60b5bae", "embedding": null, "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d3b1f70a4132f4c139d295cce97d883481aaa154c7c0b523ec1f41dc0bd846", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59aae726-591c-4939-b3a6-f027d846dbb8", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3cf09a2a73da83ac10c72ddc8ff991435581cef1318dce3fcf244826a7ba8feb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d541ec1-f767-44a8-8bc3-4939535a7e6d", "node_type": "1", "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "e34c8f251d3ff1841e2255af2e996e48f365cf0627c7a84d2c9a1cecc57b7ebf", "class_name": "RelatedNodeInfo"}}, "text": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d541ec1-f767-44a8-8bc3-4939535a7e6d": {"__data__": {"id_": "3d541ec1-f767-44a8-8bc3-4939535a7e6d", "embedding": null, "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d3b1f70a4132f4c139d295cce97d883481aaa154c7c0b523ec1f41dc0bd846", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb88628b-c38a-4a91-81d3-d269d60b5bae", "node_type": "1", "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95ea59e806fa221c9d4034cef0830977112b0e2c286e4cb76f5c5192431a51e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7679600a-783f-40f7-8275-a94e8782dd0e", "node_type": "1", "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "d25492b92d2ec5b32b469f8d2484cfabfe07af77957583bb060c65fdbb932744", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 111, "end_char_idx": 435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7679600a-783f-40f7-8275-a94e8782dd0e": {"__data__": {"id_": "7679600a-783f-40f7-8275-a94e8782dd0e", "embedding": null, "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d3b1f70a4132f4c139d295cce97d883481aaa154c7c0b523ec1f41dc0bd846", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d541ec1-f767-44a8-8bc3-4939535a7e6d", "node_type": "1", "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "040da511a82d6959f335a2fd8379dc18a8aabae78c5eb9b2a171e26895deabea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adf1e957-9e22-47bd-9d43-e5d9b986f47f", "node_type": "1", "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "30d60de162b59dba9fa1ef03e47e8fd4532ce25e76824beba3a6a27b3c58422d", "class_name": "RelatedNodeInfo"}}, "text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 435, "end_char_idx": 582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adf1e957-9e22-47bd-9d43-e5d9b986f47f": {"__data__": {"id_": "adf1e957-9e22-47bd-9d43-e5d9b986f47f", "embedding": null, "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d3b1f70a4132f4c139d295cce97d883481aaa154c7c0b523ec1f41dc0bd846", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7679600a-783f-40f7-8275-a94e8782dd0e", "node_type": "1", "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94b769c1cbc59cc456cfb7454aa8629ad3042f0721b0f927d419a0f7a239b74f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90bf1d69-2c23-450f-8244-1a0825974db4", "node_type": "1", "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "20"}, "hash": "7c70672a47accc4d76cc589eb3f530c9692ad11056683f2733f58b1f1f81745a", "class_name": "RelatedNodeInfo"}}, "text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 582, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90bf1d69-2c23-450f-8244-1a0825974db4": {"__data__": {"id_": "90bf1d69-2c23-450f-8244-1a0825974db4", "embedding": null, "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "20", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d3b1f70a4132f4c139d295cce97d883481aaa154c7c0b523ec1f41dc0bd846", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adf1e957-9e22-47bd-9d43-e5d9b986f47f", "node_type": "1", "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ac552261a1e0b70e9bb50f0846ccef61d0dda90d34750a0721c411ad3f18211", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea029605-e0f1-4560-93a6-c9727b3ead62", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "original_text": "CENC ORA, INC.\n"}, "hash": "7f09896054e406db5c6df0c5ba94fd489762b8b2040632cbf7d936c92ef85893", "class_name": "RelatedNodeInfo"}}, "text": "20", "start_char_idx": 912, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea029605-e0f1-4560-93a6-c9727b3ead62": {"__data__": {"id_": "ea029605-e0f1-4560-93a6-c9727b3ead62", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "original_text": "CENC ORA, INC.\n", "page_label": "21", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a43e8e71-79fa-4b67-adb9-9940cbdf3796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc1cabd8b03d7b914631272602798dbff9db1552e4286e71de58dae27f471e7a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90bf1d69-2c23-450f-8244-1a0825974db4", "node_type": "1", "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 20", "original_text": "20", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57ab279b0cc8039d4c98f93ae0e1b956dc3cdb767d8c82264b61e76ba9d0badb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb0c7c81-0331-4337-ad99-2f36ae5ed01b", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21"}, "hash": "5385bb58458200e23a85b88db9203629ad2d8620ea900dda52307a74967d095d", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 15, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb0c7c81-0331-4337-ad99-2f36ae5ed01b": {"__data__": {"id_": "eb0c7c81-0331-4337-ad99-2f36ae5ed01b", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a43e8e71-79fa-4b67-adb9-9940cbdf3796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc1cabd8b03d7b914631272602798dbff9db1552e4286e71de58dae27f471e7a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea029605-e0f1-4560-93a6-c9727b3ead62", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "original_text": "CENC ORA, INC.\n", "page_label": "21", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7343582e20c378284be68bed983a213f6f764fb77afdbc61767d806107b55be3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f30083e6-7521-4056-8655-3ef7e4ea7a6f", "node_type": "1", "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "original_text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n"}, "hash": "e9b8b8be7bb71866da8fa6edd6eff90b72711380a52e8689b350af242cc32ff6", "class_name": "RelatedNodeInfo"}}, "text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "start_char_idx": 15, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f30083e6-7521-4056-8655-3ef7e4ea7a6f": {"__data__": {"id_": "f30083e6-7521-4056-8655-3ef7e4ea7a6f", "embedding": null, "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "original_text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n", "page_label": "22", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c21ab07-b6aa-4446-a340-ad76849162db", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "119340a7b649da8e27a2a5ee29bdb85ab35bd794b352dfe29fc9be5bb00a2de9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb0c7c81-0331-4337-ad99-2f36ae5ed01b", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8aea21e157873b552730fe0511f3c53832fa702b85c0b23772d463ab4bcfd23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6603e679-dc64-4f96-9cf1-c2178a611e2a", "node_type": "1", "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22"}, "hash": "31093ba81a11e4a90bba0349be052b887eee4f1bc9cc72498164d1cc82202370", "class_name": "RelatedNodeInfo"}}, "text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6603e679-dc64-4f96-9cf1-c2178a611e2a": {"__data__": {"id_": "6603e679-dc64-4f96-9cf1-c2178a611e2a", "embedding": null, "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "page_label": "22", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c21ab07-b6aa-4446-a340-ad76849162db", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "119340a7b649da8e27a2a5ee29bdb85ab35bd794b352dfe29fc9be5bb00a2de9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f30083e6-7521-4056-8655-3ef7e4ea7a6f", "node_type": "1", "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "original_text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n", "page_label": "22", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8bac4d85d2f1bae4c0cfd213dad4476b462143406a44a899f65686b096da4607", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59d48b6e-9b4d-434e-bac2-03457f655ea8", "node_type": "1", "metadata": {"window": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23", "original_text": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23"}, "hash": "204a44c2bcb0d571725e5a27ce79d2cb5f043b0b95cd15ac9a6d845dc1423d68", "class_name": "RelatedNodeInfo"}}, "text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "start_char_idx": 571, "end_char_idx": 763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59d48b6e-9b4d-434e-bac2-03457f655ea8": {"__data__": {"id_": "59d48b6e-9b4d-434e-bac2-03457f655ea8", "embedding": null, "metadata": {"window": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23", "original_text": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23", "page_label": "23", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eba6faba-975d-4de3-87ed-925a72c0253f", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4899bc33ea600779656e50760068c6b0c08a4590ef3a857a14b87ff0485a2cde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6603e679-dc64-4f96-9cf1-c2178a611e2a", "node_type": "1", "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "page_label": "22", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5ffc651a6050384f20fd89f0ee487a2bbbd8617bfa31ae53105d57a7e1b7019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b0b8ba9-8d8e-4369-a420-f3487e19c0a9", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n"}, "hash": "767b69aada80965b70737e7298f4cc33889bedfd5234f1ceaaf7a917a7b2ab41", "class_name": "RelatedNodeInfo"}}, "text": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23", "start_char_idx": 0, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b0b8ba9-8d8e-4369-a420-f3487e19c0a9": {"__data__": {"id_": "3b0b8ba9-8d8e-4369-a420-f3487e19c0a9", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59d48b6e-9b4d-434e-bac2-03457f655ea8", "node_type": "1", "metadata": {"window": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23", "original_text": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23", "page_label": "23", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aec5fe19b078de49def676c3d3deb4a87a33c14d01532c5970ed69daf8f93462", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41d5c42a-4114-4f32-8ad0-2ca7cda0db2f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n"}, "hash": "6d9d6853b3581f8d9a4dd3c7676395f677efb553cad7028feab0cd9f9d2c581c", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n", "start_char_idx": 0, "end_char_idx": 320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41d5c42a-4114-4f32-8ad0-2ca7cda0db2f": {"__data__": {"id_": "41d5c42a-4114-4f32-8ad0-2ca7cda0db2f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b0b8ba9-8d8e-4369-a420-f3487e19c0a9", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63a103036a7ef3dd5b5a6bd0d91f606b9eca3d50d84f75284a88c899e8a6ba27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6df7724-3802-455f-9bcd-b76e47bd6c39", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "dd187d706175190c338f5286a1d09e56972f48add19484c8f10305f44759062d", "class_name": "RelatedNodeInfo"}}, "text": "2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "start_char_idx": 320, "end_char_idx": 410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6df7724-3802-455f-9bcd-b76e47bd6c39": {"__data__": {"id_": "b6df7724-3802-455f-9bcd-b76e47bd6c39", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41d5c42a-4114-4f32-8ad0-2ca7cda0db2f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a000a302f1b6fd8518e45e9f3dc1ec757b75a95b5fdea3f87c5f16e3af4f52d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c62ee8d8-fee2-4bdb-9ef8-9390d874132a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "0778465b4d939c8e2fe4fa713931eadcb4090864d1c4b237900d74642ddb6aa7", "class_name": "RelatedNodeInfo"}}, "text": "3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 410, "end_char_idx": 1207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c62ee8d8-fee2-4bdb-9ef8-9390d874132a": {"__data__": {"id_": "c62ee8d8-fee2-4bdb-9ef8-9390d874132a", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6df7724-3802-455f-9bcd-b76e47bd6c39", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "980cf26754867149abd7276b21a7b13c8dbcd5ed84aa8e6bb345fba57cd45355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e9b370f-b836-4913-b79c-34d778ed88be", "node_type": "1", "metadata": {"window": "2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "668927fc47a883dae4709f536f8e6ac829a48b00ddd2233b3b66f7f645d61dde", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1207, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e9b370f-b836-4913-b79c-34d778ed88be": {"__data__": {"id_": "9e9b370f-b836-4913-b79c-34d778ed88be", "embedding": null, "metadata": {"window": "2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c62ee8d8-fee2-4bdb-9ef8-9390d874132a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcb0a158bc221a11439499b5d7c72636b579b4b737f378c5da4a7d62a129387a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8b5b899-ab43-4ef6-9ab8-6ae21a16ef00", "node_type": "1", "metadata": {"window": "3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "19593a2faeee0f2670d531a0f342884233cd55d5aecf404cc4d916a95cb32493", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1322, "end_char_idx": 1462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8b5b899-ab43-4ef6-9ab8-6ae21a16ef00": {"__data__": {"id_": "d8b5b899-ab43-4ef6-9ab8-6ae21a16ef00", "embedding": null, "metadata": {"window": "3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e9b370f-b836-4913-b79c-34d778ed88be", "node_type": "1", "metadata": {"window": "2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d713b7c4a7d2c7113ea95bba17cd15aede2119c5bb3412a948647a60e654cad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21862e34-08f6-48c9-a10b-6f494a57322f", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "f6808cecc482b88b2966bb0b582ccaf6ab77345afea6cfe5ad6911100cd2bdfa", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1462, "end_char_idx": 1581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21862e34-08f6-48c9-a10b-6f494a57322f": {"__data__": {"id_": "21862e34-08f6-48c9-a10b-6f494a57322f", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8b5b899-ab43-4ef6-9ab8-6ae21a16ef00", "node_type": "1", "metadata": {"window": "3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c9e5b54aa5c5cc376279b458c2e13824b7369ae2267565d916133e9800f04a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba9120c-5bc8-45cd-8a19-950f98ce3834", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "7311569e871cd6864f11a77a931bf738c187335d924d2abc0bde33574e3ef75e", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 1581, "end_char_idx": 1800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aba9120c-5bc8-45cd-8a19-950f98ce3834": {"__data__": {"id_": "aba9120c-5bc8-45cd-8a19-950f98ce3834", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21862e34-08f6-48c9-a10b-6f494a57322f", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc098f1e63766f5de3f7a564000e012bdfb5c871ad830c236de0709a9899a0d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57dfe59e-c719-4d39-994e-4cb4e2eb0241", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "7de8b3843c873d0cdca00146e7c9927ed622db5a01efb217e5757c849032677a", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1800, "end_char_idx": 1982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57dfe59e-c719-4d39-994e-4cb4e2eb0241": {"__data__": {"id_": "57dfe59e-c719-4d39-994e-4cb4e2eb0241", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aba9120c-5bc8-45cd-8a19-950f98ce3834", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86238e93fef071b35ef08038ee657952fec37b431a20d7037ec560ac1763d7bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba07c8b6-9276-4e06-9da8-f1c5a9085293", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24"}, "hash": "e49757d33f20c9c5812cdfbcb46f4a87a346f123bcb5bdee355f14e206aec205", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1982, "end_char_idx": 2263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba07c8b6-9276-4e06-9da8-f1c5a9085293": {"__data__": {"id_": "ba07c8b6-9276-4e06-9da8-f1c5a9085293", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44648c52-62c2-495b-ae28-ed91b0616f28", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6948e042cabccfe6c4e15ed3ca2899160975c1c3f669123691ccd607d72332c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57dfe59e-c719-4d39-994e-4cb4e2eb0241", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ee86740c7468dfb0ac38ae7d37445913a5cf95d7f8a15502870925430fb81c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf02d00d-77f9-4468-be64-8b0c3fe3bdfc", "node_type": "1", "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. "}, "hash": "76e3d1ef5ea2da5cf0878d088073b8ed1ac606ee11f3ede56152f48d2f407e64", "class_name": "RelatedNodeInfo"}}, "text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "start_char_idx": 2263, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf02d00d-77f9-4468-be64-8b0c3fe3bdfc": {"__data__": {"id_": "cf02d00d-77f9-4468-be64-8b0c3fe3bdfc", "embedding": null, "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba07c8b6-9276-4e06-9da8-f1c5a9085293", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\n24", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91bce829aaf306743120372b7b40ecfffede5aa5fa69b430e63a10ee79dfe633", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c59de0b5-a5d8-4b2f-bb76-755c46f912bc", "node_type": "1", "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. "}, "hash": "08620f2e8ac3a09257c642ab9cff33209f1d2b23af1c600b7576c2a999fefaef", "class_name": "RelatedNodeInfo"}}, "text": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "start_char_idx": 0, "end_char_idx": 107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c59de0b5-a5d8-4b2f-bb76-755c46f912bc": {"__data__": {"id_": "c59de0b5-a5d8-4b2f-bb76-755c46f912bc", "embedding": null, "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf02d00d-77f9-4468-be64-8b0c3fe3bdfc", "node_type": "1", "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21a7943763a3d290ab37bb84295f4f52c72b1dfe910ee2af3e6efc1df4a0678b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7aaf5c77-2e30-48c3-a15a-f9cdd8b6d0bf", "node_type": "1", "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "182755581c3f20db7ffb43e71850e890950d6a927e1351c7f428d99b593aae09", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 107, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7aaf5c77-2e30-48c3-a15a-f9cdd8b6d0bf": {"__data__": {"id_": "7aaf5c77-2e30-48c3-a15a-f9cdd8b6d0bf", "embedding": null, "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c59de0b5-a5d8-4b2f-bb76-755c46f912bc", "node_type": "1", "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92f332b1548bb7aec46bd80d6e89255fc40d2b4c2dd894630195c73611b6ff9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9286bcf7-aa2c-4872-91b9-c2e4cd20e7ee", "node_type": "1", "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses. ", "original_text": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. "}, "hash": "85d4b75c7846f9a6a9d30ed6ae8a7df6745cdae520ccb6e1655a878f24c0a197", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 192, "end_char_idx": 349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9286bcf7-aa2c-4872-91b9-c2e4cd20e7ee": {"__data__": {"id_": "9286bcf7-aa2c-4872-91b9-c2e4cd20e7ee", "embedding": null, "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses. ", "original_text": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7aaf5c77-2e30-48c3-a15a-f9cdd8b6d0bf", "node_type": "1", "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5dd62296ebc32e8fb0351c7a89771685aaef2ef7d737342a11215c105a9a003", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "079946bb-afd5-4114-a16c-5871d77241e5", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "9d24a1dc9da92c4a69c4a340fc4b270a680566aec8bf0accb353b852be0b406b", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "start_char_idx": 349, "end_char_idx": 552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "079946bb-afd5-4114-a16c-5871d77241e5": {"__data__": {"id_": "079946bb-afd5-4114-a16c-5871d77241e5", "embedding": null, "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9286bcf7-aa2c-4872-91b9-c2e4cd20e7ee", "node_type": "1", "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses. ", "original_text": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22a2218cfedc8b344e20ab431ba2c27ac923f01c3aa38b35e91bb072d29d04a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "973eadac-3c08-40b9-a294-c359b57ef066", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n"}, "hash": "6a31a4c449e1e39f112ae75007707062b9eee278d68eab34826db74a6ada2905", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 552, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "973eadac-3c08-40b9-a294-c359b57ef066": {"__data__": {"id_": "973eadac-3c08-40b9-a294-c359b57ef066", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "079946bb-afd5-4114-a16c-5871d77241e5", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c98968e224b6074a796cacb2bffe278894a6d5e4225d815403949aa0328d909c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0190ebf7-c3f1-4459-bb0e-3e712a7ace02", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses. "}, "hash": "8c239c3eb907ec01e24b488651d026ddb7773475fcfc08e882112343c34d4925", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "start_char_idx": 848, "end_char_idx": 1030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0190ebf7-c3f1-4459-bb0e-3e712a7ace02": {"__data__": {"id_": "0190ebf7-c3f1-4459-bb0e-3e712a7ace02", "embedding": null, "metadata": {"window": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "973eadac-3c08-40b9-a294-c359b57ef066", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa0ed4fbeed546edcc098a2ebb575c3fc48fd2da8946f0f6f2c6e0dbe8f91ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb0063c-e567-4aa2-8d7f-7b3eb84814cd", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue. "}, "hash": "a48d289a48c36c1530882a805b9377ad73d8540279f5ca8aadf727a9a16871a4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses. ", "start_char_idx": 1030, "end_char_idx": 1352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb0063c-e567-4aa2-8d7f-7b3eb84814cd": {"__data__": {"id_": "dcb0063c-e567-4aa2-8d7f-7b3eb84814cd", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0190ebf7-c3f1-4459-bb0e-3e712a7ace02", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebfa9c769e00e2c32098a15055568cd742fdbd803a7cca21bab4be3279ce4e07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0e25140-cdf1-43ec-bffd-178ad6461eb0", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. "}, "hash": "5f73100c7d886b2e19b67899c1edd16a1c60d8a08db3753ec43c64bb23d129db", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue. ", "start_char_idx": 1352, "end_char_idx": 1448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0e25140-cdf1-43ec-bffd-178ad6461eb0": {"__data__": {"id_": "d0e25140-cdf1-43ec-bffd-178ad6461eb0", "embedding": null, "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb0063c-e567-4aa2-8d7f-7b3eb84814cd", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05fa810b26b16003ca6e3866261fe09ea534400f7737bccbcf43955ae2f12e80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "976c79d1-5208-4664-aa22-8654951aeac5", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities. "}, "hash": "1643a15fa65383d93cc1ca7afc4c1f678327dc8d959559b3926577efe0fcd4f3", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "start_char_idx": 1448, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "976c79d1-5208-4664-aa22-8654951aeac5": {"__data__": {"id_": "976c79d1-5208-4664-aa22-8654951aeac5", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0e25140-cdf1-43ec-bffd-178ad6461eb0", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd18742f6760112a97e6c7fe8b0ec02f856497ae6b9a1a44ec71c0f8b20bc4a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36e085af-f499-46a7-a672-16990caa79cb", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n"}, "hash": "3f1c2249caf805137ec185a7639584a549e27ed24f51580c7c9aef917979b9b9", "class_name": "RelatedNodeInfo"}}, "text": "W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities. ", "start_char_idx": 1610, "end_char_idx": 1780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36e085af-f499-46a7-a672-16990caa79cb": {"__data__": {"id_": "36e085af-f499-46a7-a672-16990caa79cb", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "976c79d1-5208-4664-aa22-8654951aeac5", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses, net; acquisition-\nrelated deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46f3d0af4cc4c8e58f927e3b8262373c384df63e33d6048db5abbe3b35b4f904", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4eb862f7-9faf-403a-b1c5-ece9293fb333", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "e133dc16138c3e380ca8b5302599ddf5880bbad96ae60490c0034b705e820308", "class_name": "RelatedNodeInfo"}}, "text": "W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "start_char_idx": 1780, "end_char_idx": 2033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4eb862f7-9faf-403a-b1c5-ece9293fb333": {"__data__": {"id_": "4eb862f7-9faf-403a-b1c5-ece9293fb333", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36e085af-f499-46a7-a672-16990caa79cb", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio\nof adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e38894dbae3fbf9e5c945e5c713e076d049bc7a42113403c0dfa00325b20d48b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc477a0-e974-4586-9a95-1feb6b4d1c5e", "node_type": "1", "metadata": {"window": "W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "30985457a86c5d859273c0271db4e4af4d75c604a871910675dde07bbd4436fd", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 2033, "end_char_idx": 2282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc477a0-e974-4586-9a95-1feb6b4d1c5e": {"__data__": {"id_": "dfc477a0-e974-4586-9a95-1feb6b4d1c5e", "embedding": null, "metadata": {"window": "W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4eb862f7-9faf-403a-b1c5-ece9293fb333", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47388c5a552988d5bf34ac2804433b9498aff4ed1baf649b8f395eff1f60e4d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbd661ce-34bc-44c3-98bb-0ac89dddef5d", "node_type": "1", "metadata": {"window": "W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "0665551a7f57cdd8fb3b740b292580b6687ea78634ffa735e93b97929705d285", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 2282, "end_char_idx": 2375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbd661ce-34bc-44c3-98bb-0ac89dddef5d": {"__data__": {"id_": "cbd661ce-34bc-44c3-98bb-0ac89dddef5d", "embedding": null, "metadata": {"window": "W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc477a0-e974-4586-9a95-1feb6b4d1c5e", "node_type": "1", "metadata": {"window": "W e exclude acquisition-related deal\nand integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring business\nactivities.  W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f518544b9a44c5c6d099ff753785fb48820d22698d0a8c17b2748390c543dbcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "693cb39d-ab09-40a2-961d-72d7d90ae222", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "663e7e97825a36077f32672efdb708bea70f61375020c1a77f3daf3f0b8e2bf6", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 2375, "end_char_idx": 2622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "693cb39d-ab09-40a2-961d-72d7d90ae222": {"__data__": {"id_": "693cb39d-ab09-40a2-961d-72d7d90ae222", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbd661ce-34bc-44c3-98bb-0ac89dddef5d", "node_type": "1", "metadata": {"window": "W e exclude the amount of litigation and opioid-related expenses, net that is unusual, non-operating, unpredictable,\nnon-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad85e2bdbe04e8aae245e281ef1ec3811b7a4b46db5ad493eed2fd9e56fc0e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b71669a-cb97-4947-ac6c-21254b463822", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "original_text": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. "}, "hash": "b0f7efec792e90d86866096c51b1c18729a44e81b625d233efab77796b860767", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 2622, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b71669a-cb97-4947-ac6c-21254b463822": {"__data__": {"id_": "0b71669a-cb97-4947-ac6c-21254b463822", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "original_text": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "693cb39d-ab09-40a2-961d-72d7d90ae222", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03d36e7e4f1539d39e2ad72100c32d8a2c0bb92d2f6cdf93cd666ce8b117dd2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38fdead0-06d0-432b-b84a-dd3cb9e17eae", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n"}, "hash": "d47f938542d5b44de0e41675222d99f5c2b5b7612eea7534b8c6318b314668a5", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "start_char_idx": 2827, "end_char_idx": 3198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38fdead0-06d0-432b-b84a-dd3cb9e17eae": {"__data__": {"id_": "38fdead0-06d0-432b-b84a-dd3cb9e17eae", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b71669a-cb97-4947-ac6c-21254b463822", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "original_text": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4af4df5a0ccf481c3d027c3ca9bf53a318761294aa1482c66df2f1ddf1524213", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0a50645-4dd5-42a3-a960-d22954155cd1", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "60702ac91c11e35914ce0344e07934894e188dc88690f5dbbe3ebcc6e7148bb8", "class_name": "RelatedNodeInfo"}}, "text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "start_char_idx": 3198, "end_char_idx": 3363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0a50645-4dd5-42a3-a960-d22954155cd1": {"__data__": {"id_": "e0a50645-4dd5-42a3-a960-d22954155cd1", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38fdead0-06d0-432b-b84a-dd3cb9e17eae", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d571ba7ed0a4e4b93c703f3ab44682fa53cb43fa67cf026808df75a83c83373", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b75493b-6412-46c6-842c-58d4c24eefe9", "node_type": "1", "metadata": {"window": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. "}, "hash": "717b9e6e75a7f954d3793ad9b3535ea2b03600ba35d356a15fae043f8b6949b3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 3363, "end_char_idx": 3601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b75493b-6412-46c6-842c-58d4c24eefe9": {"__data__": {"id_": "0b75493b-6412-46c6-842c-58d4c24eefe9", "embedding": null, "metadata": {"window": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0a50645-4dd5-42a3-a960-d22954155cd1", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f39259e13bca8b19b5cc5b56b8c4cec069fd84ad9b2eb3fd98ab9955885a3ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d266458-f544-40e0-88f8-95085fd759e0", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n"}, "hash": "54f054f8d0f4965ab05b83ed336c1fac259c2c32618ad253aa1f6341d19e548a", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "start_char_idx": 3601, "end_char_idx": 3693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d266458-f544-40e0-88f8-95085fd759e0": {"__data__": {"id_": "0d266458-f544-40e0-88f8-95085fd759e0", "embedding": null, "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b75493b-6412-46c6-842c-58d4c24eefe9", "node_type": "1", "metadata": {"window": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1437c07ee8d613d7ee5710ae2949397d8d114bbcc2afaf97c9298850a0153502", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c7ba644-d6a4-46ae-adbc-ba0a6c86bd0a", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "862405ef950bd184825adf511da9770ed5fd019581f33212a875faa0d23d8523", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n", "start_char_idx": 3693, "end_char_idx": 3850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c7ba644-d6a4-46ae-adbc-ba0a6c86bd0a": {"__data__": {"id_": "0c7ba644-d6a4-46ae-adbc-ba0a6c86bd0a", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d266458-f544-40e0-88f8-95085fd759e0", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ab4ee017cecf235f1b3187c9d0397c23f870b624e1f8994c9f8814c3ed8482f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe610356-d1d6-4197-9288-224fd2d412b7", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. "}, "hash": "1845e1163d3a4c9859efbeca76341e5a39387a23c2ccc2513826fc21586d48a7", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 3850, "end_char_idx": 4094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe610356-d1d6-4197-9288-224fd2d412b7": {"__data__": {"id_": "fe610356-d1d6-4197-9288-224fd2d412b7", "embedding": null, "metadata": {"window": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c7ba644-d6a4-46ae-adbc-ba0a6c86bd0a", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80400c9a767a82ef58b62207fa97ffbc42852a5cb3a52323ec8dd8ee9aa42b76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47ab876c-fd77-45d2-b1dc-cc36e97eb9c9", "node_type": "1", "metadata": {"window": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "17c87490d4088d163c96e6e8f735313dda60a28c2a53ec297134fa7d91a0a98a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "start_char_idx": 4094, "end_char_idx": 4283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47ab876c-fd77-45d2-b1dc-cc36e97eb9c9": {"__data__": {"id_": "47ab876c-fd77-45d2-b1dc-cc36e97eb9c9", "embedding": null, "metadata": {"window": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe610356-d1d6-4197-9288-224fd2d412b7", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80f8a8d10c98d723db2f3074021d40faa2c2d4a3375bd1d21edc2d581932b3cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca2f4900-cfe9-48be-a7a5-ef399fb96527", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. "}, "hash": "7a2eb0e7285bdb91118d97c91968ecd4982b49daa95984fdcf78a09b46aaff23", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 4283, "end_char_idx": 4556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca2f4900-cfe9-48be-a7a5-ef399fb96527": {"__data__": {"id_": "ca2f4900-cfe9-48be-a7a5-ef399fb96527", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47ab876c-fd77-45d2-b1dc-cc36e97eb9c9", "node_type": "1", "metadata": {"window": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the six months ended March 31, 2024 and 2023.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf7602c775162729b828d2163267d700ac0fa6f99a094f4ff1c974076d403f77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "422246ed-bd89-4bf8-9186-cb8167cbdc05", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "0e8e1ade072e74b6bc25a3b6e25820cc784a669d7f933f2291db740060ba80a7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "start_char_idx": 4556, "end_char_idx": 4737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "422246ed-bd89-4bf8-9186-cb8167cbdc05": {"__data__": {"id_": "422246ed-bd89-4bf8-9186-cb8167cbdc05", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca2f4900-cfe9-48be-a7a5-ef399fb96527", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e23199c6c909461f344b88e0cf8ffcd3e9e1b8b260360b278adf080c2d15298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b369f15b-f9ef-4ea3-8a01-4f9338cf481d", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. "}, "hash": "013f6085903e6e7b75795ee53a00aa85eeae9bdd58bd9b810a473ae44a5d0043", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 4737, "end_char_idx": 4981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b369f15b-f9ef-4ea3-8a01-4f9338cf481d": {"__data__": {"id_": "b369f15b-f9ef-4ea3-8a01-4f9338cf481d", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "422246ed-bd89-4bf8-9186-cb8167cbdc05", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dac15e00c836288cff436e698002f06c2d9dc0d4bf0c9b0768ff74bbada505d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cc39121-672a-4d0d-9160-0c902b59d1f4", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share. "}, "hash": "2f1be6ef9306270a7e226ca6820808ce0eb4276185f6e7e9f026b79cd78f2b70", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 4981, "end_char_idx": 5672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cc39121-672a-4d0d-9160-0c902b59d1f4": {"__data__": {"id_": "5cc39121-672a-4d0d-9160-0c902b59d1f4", "embedding": null, "metadata": {"window": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b369f15b-f9ef-4ea3-8a01-4f9338cf481d", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b97b4b6acccbbd2e3e98b4b5c2b77971d044057073208213773d532bc322ac7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af397ca0-fe10-48fe-961c-07711f7af423", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Management believes that this non-GAAP\n25"}, "hash": "95bfaf9f8bba3cea57ff2549ae0739870afd09bd5b8ec937108e9f2c2bc49f93", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share. ", "start_char_idx": 5672, "end_char_idx": 5926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af397ca0-fe10-48fe-961c-07711f7af423": {"__data__": {"id_": "af397ca0-fe10-48fe-961c-07711f7af423", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Management believes that this non-GAAP\n25", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1332a969e72861b51e1f155867af7469dd8e5b0b58de16075a09e6066d4fdda6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cc39121-672a-4d0d-9160-0c902b59d1f4", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3688acea221d12e3be915cc7420228a33d7ae627df540737589d2168ef8bfcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7edf3ef-b6d2-48d7-9607-ecbb8579a1b0", "node_type": "1", "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million. ", "original_text": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n"}, "hash": "07810200f7cc12f399abef3339e2662c46cfeb03031db4d789db42724b2b2f24", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP\n25", "start_char_idx": 5926, "end_char_idx": 5967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7edf3ef-b6d2-48d7-9607-ecbb8579a1b0": {"__data__": {"id_": "a7edf3ef-b6d2-48d7-9607-ecbb8579a1b0", "embedding": null, "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million. ", "original_text": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af397ca0-fe10-48fe-961c-07711f7af423", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses, net; acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax items, and the per share impact of certain expenses relating to 2020 S wiss tax reform for the six months ended March 31,\n2024 and 2023 are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\n25", "original_text": "Management believes that this non-GAAP\n25", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26d584470c0b119b87a454cac5dda23d4186bd9d50c894f4003142053eed506c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4ce63b9-cfd3-459f-94fd-58fbddb6217e", "node_type": "1", "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "8d935bcb7edd273fcc49a70f7404fb47b32faedc8644b00fe5a3929d76404560", "class_name": "RelatedNodeInfo"}}, "text": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 0, "end_char_idx": 315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4ce63b9-cfd3-459f-94fd-58fbddb6217e": {"__data__": {"id_": "e4ce63b9-cfd3-459f-94fd-58fbddb6217e", "embedding": null, "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7edf3ef-b6d2-48d7-9607-ecbb8579a1b0", "node_type": "1", "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million. ", "original_text": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba7ec3e694d439dcacbfe372e27b5a90bd71fae98954342ffd5335ad82c1832d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a35a495-4424-4b0e-abfb-8fe5f9adfe0e", "node_type": "1", "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. "}, "hash": "3c8de4b30389ad9b2fc3281318b8341e5a5362b7ef3e55569b6e39541cc67521", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 315, "end_char_idx": 588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a35a495-4424-4b0e-abfb-8fe5f9adfe0e": {"__data__": {"id_": "1a35a495-4424-4b0e-abfb-8fe5f9adfe0e", "embedding": null, "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4ce63b9-cfd3-459f-94fd-58fbddb6217e", "node_type": "1", "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91ccb3db4904e44d6588333c8f19529243e0dffa24cba976fb1487bf1ac5f087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30c97ff3-dffe-4419-87b2-c78b94d312ba", "node_type": "1", "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million. "}, "hash": "8eb8081b9861d3ac0f4a8180be6a32f0389f7e8f2d1f718132eae52aa4c6455c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "start_char_idx": 588, "end_char_idx": 826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30c97ff3-dffe-4419-87b2-c78b94d312ba": {"__data__": {"id_": "30c97ff3-dffe-4419-87b2-c78b94d312ba", "embedding": null, "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a35a495-4424-4b0e-abfb-8fe5f9adfe0e", "node_type": "1", "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcd8acfb1b664f68eff2cd4a3b8ad6e78368314b1dbf3d77e02ce5da09f8e6cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "841716eb-6c44-4c17-a8b5-fe4836f1892e", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n"}, "hash": "fb39544fbf4947673df46da576dc86d5d5ef5adf0aa3d3693badce1afd126e44", "class_name": "RelatedNodeInfo"}}, "text": "For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million. ", "start_char_idx": 826, "end_char_idx": 1166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "841716eb-6c44-4c17-a8b5-fe4836f1892e": {"__data__": {"id_": "841716eb-6c44-4c17-a8b5-fe4836f1892e", "embedding": null, "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30c97ff3-dffe-4419-87b2-c78b94d312ba", "node_type": "1", "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "684cc24d740d5f8d29cacd5f86b8ff0e89246132b392aacd1866c718e50585f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f297e84-29db-44e6-878e-6f01c9df4f17", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. "}, "hash": "ea0ceed27d98931919537e68512d4119d5c70951e18c2b13b4c1ee5b20250d09", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "start_char_idx": 1166, "end_char_idx": 1462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f297e84-29db-44e6-878e-6f01c9df4f17": {"__data__": {"id_": "6f297e84-29db-44e6-878e-6f01c9df4f17", "embedding": null, "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "841716eb-6c44-4c17-a8b5-fe4836f1892e", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7666e6238538a5a22944b70894f747e7cb3b7f03c64be3e18d0bf9135f2fe03e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48b8e9f6-46ee-44f5-a52a-3f8ae6b6f2a9", "node_type": "1", "metadata": {"window": "For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. "}, "hash": "34af7515eda1f038d89092431f2348ca8cd2327602b2be7bfc68042fe013147d", "class_name": "RelatedNodeInfo"}}, "text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "start_char_idx": 1462, "end_char_idx": 1616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48b8e9f6-46ee-44f5-a52a-3f8ae6b6f2a9": {"__data__": {"id_": "48b8e9f6-46ee-44f5-a52a-3f8ae6b6f2a9", "embedding": null, "metadata": {"window": "For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f297e84-29db-44e6-878e-6f01c9df4f17", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "700a70ab727c7ecd2219a296cbb5c6180661fdd98bbdaa7aea681a81c14499ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "183541d7-b8ad-4ff1-87aa-25ace852edcf", "node_type": "1", "metadata": {"window": "The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. "}, "hash": "7b4068aaaaea6086e6c7433bcf9b3ee057cbde74ea6bf389cbc8a4bd4ac8e9eb", "class_name": "RelatedNodeInfo"}}, "text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "start_char_idx": 1616, "end_char_idx": 1771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "183541d7-b8ad-4ff1-87aa-25ace852edcf": {"__data__": {"id_": "183541d7-b8ad-4ff1-87aa-25ace852edcf", "embedding": null, "metadata": {"window": "The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48b8e9f6-46ee-44f5-a52a-3f8ae6b6f2a9", "node_type": "1", "metadata": {"window": "For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd0a04d22efc719c3f4481652d6bc6e2b13a7d009c64df6204bd06e35dc6429", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2948d9af-db39-412a-ae0e-89e8a953d8db", "node_type": "1", "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. "}, "hash": "c3bc57b11fb29859bb7c41797cb90a040e469f0eb22504dd45eb3747fd515b61", "class_name": "RelatedNodeInfo"}}, "text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "start_char_idx": 1771, "end_char_idx": 1949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2948d9af-db39-412a-ae0e-89e8a953d8db": {"__data__": {"id_": "2948d9af-db39-412a-ae0e-89e8a953d8db", "embedding": null, "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "183541d7-b8ad-4ff1-87aa-25ace852edcf", "node_type": "1", "metadata": {"window": "The Company does not\nprovide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ef87adb72190ccdf0dca93d912e73f56768bc084129d1b5c8c2f9339b44c4bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e010476c-eba7-4e27-b570-efdd0602c146", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion. "}, "hash": "74be74c192b28e709ea361a1651a0d3402d660a903a2e470f19c66f88b024168", "class_name": "RelatedNodeInfo"}}, "text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "start_char_idx": 1949, "end_char_idx": 2105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e010476c-eba7-4e27-b570-efdd0602c146": {"__data__": {"id_": "e010476c-eba7-4e27-b570-efdd0602c146", "embedding": null, "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2948d9af-db39-412a-ae0e-89e8a953d8db", "node_type": "1", "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2be0c2d01371b27328c528efd83bea7748f94af97f3d70c654d1941753e31f8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "399c890a-ccb3-484e-be4d-4ae260f5144d", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n"}, "hash": "9a50bec17ede0e81ab7586098812cbaee8d420593b1c377e9dcf30c8b4f01ac7", "class_name": "RelatedNodeInfo"}}, "text": "For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion. ", "start_char_idx": 2105, "end_char_idx": 2508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "399c890a-ccb3-484e-be4d-4ae260f5144d": {"__data__": {"id_": "399c890a-ccb3-484e-be4d-4ae260f5144d", "embedding": null, "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e010476c-eba7-4e27-b570-efdd0602c146", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55075024f81f9d5225f63aa5a759e8403a0da0fd6af28055005b82c0688ba41b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cb51f76-b49b-43fe-8b99-3d5ed8e6287b", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "e9d4ebb823bdfc90145334af82d0140e489d4cd4f539dc0ae429cdfc7412d0cc", "class_name": "RelatedNodeInfo"}}, "text": "For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n", "start_char_idx": 2508, "end_char_idx": 2963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cb51f76-b49b-43fe-8b99-3d5ed8e6287b": {"__data__": {"id_": "6cb51f76-b49b-43fe-8b99-3d5ed8e6287b", "embedding": null, "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "399c890a-ccb3-484e-be4d-4ae260f5144d", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "347de68a9630cb43fb3bd5b9a976ef21d70b6c3955c79607a7232bbb68f4ab09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebdaa66b-c6f0-46d3-bc72-238cf11687ab", "node_type": "1", "metadata": {"window": "For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. "}, "hash": "cdc49b4d37e2673e54f3e0ac2d015801a4c87eab9fbe892f70af1899bcaf804d", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 2963, "end_char_idx": 3413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebdaa66b-c6f0-46d3-bc72-238cf11687ab": {"__data__": {"id_": "ebdaa66b-c6f0-46d3-bc72-238cf11687ab", "embedding": null, "metadata": {"window": "For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cb51f76-b49b-43fe-8b99-3d5ed8e6287b", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60b1961160a8dabee7cf40e0bac7e8bd87b41fb1c357bc35c6b3a9ba7b8bd29f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb49e9c-7305-485a-94ae-0aca7b156ec4", "node_type": "1", "metadata": {"window": "For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "5ad2ed42f9b8fa1611a91d4acc1e381d14525801a1ad42b03e4d838829f5cfce", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "start_char_idx": 3413, "end_char_idx": 3649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb49e9c-7305-485a-94ae-0aca7b156ec4": {"__data__": {"id_": "dcb49e9c-7305-485a-94ae-0aca7b156ec4", "embedding": null, "metadata": {"window": "For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebdaa66b-c6f0-46d3-bc72-238cf11687ab", "node_type": "1", "metadata": {"window": "For the\nsecond quarter of fiscal 2024, (i) revenue of $68.4 billion was negatively impacted by foreign currency translation of $304.2 million,\nresulting in revenue on a constant currency basis of $68.7 billion, and (ii) operating income of $1.0 billion was negatively impacted\nby foreign currency translation of $22.2 million, resulting in operating income on a constant currency basis of $1.1 billion.  For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72bc918a02891a9d2011ee6de0f5de18338e7cbc3f5d6326031d904325c7231d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a853307-0011-4964-899d-3be5937effd7", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n"}, "hash": "acc985944fd136e5ddf1b860f5f1b7a4652f6443e2324594794d6aacb2240ad1", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 3649, "end_char_idx": 3965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a853307-0011-4964-899d-3be5937effd7": {"__data__": {"id_": "2a853307-0011-4964-899d-3be5937effd7", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb49e9c-7305-485a-94ae-0aca7b156ec4", "node_type": "1", "metadata": {"window": "For the\nsecond quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted\nby foreign currency translation of $304.2 million, resulting in revenue on a constant currency basis of $7.4 billion, and (ii) operating\nincome of $192.7 million was negatively impacted by foreign currency translation of $22.2 million, resulting in operating income on\na constant currency basis of $215.0 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3471c1d407f278926708081fd9be9109b80883fc722bb5c574b207e602a86a7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a957daa4-0cc7-4043-85a7-58fae9a3cca0", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26"}, "hash": "5a0da514adfe9d18a694e51c26280481bf830c7ef98605e8270587c1cbf05fa7", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "start_char_idx": 3965, "end_char_idx": 4149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a957daa4-0cc7-4043-85a7-58fae9a3cca0": {"__data__": {"id_": "a957daa4-0cc7-4043-85a7-58fae9a3cca0", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce2d6a07-8da0-4106-a61e-5a203941e598", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d62438e716241d90c447e921af7d104c9d32a3e64ae342ce6f75d05e07b449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a853307-0011-4964-899d-3be5937effd7", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a4ac0580391a34a998cdcfe7e7ff72a6328f138d1ae72a1ca0ca8e515cdc560", "class_name": "RelatedNodeInfo"}}, "text": "Bennett S. Murphy \n \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n \n610-727-3693 \n \nbennett.murphy@cencora.com\nSource: Cencora\n26", "start_char_idx": 4149, "end_char_idx": 4301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"7b7551af-91b8-4d42-a2c7-9b84f4905a6f": {"doc_hash": "52de1557888afce4318a1665ab0d86af6870c32f1b88b2f4daa32568123624fd", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "7d280ea9-3867-4b39-a95c-f1eea85593d8": {"doc_hash": "64ad28723ddc481065ec31f1b55b9e5263e1d817db5bcaf20b58dcc1a3f40dc7", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "1f076b99-e4d1-4b13-b2e4-c0ec435fd3aa": {"doc_hash": "7c1c945fee8e05e90f97f51193cb65b60921859096ecd0d62eb89c0445bdc15b", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "06300998-4d7d-4395-841a-7d2f9e07de86": {"doc_hash": "c0607256699520c094e30b13a5753710b2a99f4337225748aaa86959377d9a90", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "768b9e47-0c40-4c9a-8b79-2ccaae9de5ce": {"doc_hash": "72f7fa5b838ce6397789d41c4dd2dfb44c6f6f888667391fbdf723b00727ace5", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "5e01b110-b5a6-4998-81a0-61f1fc6e3b95": {"doc_hash": "72877cedadd931205bd19cbc2ce07e414995e80edb81c2be2af56c463dcbebba", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "d1cc91ab-3d5b-4a1d-bbb6-fb3b074ff279": {"doc_hash": "9034e3228b60e0db9cdd1a234df61ccf5a37cbc05b438f09ddefce27129e76f3", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "3204ef13-7d1c-4266-bb07-8b312e8c21cd": {"doc_hash": "12d80eca75fec35cb65de98528011b33304b9597cc97274fcca3c4f8e7e56a2f", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "e579c2b1-d64c-4cdd-abab-ffd3930fe584": {"doc_hash": "56c9a959b086787db7b2a8637ddfbcfb1b1c8dc6a3df562a4e4c684badf37189", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "5b0cbb72-6f74-44f7-950b-7e12f9c8bcb3": {"doc_hash": "201b18fff00d4e8dc9415068dc50e73aeea8a8ed4d20891fde191f9e9faa8aa8", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "714d7593-722a-4dde-8726-8179b5e2a1d7": {"doc_hash": "4b0cac0274fdd935034a61c06ee7e5b54bc294f856cd4e7bcb95c2a7665b0875", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "a1289f16-a84c-490a-a0cf-db9e9e889480": {"doc_hash": "44ce669279275f56ed94630d78b05310bf6bc2378bfea75346235249f9af5e32", "ref_doc_id": "5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb"}, "2ba2d219-11a7-4a7d-b752-0708d15001ce": {"doc_hash": "d4be3c2090e4af431c0fd51c3a2903b64f058b0a3bd92ce46d8360989a080001", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "14b0abe4-308b-42e7-9d3f-00add87aea76": {"doc_hash": "5d1242d8bf07513bd7f57f58045249fa325c687006de447425792296f9f41682", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "e9c6385d-b340-4348-97b6-9a1edea7de4c": {"doc_hash": "8098babda323c424820bd9c77e65cc2f080c1580b857a17d695fc06e12a37e3b", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "8a5c5897-38fd-4b09-afab-ba20ba5c923a": {"doc_hash": "70d3498ab4b9d79d65484dd0ea37212765cf556ea17c19365d3432b31ed24acf", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "f5412e34-7d30-43d2-ae9c-d8353cd9af56": {"doc_hash": "fb9e132ce14227f87b332123f05ca4319ec46bc149a3c3fa000e1fec75bbcc00", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "0247707e-ddec-4f29-947d-79f502877126": {"doc_hash": "a9784a8a2ece3774ca74cb47a707e9a4be5607106f573a65fe60753cbc75aa8b", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "2ebbeefc-b54a-4c97-89de-b947fb06cb14": {"doc_hash": "fae71e07564491f8edd6080139e9fd88c301637994aa21931c220ec9ced3d3e7", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "9db7ff35-eb42-4d07-bc71-25abd39af2d1": {"doc_hash": "8eaa5533438e83bb5004bba53fa84225abb079382828ed5208c0ed86605d655c", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "0037dc5f-080e-4d22-80f9-93725b240343": {"doc_hash": "127c07f2ec2466d8d9e05ec1cae80eea07f265347676f71e0e35afde4ce445c9", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "9f34a3c0-5d03-4802-ab95-7e79a9bf2377": {"doc_hash": "b510d9f95e238eacb26a5d7fc5c32df412c5690d39451c291fc9a1628c08f2cf", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "4e9e4b08-d526-4673-b66d-44e0a5c77a3e": {"doc_hash": "9bb17eeca5d183c9d10c0c5e0b3dd2ff3ce15f5d2050112cac1076cc022e2794", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "315c9616-8c4e-485b-b0b3-c39fee77fda1": {"doc_hash": "72238d74ab4d276230c84c303a9487133896a422713e1200aee88bcc488f7710", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "5e830766-fa2d-4867-84c2-b3301147a455": {"doc_hash": "cdcfe1ce49536af01036fa5804db74f378387c81d866bc43cb0aa020d0282497", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "76c01d6f-7f8d-4085-bae0-a33ecc5f52d8": {"doc_hash": "2408227329b1b3b0590d989ad160cb894aca7e8f40780d0f843dca91d9ee1945", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "82438e8f-f731-464f-97da-04b34db40f0c": {"doc_hash": "f1871443f232b7085f0779f898638e88e19990091003ab160c2045ab11ae117c", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "e807cde0-587f-43cd-93d9-6423561b050a": {"doc_hash": "474bd07c6ca56a0d4d95b9f5ee03d456c0b11b1fbe5b4f7c85c0688f8ab6db8c", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "bea75ad4-7693-47f4-936d-32ba612a5429": {"doc_hash": "1f85ca13851c53ac550077bcb9f0aeec5b32681d750648f5f6bbe6510e997534", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "d06e57f1-9173-48a5-bd82-26e44da47c3e": {"doc_hash": "e4fca668701bca69d044adc9cfa922d3b1d8ee54154dd48a859add556e21ac4b", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "8a007954-3f9a-41ed-8c7e-218abb909868": {"doc_hash": "abb912c36e18a1a787424dcfcebfb512316285795c99ebfc83a7d5aa9f6dc01c", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "46f512a4-624d-4f9c-9be1-6db34f99f8ad": {"doc_hash": "bdb1855aef0531ba6c6464b166c712d45558abdda1d6115d1bd0309c20ea9db6", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "4f21d4ea-63c8-4a96-8538-cb0344237724": {"doc_hash": "6cfcc4eeda299eb2dc8e0d35650d90b78f96e5039f825f010bdfc0e89ecb45a1", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "c58cafe6-aba2-4389-805a-e24bb440f93c": {"doc_hash": "e18fa60bf3b34980f5a1176c081b9f227e93b7c88dc07312743bd2d26c5497e4", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "12bcb8d1-148a-4d2e-a976-f12ecea846ab": {"doc_hash": "57560ce8c08392595e45fe54439e2d28ba9c77fbd2580ba591ddc157b46ccd7e", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "311f9fca-1f75-4ccf-a6a1-152beafbb075": {"doc_hash": "0493220d6efb79d54db8f94152d0825b5fb47f47f899cf009ba7eff94c8a1405", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "61f9ff46-2777-4524-91f5-906fbe69bdad": {"doc_hash": "4ae0e6f46a81e22c1667928f0ec1a282827565be61ba61c27c9eee661cad91d2", "ref_doc_id": "ee3cbea2-3379-4143-8a25-1910e8ee065f"}, "5fa97b84-1841-4eaa-adc7-79520412a51e": {"doc_hash": "4515a7d529df76e7e57f8da998a899b389f06ce2d8b90ba607b95fb38097fa21", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "225de017-22a1-40ee-8e39-c966d626403a": {"doc_hash": "3fdac77734ba5f64c942ade591cbd299edefb90b4d0025d83c3a73c8563b87ba", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "4cb1e7c1-8ada-4b42-a1f6-060a3b01808f": {"doc_hash": "d11004567c4f0c93f848d2b9adc91d0433a3543728e8deb8097922476561e47b", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "df4e884c-05ae-4e84-abc9-0af5328d6436": {"doc_hash": "e4491def979052f062c67454eafe051e96aab69ca7279fb41e61255bd0e69c1b", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "1813be28-c698-46d7-ae4b-802fda2c40f5": {"doc_hash": "d51e68f1b1335e4f75fba20d7914e297b0a8e78cc0b70cb9f2b36fdd7973650a", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "75990a33-f217-4fc6-a1b0-daa83d94af53": {"doc_hash": "21ed85f4a6bd048aceae8bdf27d369643face750454a8b48035a9c12670402a1", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "40a0d820-1fc7-432d-8f88-51340b1a9290": {"doc_hash": "3511ee488a84b9a94dcc30f86ec8daedb437b49960d18641ebb997b9a43140cd", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "2866b945-9986-4290-a209-1ce9875ddb07": {"doc_hash": "24321c055a7ae0764d820855f2006d220f6846d5b783e3bf70f4a4ef43d08c75", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "e110028b-1c06-4f6c-ab1a-52d1e26a4079": {"doc_hash": "7c68f3f58db2dcc699447dc2d1ea00e1d84c9cbe720d17d094c7572504f99e05", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "9991ff59-fbf0-4934-ac33-49713cd98796": {"doc_hash": "81cac6a603502181f8f71be35d44f023520c895b3729cbdf611a4e40436061ae", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "f377518b-8ec0-4e8b-bcec-bb2aecc44bc8": {"doc_hash": "1775d3d59abc80354273cb47ca9e59400a078ecdd262fb9c7d2c3451212f4c55", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "c8ead5d9-6011-4dfd-9f88-12a67f4996ae": {"doc_hash": "a4384c48a630d846ce439997f18a21450ac3c8e3960a0d2a4312221beb815dbd", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "c1af0fb9-7590-42e1-bd65-ca5b5211e1fd": {"doc_hash": "73ed5f7802c219baca4111e8b10c43bcb78ed012ff984df341ca7c3b08823a7c", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "a3903d68-8a8d-4daf-a417-7f53fbb1d488": {"doc_hash": "6b4fcba21da176e7902a0ef534a089b7ddd689371da166f8c4d7a2961191a6c6", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "e5c9ebc3-1a12-4978-a3ec-520550817f4b": {"doc_hash": "f1b2b4cf648d1476657847b2ad4358601e2204fd091508255cd4455f771907da", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "4c21d133-dcf4-4b57-9933-5a3540634691": {"doc_hash": "63f78db06330081e5ce3c17dc973c170ab14d7a6cbfe08a016d7d33a7e24110b", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "2a3a6e9f-96d5-4be9-a2d1-2d00c654ee19": {"doc_hash": "e81e3c783886d086b66af22d0b1279c8011c65e01a6f79fa5bcec5ffc6e2da7f", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "d7009740-e4e7-46cf-b3ba-4bcce68b05cc": {"doc_hash": "87ff79e4115f84e660dfeeeb80320ac4f4c957b15d657a0a7fc567038e9f3664", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "6ac55e06-8cb8-4d4c-a569-b1cb0f04aabe": {"doc_hash": "a0a239b54fbab860c2630da7e5825398706cd7a0bbdc84fccd70836ed54641d2", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "1578410e-4cce-48e4-9d40-7af66c38ca76": {"doc_hash": "f7897accd9ccca9369b8845083c875c9e3fad1100a7f40c9c57fd46d9a37e42e", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "f01daddc-8898-46a7-b22d-3aad5f21f574": {"doc_hash": "8910e9f26726e1cee4baf94ad21131a9f9edb2084cd6a96d0c8f99588dfca556", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "9adb94ce-087e-4938-a10e-468ab3b3b61c": {"doc_hash": "194036af28067358fb9b7993484eeb0a730f74a4338f8a599a9d1f70469e93dc", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "bf380379-48d2-4964-90e8-bcda96d7bf0d": {"doc_hash": "98aff4a04d0a3df10b727ed8904c49643a03bcb8591540b03f1801223718141d", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "7a30bea5-56f8-4fbe-8d7b-e830b9f82c96": {"doc_hash": "617123a001209899b496f2537ac3a67ba3cc9dc15021a814ec3ae92018e05a3c", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "43c670a2-0fde-462c-a0f8-0c9447e93496": {"doc_hash": "8a09792d15144b97fb919ddbcdc5ea89349bd89bb8d4c29958d377ad12c41947", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "2adab6de-f6b8-4505-9efa-0cccf7930d2e": {"doc_hash": "9d5cd5afc35922988698b8849c385639eab39965fe665661dbea32243d03f681", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "e131dbbf-0a0d-435e-a2d2-c6a0498e1d1c": {"doc_hash": "4bde1e7324d587a80b5502a20f7a398d598334ff9dff8a9d8577244f628d3695", "ref_doc_id": "f917433c-c0a4-4064-a6f5-b4eeb7f77242"}, "328af804-ad17-4e02-9c1a-c4bf2a7880a7": {"doc_hash": "8526257032213294195d108079351e51126efd351f3f75ce0197999836479161", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "53eb4c08-ea28-41eb-98bb-c283fdcd4696": {"doc_hash": "db5a968c9a611519b983f176adb5d2b6741cc6e2f3a42b18250b6e1497f785e3", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "3ba83c3e-2920-40c9-94db-9f7dff3e6f89": {"doc_hash": "e5e152de955320ec126b5e99e0aefd8e96b99e5118c3cbf6ddef8da7a53dd3fe", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "fbf58b1b-3c9b-4825-8c2e-19e698d9927d": {"doc_hash": "c07b8ed883977ee09f8f8db17a5b9c0a97481845eaeb69317ecdf0f10b64419c", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "5d30a103-9b83-4449-aa78-db791f62cb5f": {"doc_hash": "067a0a795f364d080ef7f2dff4c83cee9b8a49239faa5ba38b3b1374979c2e17", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "05d1321a-73ba-49a7-b2a6-68c950236fe1": {"doc_hash": "975b8422a5ad0b4a25566660aae8f5f3e886e3cd9e797cff60a15fb24c68489d", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "c4b10982-24cc-4335-b5c6-e6807a1d5029": {"doc_hash": "2823c436dd6e2755dff6ad199dba3a963748aec8ff09ea87612273f7df613ce3", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "0785fca2-84ae-45df-aa22-6e6e9725a04d": {"doc_hash": "d5cbce17df7921836751f07ec005308192a5b5e0585b68d487ba780a4b3af196", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "57342f3b-c7d4-456b-bf6a-43b082c9f353": {"doc_hash": "fb77690e68ebba3e672a22d033f6ba2143ed3463bff791a780cda775a5fc451a", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "74b229fd-c6d5-4a8c-b5b3-07b8c018d14f": {"doc_hash": "9b65e32fb4d045167f494cd7adaeaa8df3a814c7cc352cbf7c2ec4316d0b6af2", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "025e83c7-8a32-4a73-ab5c-2ca570f5982d": {"doc_hash": "574b03d649d20109e05bb45149880af4ecd186b1d0c87170c866dac0fb2ec571", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "52b8526c-1d33-461d-b0d7-7e8e127dd513": {"doc_hash": "7212bfcb05c4d5e981aca15b7d1014b1cf8615c0effda6a3ec6d4de5074e8a29", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "2ebed0e8-b156-4c30-87a9-979dfab11391": {"doc_hash": "f7f82482966e5349053531d33344b0a4e2e5f016d82eb646470799db67a6ff2a", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "713b037c-5e3c-419e-9441-a1b86e46fe02": {"doc_hash": "b3b8e54da53e1108ead6a7405e78f1423c7c2abb977148a2037d05b93a92a9fc", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "f8dfce02-ecae-47d5-aeb0-c1f7cf8915de": {"doc_hash": "054b209eace99a079720f7c47e76304088558562c2d04f110814f159cc371d43", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "c5a59f1d-fe2e-419a-8f4a-e83c5741a535": {"doc_hash": "338e7f623cd748233d391ef19013bae9ac1be55a69ade78592490bd0b27e7524", "ref_doc_id": "05c409f6-8f41-409c-bf2b-53d685f0cd33"}, "e9cdd5da-f2c4-43c2-97fe-6d864ff05352": {"doc_hash": "eb02ceac12a7d5ff4d0ad4b3091257f3b1779db46a4e75341cbbed70a34f4b14", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "db97e0cc-0907-49b2-bd50-f71195fdcee1": {"doc_hash": "f179171f72975c79d32221cac2caa236fff7bb3547e7ea120dd2a0b1c8ae5fd3", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "ee231c5f-0133-4a83-a31c-92aa0f877325": {"doc_hash": "5315140f7b9c44c48b3fb7a68a0ea47201f004febd9d94ae0d9f9c010adfdbce", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "c5f050c2-9184-4dac-ab72-469afc02a491": {"doc_hash": "592c086f06e36b241c6654a904ada6d1481c11580b140781fe02047e437d996d", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "5b86a53c-f919-4f93-899b-1a81a207ed7d": {"doc_hash": "439e75b4f987394edeb76c698eef558c9379e79d3136717e445645109fd49311", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "8a60c433-1b63-4637-9534-0934aa8237fd": {"doc_hash": "1b9b6ba0e5838e0fc987486b70ff5e872714116979e4a30b71ded8eed96b4829", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "07340f46-c907-46cc-a472-29ccc9633fe5": {"doc_hash": "bddc5369ddb682194225877ec3258f14778457dfa4e64de762a2c5dab8b0659c", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "d90a6932-a376-4dd4-a667-0196a1f84280": {"doc_hash": "4c22d59ad8505736786e79660b525cf55fcef2d14a7f20bc96c595eb79a63775", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "40d55e68-bbb2-42bc-b103-4302cde4fb49": {"doc_hash": "e236838cffabcb66e7c47a467686577cb4e57521c647e69e670b5434f46d8035", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "7526e408-4778-4e05-bd77-ecba90053fa2": {"doc_hash": "c178f9e051492c1efbd9fbbe849dfd6de1a6211c7326ec6fbed62af7f765c04f", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "9e96f8a8-59d9-4643-bb95-4c2061d630de": {"doc_hash": "bd3af71aaa7a8526699687a08cc9eb5ceb94a76e90e0ba22c01ee97a90a8add0", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "403efabc-4574-476c-b4bf-fce72de65122": {"doc_hash": "3b6da709cc6297ea9691886fccf786c57f6af5932df4902b0bb0944f73687b58", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "a6b504a2-e20d-4bf9-9299-27d312f0e95f": {"doc_hash": "3edca15bc24c4207d5ccd8efadce543f0b9f7bbe4fc1988518a982e1750aeda4", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "69a11c44-6cc4-4542-80aa-8518dfb89104": {"doc_hash": "c015564a3d468af77b5a461823687ac171dfc88f98ffcc3835e0c9c784e7bf2a", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "292e67c5-1a5a-403c-b12d-dcb25030fc03": {"doc_hash": "73ad269e0da2a837b144fed22e005c82bd25fb4ee3e903e326a7577f40c3a717", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "c851b4fe-b7bc-45cf-adc7-94e6c6fe20b3": {"doc_hash": "6f853e78c35bfe5a6c6ac791eff723846dd6422f846e5bb54ca4e32cb424dcbc", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "5d6fd5c1-5a17-4da9-b639-440e5e1193cd": {"doc_hash": "cde942138354c4be7c911fdf64c44978d82b79d79bc42738f9ea9fa38cf2bb23", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "f0872f7c-2fe8-4bf2-ad33-26a316747698": {"doc_hash": "865b8f3b28bd2a5e4ccaddd8981ac2a023c7bd89539cd1723c3a749e76d3b4a5", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "f3fdc0d8-1222-455b-9299-227b727b74d2": {"doc_hash": "4490761683bef2971adeb50e12a8795ed227e0c1424ab38513afda53addb8b75", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "43a5f7bf-f833-42ec-be5a-60f34015cf84": {"doc_hash": "5d4254ebba377f6da466592c186f97eea96a5b04ce7b66a677b13c85282e4643", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "276a92b0-090e-4fe2-b100-a3410d5f0ef4": {"doc_hash": "13a09475376a22f62dd523d7630998d167f8d7e8c1fcd208bed5261493755e4a", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "66b939a5-a757-4aa1-b71d-ba0f7c2a1daa": {"doc_hash": "dcb7cad5ee63e9fb878ed227c51076fc3f3c6b1fb4e74974f9e3079aadb88331", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "e42d9434-2b2f-4f03-b5d4-29d862f36f85": {"doc_hash": "9c3dd0e16c1dcb73946a8c699fafdb6dd26fd4d7f9f20fb90623e080f56accdb", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "c6803601-6d9f-48ea-8414-5ff00d8dbf68": {"doc_hash": "b465da74d0a61f17ea556018d79e33fce1a84bde139fc69543f8d66bce36462c", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "4c83fc0a-a96d-4c19-8b22-a14a9ddd59c6": {"doc_hash": "4da6be068b7e8636935d50564a2e712578f322f5c3c962feaaf3ffee4cfa2e54", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "4eb2b667-d210-45cf-a9e9-fcb4a93508e4": {"doc_hash": "970e220223db5c6fadd552fc3d477a5abcb7ecc29c5a88232e60cd5a74ba2fe9", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "52c14d94-0e10-4de0-996c-2c587441bbc4": {"doc_hash": "87c4032b1390a09d45ed76f2d5510de980ff11cd3ad8becef08aace6fd24e2d6", "ref_doc_id": "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4"}, "a0431000-c468-496f-b273-0a1dd357b18a": {"doc_hash": "5de7d43d27c6e868c1143ebd335336d69bab08460e8238e1325193ee40ff6707", "ref_doc_id": "c2fbe393-a348-40f2-ad00-b60f8963e0b2"}, "239d6526-250b-4ab5-98f1-c1276c5655aa": {"doc_hash": "8052a206cef22494947e63d1813aa016e67f0f21f5db7ad7ab71d4c872894bd6", "ref_doc_id": "86400052-ca68-4aad-b381-1be5923275a2"}, "32b9e30c-fb3f-4f51-aa79-44d4aaaf8c32": {"doc_hash": "777fcf4ef1261241c80b09c281511f8b9519decaff78769d1aad435648bab1ba", "ref_doc_id": "86400052-ca68-4aad-b381-1be5923275a2"}, "35d7bf03-77ef-4feb-b81a-5aa588d9d5f6": {"doc_hash": "f3cae02e625c1b2793924909e902ec135e8a3a97bcd11bcfc4281b344b2fbc3a", "ref_doc_id": "86400052-ca68-4aad-b381-1be5923275a2"}, "72cadb08-a6c2-4ca9-8869-44effa0f12d6": {"doc_hash": "2df6108fc1a1bce16307e417136e92975f60abcc8569f0c360050170e8a2539c", "ref_doc_id": "86400052-ca68-4aad-b381-1be5923275a2"}, "c42d7d65-301d-4197-b22a-70fadf588145": {"doc_hash": "6b20df28c48575f539a0c1241a07e99b58702c648c01ab38277ff530bb525513", "ref_doc_id": "86400052-ca68-4aad-b381-1be5923275a2"}, "7f5c7b00-3249-40ec-b4ff-84a66d15f729": {"doc_hash": "54106737effc2f8168b4891f6f50110c1d38e0c58c6ea63a97cfb2ad93d0e3e8", "ref_doc_id": "86400052-ca68-4aad-b381-1be5923275a2"}, "a3827c93-79b6-422d-a3ea-f4390d8e40b1": {"doc_hash": "f45bd2ff7f9fe28151ce3654618de2ea646282cd7cf599d402a299efcbeef495", "ref_doc_id": "0e20bd6c-b0bd-4425-ba28-47e289fb62e7"}, "2dc2ecba-748d-48cf-8be8-e580cef4b8e2": {"doc_hash": "ed0fcf83fa6f7349442512f70899a5ab23e3567879b0066240b929bc9b71720c", "ref_doc_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506"}, "a007d0c4-13ca-4eba-8a42-13503980d9a5": {"doc_hash": "4f0a8b5d59eb9c295f95582f0cbb5c091130bbaad81f89665e570b6e2a7f3920", "ref_doc_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506"}, "03456a72-7aa9-4777-886a-7ed15e2a9bb1": {"doc_hash": "8e58614783af1f3d8b6535abeaaf5a86d987a87262d37a48f976643980387737", "ref_doc_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506"}, "e807335b-998e-42e0-a1e5-1e8175e78ec4": {"doc_hash": "626568b6c6e45f9f3426655dc0f8a1f695f6a797269e5d1e112fa9b142975832", "ref_doc_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506"}, "639927b8-2190-4eef-9f89-7469c75540ed": {"doc_hash": "fb86b534896f73628cf911744e78098adbc1fa3388a65006b76667a06c841e20", "ref_doc_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506"}, "858b26ab-b174-43fd-8281-73d030e311cc": {"doc_hash": "deedac8c4c33e9ff8a05de9836de8e992c9e645e180b1f8618468e583e7d3f7a", "ref_doc_id": "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506"}, "1e5cfa1c-375c-4ea3-9b06-949fdfc98ad9": {"doc_hash": "9b2872c931fae109724098388130388604ef229794e53cb4b1eaa7f5462c6701", "ref_doc_id": "83fc4a8f-d731-478a-aa5e-9e1d6a44e640"}, "bbf02833-fe40-4860-8460-e53f5df00670": {"doc_hash": "73cc66cd3d7780d28f8942c5027b77d9730e3f845474b4a3e8e56da11d006d6c", "ref_doc_id": "62e75998-5959-41c0-a06a-9bb5eaa87858"}, "761957b0-439b-4652-9171-c3044e52f0b3": {"doc_hash": "a2d00cd6035cd928af398f91a928e1c0b26a3d9c14cd520e9b95332e1517fdf9", "ref_doc_id": "62e75998-5959-41c0-a06a-9bb5eaa87858"}, "09f08ef6-c5e1-4c95-a38b-eec72bacdff0": {"doc_hash": "92be177ec67b8f8e8d0bbc0d907e6de346a561952b8699e4abf0e017697a786d", "ref_doc_id": "62e75998-5959-41c0-a06a-9bb5eaa87858"}, "ab03d49e-aaf6-4d97-b886-082f6ea837e0": {"doc_hash": "df2237a918c29e1d119c186fd9be5df16bda33441f71408cedae946e2fe55240", "ref_doc_id": "62e75998-5959-41c0-a06a-9bb5eaa87858"}, "c7173bba-f621-4909-aec5-ac7521290be2": {"doc_hash": "9986219f5822284ddb87899c7f7ddabaca0b18c7fb8e10bea31c89d9a13739ae", "ref_doc_id": "62e75998-5959-41c0-a06a-9bb5eaa87858"}, "fd6ab857-e118-457c-9cbd-ba95ac26a1d5": {"doc_hash": "2f8d91eab9dad30ff1610a0de8ef9772666206d33b2b0dc45329a92cb26db44a", "ref_doc_id": "62e75998-5959-41c0-a06a-9bb5eaa87858"}, "be1bb707-3dbb-4c6c-9772-275a019d46f6": {"doc_hash": "fad28304eca4ee01249caf76555227fa38e38b91f14d748bfe274eb0e2879884", "ref_doc_id": "62e75998-5959-41c0-a06a-9bb5eaa87858"}, "36abdebd-05c0-4af3-823c-2772d35babde": {"doc_hash": "3dc03bd6ca9686a83c160d5bc8f1fd266107433f5170bc4e651a5812ddf9dd2c", "ref_doc_id": "a81bcfaa-f328-44f6-813d-f24531c85447"}, "d63250a0-a804-40f4-a00e-e3b3edc4bbb1": {"doc_hash": "b7a55f3d3c88f8ec4c66f70df6ee63feaec9cff58e0ad7037041770937db7b78", "ref_doc_id": "a64808f1-ce11-4767-afc4-6e88c2c164b5"}, "de2166dc-cf5e-4f9b-9baf-bc5b71618542": {"doc_hash": "77f21207e36e2046c78435341c0fa47088fa171cb88031f9e154fcce0b40e546", "ref_doc_id": "a64808f1-ce11-4767-afc4-6e88c2c164b5"}, "5239d60e-7297-480c-ac45-91427851d131": {"doc_hash": "a202b4d514d03b6c872c35c99ff7b4251e4268cc12fed0a83a5c08a7c3f86be7", "ref_doc_id": "a64808f1-ce11-4767-afc4-6e88c2c164b5"}, "5e1f72e8-287f-4621-8640-7bcc5a846d21": {"doc_hash": "56ee51f20c2bb30f3540441ae3fc2ad2a8b8d18fb5115e6f0866557dfc441125", "ref_doc_id": "a64808f1-ce11-4767-afc4-6e88c2c164b5"}, "344f3c9e-c857-4ca1-af9e-5bb42e9988e1": {"doc_hash": "3e167016aa2d3f3d1f2bdf78b293040ce3d25af01464b31a74346f9c461160e2", "ref_doc_id": "44dcd1ff-0364-46a7-bd0c-532862c300d1"}, "83a5d413-dfb1-4825-a3b4-befd27c3333c": {"doc_hash": "5dc59b07973ccbf7be629f32466ad1eaeaac4ba7bb44cba6e8b92aec46da27ba", "ref_doc_id": "44dcd1ff-0364-46a7-bd0c-532862c300d1"}, "ca1450bb-9c9e-44b6-bd2a-44ca6393b899": {"doc_hash": "d69af90c935332dce13352912010e5c4767f0e08a91158266732e560093551b4", "ref_doc_id": "44dcd1ff-0364-46a7-bd0c-532862c300d1"}, "07bfa497-0b82-4bf5-901a-d5ff6134bafd": {"doc_hash": "a0f0089389f1ca06429286903b44f2fa075ecb4b83a4faf095d0db0d4d38a055", "ref_doc_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e"}, "fccc8ee0-ab94-4244-8a72-a07038f24310": {"doc_hash": "f070ecd4441e14c6b568566f211b6f3fe33b9c66c746215eb3e9e7e7662da4b8", "ref_doc_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e"}, "6c434626-4aab-46a5-be8e-2d51619ce329": {"doc_hash": "04edf3672412a3e232e1d3fe446d365faadd45e1879e179f8f3f422d964a1c62", "ref_doc_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e"}, "dbd1f504-8904-479e-9f43-9317e563c650": {"doc_hash": "e9c029af587f5ea2744397cc2f6609138e4613491b9e334a26a5a488ee1e66f5", "ref_doc_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e"}, "1d24d70b-2911-454c-b568-d2de6b5dfb58": {"doc_hash": "b49cafc90e285c5ca24e049deba5c560fd0377c139f7a2c1407f378885c39f2b", "ref_doc_id": "fcd64c8f-38e7-4e84-9c4e-797c5956f95e"}, "323e347a-14d2-4fb4-885c-864b3222648e": {"doc_hash": "80b33e580b843072e8b3279df435b5d84fc4669b6e2d78173265aba9df2180f8", "ref_doc_id": "9d424d89-7111-4b99-9ca1-4cedb48c0000"}, "5885b961-6701-4602-9179-c63488e128ad": {"doc_hash": "589d5f2b7e4018e40117c76e0afabdcac93c8a3ba3cab7e7b737b9451fba6a8a", "ref_doc_id": "9d424d89-7111-4b99-9ca1-4cedb48c0000"}, "b52a2e02-9571-400e-b9cf-4ea086eef033": {"doc_hash": "e62215774ee007ee5f5814d39e877130265dfc020195c2884968311cb8acd610", "ref_doc_id": "9d424d89-7111-4b99-9ca1-4cedb48c0000"}, "cb86db53-c9f2-48d3-a099-9179eaf88550": {"doc_hash": "1ab2f32edb2a54f95f9813206541c20e7e078541a74f0fe6a8251fceb09d08d7", "ref_doc_id": "9d424d89-7111-4b99-9ca1-4cedb48c0000"}, "b1248432-5856-4eda-add8-cfc0e1dc19ed": {"doc_hash": "01aa20b6916f93325462f8be85e6a00884fd0e24ced91407a287a0089a77495a", "ref_doc_id": "43aee5d8-c5c7-4b62-a8c8-604ff2579d97"}, "49509dfe-ea7f-4ec7-adca-1f7e9514116a": {"doc_hash": "bef2194c7537efb46ca60281f74f468f429fd658f3787bbea7bdd03aa91f094c", "ref_doc_id": "43aee5d8-c5c7-4b62-a8c8-604ff2579d97"}, "8634038e-b6f3-454e-9237-ce0f1a06bb42": {"doc_hash": "36217b27a2349c5d52f191a9edb2940ce9a06ed21bbbe5912976b2d6391ab99e", "ref_doc_id": "43aee5d8-c5c7-4b62-a8c8-604ff2579d97"}, "4ab4ed94-55ac-465e-816e-a0fa4f05c5bb": {"doc_hash": "4db21522a25d322aa74206a1989444a3f944df40ba1c8eecb326fac434e2f90c", "ref_doc_id": "43aee5d8-c5c7-4b62-a8c8-604ff2579d97"}, "13755b78-9a87-4904-a574-70c04906a7f5": {"doc_hash": "94c769a6994a8fcc81af6ed39e18c0ebbcef9864c8cfd0d5c00d5046f525af79", "ref_doc_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a"}, "8abd9258-016c-4ec1-9a9d-7445abfd3ebe": {"doc_hash": "9dd0e7b67e8365e09c1d07c9c92d84b70b7a903c06f8249ae719427101a37c50", "ref_doc_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a"}, "6c7b3d39-ee49-407a-afa7-c2f1e55f4956": {"doc_hash": "67364bce7cb7fbf5a6cc014d9ccd7319fb80972a52303a966f829d5b2aad0ddf", "ref_doc_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a"}, "edd09976-3685-492d-92be-329add1ad645": {"doc_hash": "76c665a91714b06edec87c89217da92fc2e758d3d0bfa17b256da3f2b92c4438", "ref_doc_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a"}, "9b66b757-01b3-4f4e-bdd5-fce7d4b6eab2": {"doc_hash": "d7afc3637ceb96d74d05edac63e5a42d1140d9adee0784d9f1e3fcfcbae18fa3", "ref_doc_id": "6477e49d-e2e0-455b-b2eb-377bfe97098a"}, "d8234117-73cf-4f20-9e15-820e83dad97a": {"doc_hash": "cfc05ed32d349a3be8677d9a5c877342a1cd88ad3c53733bb34ef0f260eca1a9", "ref_doc_id": "d75023b3-9659-451e-a937-7277b012911b"}, "a989f9e9-5479-4b59-b639-5d7495d49766": {"doc_hash": "cdb7ffa65512df1e22e86641146c40230be198db5eecd36576b3dc3bc38c0162", "ref_doc_id": "d75023b3-9659-451e-a937-7277b012911b"}, "5f67c9f5-ad18-4ba6-bf90-e459cad69656": {"doc_hash": "1f45517836c355be8d007c8c02ae491f54328bbed0d7f5586764069826fcce33", "ref_doc_id": "d75023b3-9659-451e-a937-7277b012911b"}, "59aae726-591c-4939-b3a6-f027d846dbb8": {"doc_hash": "3cf09a2a73da83ac10c72ddc8ff991435581cef1318dce3fcf244826a7ba8feb", "ref_doc_id": "d75023b3-9659-451e-a937-7277b012911b"}, "fb88628b-c38a-4a91-81d3-d269d60b5bae": {"doc_hash": "95ea59e806fa221c9d4034cef0830977112b0e2c286e4cb76f5c5192431a51e4", "ref_doc_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325"}, "3d541ec1-f767-44a8-8bc3-4939535a7e6d": {"doc_hash": "040da511a82d6959f335a2fd8379dc18a8aabae78c5eb9b2a171e26895deabea", "ref_doc_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325"}, "7679600a-783f-40f7-8275-a94e8782dd0e": {"doc_hash": "94b769c1cbc59cc456cfb7454aa8629ad3042f0721b0f927d419a0f7a239b74f", "ref_doc_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325"}, "adf1e957-9e22-47bd-9d43-e5d9b986f47f": {"doc_hash": "2ac552261a1e0b70e9bb50f0846ccef61d0dda90d34750a0721c411ad3f18211", "ref_doc_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325"}, "90bf1d69-2c23-450f-8244-1a0825974db4": {"doc_hash": "57ab279b0cc8039d4c98f93ae0e1b956dc3cdb767d8c82264b61e76ba9d0badb", "ref_doc_id": "9c9c8977-bbed-4d80-ba16-b8a7c5903325"}, "ea029605-e0f1-4560-93a6-c9727b3ead62": {"doc_hash": "7343582e20c378284be68bed983a213f6f764fb77afdbc61767d806107b55be3", "ref_doc_id": "a43e8e71-79fa-4b67-adb9-9940cbdf3796"}, "eb0c7c81-0331-4337-ad99-2f36ae5ed01b": {"doc_hash": "a8aea21e157873b552730fe0511f3c53832fa702b85c0b23772d463ab4bcfd23", "ref_doc_id": "a43e8e71-79fa-4b67-adb9-9940cbdf3796"}, "f30083e6-7521-4056-8655-3ef7e4ea7a6f": {"doc_hash": "8bac4d85d2f1bae4c0cfd213dad4476b462143406a44a899f65686b096da4607", "ref_doc_id": "5c21ab07-b6aa-4446-a340-ad76849162db"}, "6603e679-dc64-4f96-9cf1-c2178a611e2a": {"doc_hash": "f5ffc651a6050384f20fd89f0ee487a2bbbd8617bfa31ae53105d57a7e1b7019", "ref_doc_id": "5c21ab07-b6aa-4446-a340-ad76849162db"}, "59d48b6e-9b4d-434e-bac2-03457f655ea8": {"doc_hash": "aec5fe19b078de49def676c3d3deb4a87a33c14d01532c5970ed69daf8f93462", "ref_doc_id": "eba6faba-975d-4de3-87ed-925a72c0253f"}, "3b0b8ba9-8d8e-4369-a420-f3487e19c0a9": {"doc_hash": "63a103036a7ef3dd5b5a6bd0d91f606b9eca3d50d84f75284a88c899e8a6ba27", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "41d5c42a-4114-4f32-8ad0-2ca7cda0db2f": {"doc_hash": "9a000a302f1b6fd8518e45e9f3dc1ec757b75a95b5fdea3f87c5f16e3af4f52d", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "b6df7724-3802-455f-9bcd-b76e47bd6c39": {"doc_hash": "980cf26754867149abd7276b21a7b13c8dbcd5ed84aa8e6bb345fba57cd45355", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "c62ee8d8-fee2-4bdb-9ef8-9390d874132a": {"doc_hash": "fcb0a158bc221a11439499b5d7c72636b579b4b737f378c5da4a7d62a129387a", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "9e9b370f-b836-4913-b79c-34d778ed88be": {"doc_hash": "4d713b7c4a7d2c7113ea95bba17cd15aede2119c5bb3412a948647a60e654cad", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "d8b5b899-ab43-4ef6-9ab8-6ae21a16ef00": {"doc_hash": "9c9e5b54aa5c5cc376279b458c2e13824b7369ae2267565d916133e9800f04a0", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "21862e34-08f6-48c9-a10b-6f494a57322f": {"doc_hash": "dc098f1e63766f5de3f7a564000e012bdfb5c871ad830c236de0709a9899a0d6", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "aba9120c-5bc8-45cd-8a19-950f98ce3834": {"doc_hash": "86238e93fef071b35ef08038ee657952fec37b431a20d7037ec560ac1763d7bd", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "57dfe59e-c719-4d39-994e-4cb4e2eb0241": {"doc_hash": "1ee86740c7468dfb0ac38ae7d37445913a5cf95d7f8a15502870925430fb81c6", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "ba07c8b6-9276-4e06-9da8-f1c5a9085293": {"doc_hash": "91bce829aaf306743120372b7b40ecfffede5aa5fa69b430e63a10ee79dfe633", "ref_doc_id": "44648c52-62c2-495b-ae28-ed91b0616f28"}, "cf02d00d-77f9-4468-be64-8b0c3fe3bdfc": {"doc_hash": "21a7943763a3d290ab37bb84295f4f52c72b1dfe910ee2af3e6efc1df4a0678b", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "c59de0b5-a5d8-4b2f-bb76-755c46f912bc": {"doc_hash": "92f332b1548bb7aec46bd80d6e89255fc40d2b4c2dd894630195c73611b6ff9d", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "7aaf5c77-2e30-48c3-a15a-f9cdd8b6d0bf": {"doc_hash": "d5dd62296ebc32e8fb0351c7a89771685aaef2ef7d737342a11215c105a9a003", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "9286bcf7-aa2c-4872-91b9-c2e4cd20e7ee": {"doc_hash": "22a2218cfedc8b344e20ab431ba2c27ac923f01c3aa38b35e91bb072d29d04a5", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "079946bb-afd5-4114-a16c-5871d77241e5": {"doc_hash": "c98968e224b6074a796cacb2bffe278894a6d5e4225d815403949aa0328d909c", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "973eadac-3c08-40b9-a294-c359b57ef066": {"doc_hash": "fa0ed4fbeed546edcc098a2ebb575c3fc48fd2da8946f0f6f2c6e0dbe8f91ad3", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "0190ebf7-c3f1-4459-bb0e-3e712a7ace02": {"doc_hash": "ebfa9c769e00e2c32098a15055568cd742fdbd803a7cca21bab4be3279ce4e07", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "dcb0063c-e567-4aa2-8d7f-7b3eb84814cd": {"doc_hash": "05fa810b26b16003ca6e3866261fe09ea534400f7737bccbcf43955ae2f12e80", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "d0e25140-cdf1-43ec-bffd-178ad6461eb0": {"doc_hash": "bd18742f6760112a97e6c7fe8b0ec02f856497ae6b9a1a44ec71c0f8b20bc4a4", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "976c79d1-5208-4664-aa22-8654951aeac5": {"doc_hash": "46f3d0af4cc4c8e58f927e3b8262373c384df63e33d6048db5abbe3b35b4f904", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "36e085af-f499-46a7-a672-16990caa79cb": {"doc_hash": "e38894dbae3fbf9e5c945e5c713e076d049bc7a42113403c0dfa00325b20d48b", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "4eb862f7-9faf-403a-b1c5-ece9293fb333": {"doc_hash": "47388c5a552988d5bf34ac2804433b9498aff4ed1baf649b8f395eff1f60e4d1", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "dfc477a0-e974-4586-9a95-1feb6b4d1c5e": {"doc_hash": "f518544b9a44c5c6d099ff753785fb48820d22698d0a8c17b2748390c543dbcd", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "cbd661ce-34bc-44c3-98bb-0ac89dddef5d": {"doc_hash": "5ad85e2bdbe04e8aae245e281ef1ec3811b7a4b46db5ad493eed2fd9e56fc0e1", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "693cb39d-ab09-40a2-961d-72d7d90ae222": {"doc_hash": "03d36e7e4f1539d39e2ad72100c32d8a2c0bb92d2f6cdf93cd666ce8b117dd2c", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "0b71669a-cb97-4947-ac6c-21254b463822": {"doc_hash": "4af4df5a0ccf481c3d027c3ca9bf53a318761294aa1482c66df2f1ddf1524213", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "38fdead0-06d0-432b-b84a-dd3cb9e17eae": {"doc_hash": "6d571ba7ed0a4e4b93c703f3ab44682fa53cb43fa67cf026808df75a83c83373", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "e0a50645-4dd5-42a3-a960-d22954155cd1": {"doc_hash": "4f39259e13bca8b19b5cc5b56b8c4cec069fd84ad9b2eb3fd98ab9955885a3ed", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "0b75493b-6412-46c6-842c-58d4c24eefe9": {"doc_hash": "1437c07ee8d613d7ee5710ae2949397d8d114bbcc2afaf97c9298850a0153502", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "0d266458-f544-40e0-88f8-95085fd759e0": {"doc_hash": "5ab4ee017cecf235f1b3187c9d0397c23f870b624e1f8994c9f8814c3ed8482f", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "0c7ba644-d6a4-46ae-adbc-ba0a6c86bd0a": {"doc_hash": "80400c9a767a82ef58b62207fa97ffbc42852a5cb3a52323ec8dd8ee9aa42b76", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "fe610356-d1d6-4197-9288-224fd2d412b7": {"doc_hash": "80f8a8d10c98d723db2f3074021d40faa2c2d4a3375bd1d21edc2d581932b3cc", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "47ab876c-fd77-45d2-b1dc-cc36e97eb9c9": {"doc_hash": "bf7602c775162729b828d2163267d700ac0fa6f99a094f4ff1c974076d403f77", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "ca2f4900-cfe9-48be-a7a5-ef399fb96527": {"doc_hash": "2e23199c6c909461f344b88e0cf8ffcd3e9e1b8b260360b278adf080c2d15298", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "422246ed-bd89-4bf8-9186-cb8167cbdc05": {"doc_hash": "dac15e00c836288cff436e698002f06c2d9dc0d4bf0c9b0768ff74bbada505d2", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "b369f15b-f9ef-4ea3-8a01-4f9338cf481d": {"doc_hash": "6b97b4b6acccbbd2e3e98b4b5c2b77971d044057073208213773d532bc322ac7", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "5cc39121-672a-4d0d-9160-0c902b59d1f4": {"doc_hash": "b3688acea221d12e3be915cc7420228a33d7ae627df540737589d2168ef8bfcd", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "af397ca0-fe10-48fe-961c-07711f7af423": {"doc_hash": "26d584470c0b119b87a454cac5dda23d4186bd9d50c894f4003142053eed506c", "ref_doc_id": "2ce0d458-440b-40c1-bca9-19f491b0d2c5"}, "a7edf3ef-b6d2-48d7-9607-ecbb8579a1b0": {"doc_hash": "ba7ec3e694d439dcacbfe372e27b5a90bd71fae98954342ffd5335ad82c1832d", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "e4ce63b9-cfd3-459f-94fd-58fbddb6217e": {"doc_hash": "91ccb3db4904e44d6588333c8f19529243e0dffa24cba976fb1487bf1ac5f087", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "1a35a495-4424-4b0e-abfb-8fe5f9adfe0e": {"doc_hash": "fcd8acfb1b664f68eff2cd4a3b8ad6e78368314b1dbf3d77e02ce5da09f8e6cb", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "30c97ff3-dffe-4419-87b2-c78b94d312ba": {"doc_hash": "684cc24d740d5f8d29cacd5f86b8ff0e89246132b392aacd1866c718e50585f9", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "841716eb-6c44-4c17-a8b5-fe4836f1892e": {"doc_hash": "7666e6238538a5a22944b70894f747e7cb3b7f03c64be3e18d0bf9135f2fe03e", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "6f297e84-29db-44e6-878e-6f01c9df4f17": {"doc_hash": "700a70ab727c7ecd2219a296cbb5c6180661fdd98bbdaa7aea681a81c14499ea", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "48b8e9f6-46ee-44f5-a52a-3f8ae6b6f2a9": {"doc_hash": "ebd0a04d22efc719c3f4481652d6bc6e2b13a7d009c64df6204bd06e35dc6429", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "183541d7-b8ad-4ff1-87aa-25ace852edcf": {"doc_hash": "2ef87adb72190ccdf0dca93d912e73f56768bc084129d1b5c8c2f9339b44c4bc", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "2948d9af-db39-412a-ae0e-89e8a953d8db": {"doc_hash": "2be0c2d01371b27328c528efd83bea7748f94af97f3d70c654d1941753e31f8b", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "e010476c-eba7-4e27-b570-efdd0602c146": {"doc_hash": "55075024f81f9d5225f63aa5a759e8403a0da0fd6af28055005b82c0688ba41b", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "399c890a-ccb3-484e-be4d-4ae260f5144d": {"doc_hash": "347de68a9630cb43fb3bd5b9a976ef21d70b6c3955c79607a7232bbb68f4ab09", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "6cb51f76-b49b-43fe-8b99-3d5ed8e6287b": {"doc_hash": "60b1961160a8dabee7cf40e0bac7e8bd87b41fb1c357bc35c6b3a9ba7b8bd29f", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "ebdaa66b-c6f0-46d3-bc72-238cf11687ab": {"doc_hash": "72bc918a02891a9d2011ee6de0f5de18338e7cbc3f5d6326031d904325c7231d", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "dcb49e9c-7305-485a-94ae-0aca7b156ec4": {"doc_hash": "3471c1d407f278926708081fd9be9109b80883fc722bb5c574b207e602a86a7e", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "2a853307-0011-4964-899d-3be5937effd7": {"doc_hash": "6a4ac0580391a34a998cdcfe7e7ff72a6328f138d1ae72a1ca0ca8e515cdc560", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}, "a957daa4-0cc7-4043-85a7-58fae9a3cca0": {"doc_hash": "07167384626794fc87d162534563fb2df5e109c93e2947fa4678658306ab5c9a", "ref_doc_id": "ce2d6a07-8da0-4106-a61e-5a203941e598"}}, "docstore/ref_doc_info": {"5d7dbd4a-4d3f-4fce-a766-8dc640c4abbb": {"node_ids": ["7b7551af-91b8-4d42-a2c7-9b84f4905a6f", "7d280ea9-3867-4b39-a95c-f1eea85593d8", "1f076b99-e4d1-4b13-b2e4-c0ec435fd3aa", "06300998-4d7d-4395-841a-7d2f9e07de86", "768b9e47-0c40-4c9a-8b79-2ccaae9de5ce", "5e01b110-b5a6-4998-81a0-61f1fc6e3b95", "d1cc91ab-3d5b-4a1d-bbb6-fb3b074ff279", "3204ef13-7d1c-4266-bb07-8b312e8c21cd", "e579c2b1-d64c-4cdd-abab-ffd3930fe584", "5b0cbb72-6f74-44f7-950b-7e12f9c8bcb3", "714d7593-722a-4dde-8726-8179b5e2a1d7", "a1289f16-a84c-490a-a0cf-db9e9e889480"], "metadata": {"window": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 second quarter\nended March 31, 2024, revenue increased  7.8 percent  year-over-year to $68.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in\nthe prior year second quarter. ", "original_text": "Cencora R epor ts Fiscal 2024 Second Quar ter Results\n5/1/2024\nRevenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80\nAdjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ee3cbea2-3379-4143-8a25-1910e8ee065f": {"node_ids": ["2ba2d219-11a7-4a7d-b752-0708d15001ce", "14b0abe4-308b-42e7-9d3f-00add87aea76", "e9c6385d-b340-4348-97b6-9a1edea7de4c", "8a5c5897-38fd-4b09-afab-ba20ba5c923a", "f5412e34-7d30-43d2-ae9c-d8353cd9af56", "0247707e-ddec-4f29-947d-79f502877126", "2ebbeefc-b54a-4c97-89de-b947fb06cb14", "9db7ff35-eb42-4d07-bc71-25abd39af2d1", "0037dc5f-080e-4d22-80f9-93725b240343", "9f34a3c0-5d03-4802-ab95-7e79a9bf2377", "4e9e4b08-d526-4673-b66d-44e0a5c77a3e", "315c9616-8c4e-485b-b0b3-c39fee77fda1", "5e830766-fa2d-4867-84c2-b3301147a455", "76c01d6f-7f8d-4085-bae0-a33ecc5f52d8", "82438e8f-f731-464f-97da-04b34db40f0c", "e807cde0-587f-43cd-93d9-6423561b050a", "bea75ad4-7693-47f4-936d-32ba612a5429", "d06e57f1-9173-48a5-bd82-26e44da47c3e", "8a007954-3f9a-41ed-8c7e-218abb909868", "46f512a4-624d-4f9c-9be1-6db34f99f8ad", "4f21d4ea-63c8-4a96-8538-cb0344237724", "c58cafe6-aba2-4389-805a-e24bb440f93c", "12bcb8d1-148a-4d2e-a976-f12ecea846ab", "311f9fca-1f75-4ccf-a6a1-152beafbb075", "61f9ff46-2777-4524-91f5-906fbe69bdad"], "metadata": {"window": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc.  $421M $765M\nDilut ed Earnings P er Shar e$2.09 $3.80\nDilut ed Shar es Outstanding 201.2M 201.2M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "original_text": "9.8% 20.9%\nNet Income A ttributable t o Cencora, Inc. ", "page_label": "2", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f917433c-c0a4-4064-a6f5-b4eeb7f77242": {"node_ids": ["5fa97b84-1841-4eaa-adc7-79520412a51e", "225de017-22a1-40ee-8e39-c966d626403a", "4cb1e7c1-8ada-4b42-a1f6-060a3b01808f", "df4e884c-05ae-4e84-abc9-0af5328d6436", "1813be28-c698-46d7-ae4b-802fda2c40f5", "75990a33-f217-4fc6-a1b0-daa83d94af53", "40a0d820-1fc7-432d-8f88-51340b1a9290", "2866b945-9986-4290-a209-1ce9875ddb07", "e110028b-1c06-4f6c-ab1a-52d1e26a4079", "9991ff59-fbf0-4934-ac33-49713cd98796", "f377518b-8ec0-4e8b-bcec-bb2aecc44bc8", "c8ead5d9-6011-4dfd-9f88-12a67f4996ae", "c1af0fb9-7590-42e1-bd65-ca5b5211e1fd", "a3903d68-8a8d-4daf-a417-7f53fbb1d488", "e5c9ebc3-1a12-4978-a3ec-520550817f4b", "4c21d133-dcf4-4b57-9933-5a3540634691", "2a3a6e9f-96d5-4be9-a2d1-2d00c654ee19", "d7009740-e4e7-46cf-b3ba-4bcce68b05cc", "6ac55e06-8cb8-4d4c-a569-b1cb0f04aabe", "1578410e-4cce-48e4-9d40-7af66c38ca76", "f01daddc-8898-46a7-b22d-3aad5f21f574", "9adb94ce-087e-4938-a10e-468ab3b3b61c", "bf380379-48d2-4964-90e8-bcda96d7bf0d", "7a30bea5-56f8-4fbe-8d7b-e830b9f82c96", "43c670a2-0fde-462c-a0f8-0c9447e93496", "2adab6de-f6b8-4505-9efa-0cccf7930d2e", "e131dbbf-0a0d-435e-a2d2-c6a0498e1d1c"], "metadata": {"window": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S.  Healthcare Solutions\nand a 9.5 percent increase in International Healthcare Solutions.  Adjusted operating income as a percentage of revenue was\n1.51 percent in the fiscal 2024 second quarter, an increase of 4 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "increase compared to the same period in the prior fiscal year, driven by an 11.2 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "05c409f6-8f41-409c-bf2b-53d685f0cd33": {"node_ids": ["328af804-ad17-4e02-9c1a-c4bf2a7880a7", "53eb4c08-ea28-41eb-98bb-c283fdcd4696", "3ba83c3e-2920-40c9-94db-9f7dff3e6f89", "fbf58b1b-3c9b-4825-8c2e-19e698d9927d", "5d30a103-9b83-4449-aa78-db791f62cb5f", "05d1321a-73ba-49a7-b2a6-68c950236fe1", "c4b10982-24cc-4335-b5c6-e6807a1d5029", "0785fca2-84ae-45df-aa22-6e6e9725a04d", "57342f3b-c7d4-456b-bf6a-43b082c9f353", "74b229fd-c6d5-4a8c-b5b3-07b8c018d14f", "025e83c7-8a32-4a73-ab5c-2ca570f5982d", "52b8526c-1d33-461d-b0d7-7e8e127dd513", "2ebed0e8-b156-4c30-87a9-979dfab11391", "713b037c-5e3c-419e-9441-a1b86e46fe02", "f8dfce02-ecae-47d5-aeb0-c1f7cf8915de", "c5a59f1d-fe2e-419a-8f4a-e83c5741a535"], "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year\nand a higher effective tax rate and expected share count.  The Company now expects:\nAdjusted diluted earnings per share to be in the range of $13.30 to $13.50, from the previous range of $13.25 to $13.50.\n", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "de0ace93-c22a-4f2f-a4de-5ae29a9e37b4": {"node_ids": ["e9cdd5da-f2c4-43c2-97fe-6d864ff05352", "db97e0cc-0907-49b2-bd50-f71195fdcee1", "ee231c5f-0133-4a83-a31c-92aa0f877325", "c5f050c2-9184-4dac-ab72-469afc02a491", "5b86a53c-f919-4f93-899b-1a81a207ed7d", "8a60c433-1b63-4637-9534-0934aa8237fd", "07340f46-c907-46cc-a472-29ccc9633fe5", "d90a6932-a376-4dd4-a667-0196a1f84280", "40d55e68-bbb2-42bc-b103-4302cde4fb49", "7526e408-4778-4e05-bd77-ecba90053fa2", "9e96f8a8-59d9-4643-bb95-4c2061d630de", "403efabc-4574-476c-b4bf-fce72de65122", "a6b504a2-e20d-4bf9-9299-27d312f0e95f", "69a11c44-6cc4-4542-80aa-8518dfb89104", "292e67c5-1a5a-403c-b12d-dcb25030fc03", "c851b4fe-b7bc-45cf-adc7-94e6c6fe20b3", "5d6fd5c1-5a17-4da9-b639-440e5e1193cd", "f0872f7c-2fe8-4bf2-ad33-26a316747698", "f3fdc0d8-1222-455b-9299-227b727b74d2", "43a5f7bf-f833-42ec-be5a-60f34015cf84", "276a92b0-090e-4fe2-b100-a3410d5f0ef4", "66b939a5-a757-4aa1-b71d-ba0f7c2a1daa", "e42d9434-2b2f-4f03-b5d4-29d862f36f85", "c6803601-6d9f-48ea-8414-5ff00d8dbf68", "4c83fc0a-a96d-4c19-8b22-a14a9ddd59c6", "4eb2b667-d210-45cf-a9e9-fcb4a93508e4", "52c14d94-0e10-4de0-996c-2c587441bbc4"], "metadata": {"window": "The dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 161532.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "original_text": "The dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c2fbe393-a348-40f2-ad00-b60f8963e0b2": {"node_ids": ["a0431000-c468-496f-b273-0a1dd357b18a"], "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0Three Months \n  \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$68,414,307 \u00a0\u00a0\u00a0 \u00a0$63,457,205 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a065,876,284 \u00a0\u00a0\u00a0 \u00a0\u00a061,161,763 \u00a0\u00a0\u00a0 \u00a07.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,538,023 \u00a0\u00a03.71% \u00a0\u00a02,295,442 \u00a0\u00a03.62% \u00a010.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,388,810 \u00a0\u00a02.03% \u00a0\u00a01,321,087 \u00a0\u00a02.08% \u00a05.1%\nDepreciation and amortization \u00a0\u00a0271,732 \u00a0\u00a00.40% \u00a0\u00a0241,466 \u00a0\u00a00.38% \u00a012.5%\nLitigation and opioid-related expenses 2 \u00a0\u00a0225,985 \u00a0\u00a0\u00a0 \u00a0\u00a015,813 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a022,610 \u00a0\u00a0\u00a0 \u00a0\u00a059,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a075,627 \u00a0\u00a0\u00a0 \u00a0\u00a097,444 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,984,764 \u00a0\u00a02.90% \u00a0\u00a01,734,923 \u00a0\u00a02.73% \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0553,259 \u00a0\u00a00.81% \u00a0\u00a0560,519 \u00a0\u00a00.88% \u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a022,063 \u00a0\u00a0\u00a0 \u00a0\u00a0(15,720 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,130 \u00a0\u00a0\u00a0 \u00a0\u00a064,109 \u00a0\u00a0\u00a0 \u00a0\u2014\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0467,066 \u00a0\u00a00.68% \u00a0\u00a0512,130 \u00a0\u00a00.81% \u00a0(8.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a045,861 \u00a0\u00a0\u00a0 \u00a0\u00a083,917 \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "86400052-ca68-4aad-b381-1be5923275a2": {"node_ids": ["239d6526-250b-4ab5-98f1-c1276c5655aa", "32b9e30c-fb3f-4f51-aa79-44d4aaaf8c32", "35d7bf03-77ef-4feb-b81a-5aa588d9d5f6", "72cadb08-a6c2-4ca9-8869-44effa0f12d6", "c42d7d65-301d-4197-b22a-70fadf588145", "7f5c7b00-3249-40ec-b4ff-84a66d15f729"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $420,775 \u00a0\u00a00.62% \u00a0$435,402 \u00a0\u00a00.69% \u00a0(3.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a0(1.9)%\nDiluted \u00a0$2.09 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a0(1.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,406 \u00a0\u00a0\u00a0 \u00a0\u00a0202,316 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0\u00a0201,177 \u00a0\u00a0\u00a0 \u00a0\u00a0204,256 \u00a0\u00a0\u00a0 \u00a0(1.5)%\n_______________________\n1Includes an $8.7 million gain from antitrust litigation settlements, a $22.8 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $23.1 million in the three months ended March 31, 2024.  Includes a $54.3 million LIFO expense and\nTurkey foreign currency remeasurement expense of $4.9 million in the three months ended March 31, 2023.\n 2Includes a $214.0 million opioid litigation accrual in the three months ended March 31, 2024.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0421,205 \u00a0\u00a00.62% \u00a0\u00a0428,213 \u00a0\u00a00.67% \u00a0(1.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(430 )\u00a0\u00a0 \u00a0\u00a07,189 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "7", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0e20bd6c-b0bd-4425-ba28-47e289fb62e7": {"node_ids": ["a3827c93-79b6-422d-a3ea-f4390d8e40b1"], "metadata": {"window": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "\u00a0 \u00a0 \nEnded \n  \nMarch 31, 2024 \u00a0% of \n  \nRevenue \u00a0 \nEnded \n  \nMarch 31, 2023 \u00a0% of \n  \nRevenue \u00a0% \n  \nChange\nRevenue \u00a0$140,667,140 \u00a0\u00a0\u00a0 \u00a0$126,304,037 \u00a0\u00a0\u00a0 \u00a011.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0135,660,305 \u00a0\u00a0\u00a0 \u00a0\u00a0121,862,642 \u00a0\u00a0\u00a0 \u00a011.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a05,006,835 \u00a0\u00a03.56% \u00a0\u00a04,441,395 \u00a0\u00a03.52% \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,787,557 \u00a0\u00a01.98% \u00a0\u00a02,612,015 \u00a0\u00a02.07% \u00a06.7%\nDepreciation and amortization \u00a0\u00a0542,335 \u00a0\u00a00.39% \u00a0\u00a0413,406 \u00a0\u00a00.33% \u00a031.2%\nLitigation and opioid-related expenses, net 2 \u00a0\u00a0147,068 \u00a0\u00a0\u00a0 \u00a0\u00a028,519 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a043,673 \u00a0\u00a0\u00a0 \u00a0\u00a080,109 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0110,068 \u00a0\u00a0\u00a0 \u00a0\u00a0113,684 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,630,701 \u00a0\u00a02.58% \u00a0\u00a03,247,733 \u00a0\u00a02.57% \u00a011.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,376,134 \u00a0\u00a00.98% \u00a0\u00a01,193,662 \u00a0\u00a00.95% \u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a0\u00a020,976 \u00a0\u00a0\u00a0 \u00a0\u00a0(22,048 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0104,694 \u00a0\u00a0\u00a0 \u00a0\u00a0110,125 \u00a0\u00a0\u00a0 \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,250,464 \u00a0\u00a00.89% \u00a0\u00a01,105,585 \u00a0\u00a00.88% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0226,251 \u00a0\u00a0\u00a0 \u00a0\u00a0201,202 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,024,213 \u00a0\u00a00.73% \u00a0\u00a0904,383 \u00a0\u00a00.72% \u00a013.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8f12ce6d-7d7c-4507-b6d8-91f3ab2ca506": {"node_ids": ["2dc2ecba-748d-48cf-8be8-e580cef4b8e2", "a007d0c4-13ca-4eba-8a42-13503980d9a5", "03456a72-7aa9-4777-886a-7ed15e2a9bb1", "e807335b-998e-42e0-a1e5-1e8175e78ec4", "639927b8-2190-4eef-9f89-7469c75540ed", "858b26ab-b174-43fd-8281-73d030e311cc"], "metadata": {"window": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,022,275 \u00a0\u00a00.73% \u00a0$915,147 \u00a0\u00a00.72% \u00a011.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.12 \u00a0\u00a0\u00a0 \u00a0$4.50 \u00a0\u00a0\u00a0 \u00a013.8%\nDiluted \u00a0$5.07 \u00a0\u00a0\u00a0 \u00a0$4.46 \u00a0\u00a0\u00a0 \u00a013.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0199,747 \u00a0\u00a0\u00a0 \u00a0\u00a0203,188 \u00a0\u00a0\u00a0 \u00a0(1.7)%\nDiluted \u00a0\u00a0201,510 \u00a0\u00a0\u00a0 \u00a0\u00a0205,306 \u00a0\u00a0\u00a0 \u00a0(1.8)%\n_______________________\n1Includes a $57.0 million gain from antitrust litigation settlements, a $71.3 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $40.3 million in the six months ended March 31, 2024.  Includes a $49.9 million gain from antitrust\nlitigation settlements, a $79.3 million LIFO expense, and Turkey foreign currency remeasurement expense of $8.4 million in the\nsix months ended March 31, 2023.\n 2The six months ended March 31, 2024 includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid\nsettlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as\npermitted under its opioid settlement agreements.\n", "original_text": "Net (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,938 )\u00a0\u00a0 \u00a0\u00a010,764 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "9", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "83fc4a8f-d731-478a-aa5e-9e1d6a44e640": {"node_ids": ["1e5cfa1c-375c-4ea3-9b06-949fdfc98ad9"], "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0 \nExpenses \u00a0 \nIncome \u00a0 \nIncome T axes\u00a0 \nExpense \u00a0 \nto Cencora \u00a0 \nPer Shar e\u00a0\nGAAP \u00a0$2,538,023 \u00a0\u00a0$1,984,764 \u00a0\u00a0$553,259 \u00a0\u00a0$467,066 \u00a0\u00a0$45,861 \u00a0\u00a0$420,775 \u00a0\u00a0$2.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(8,714 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,714 )\u00a0\u00a0(8,714 )\u00a0\u00a0(4,259 )\u00a0\u00a0(4,455 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(22,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,835 )\u00a0\u00a0(22,835 )\u00a0\u00a0(7,915 )\u00a0\u00a0(14,920 )\u00a0\u00a0(0.07 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a023,053 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,053 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,210 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(164,799 )\u00a0\u00a0164,799 \u00a0\u00a0\u00a0164,799 \u00a0\u00a0\u00a049,444 \u00a0\u00a0\u00a0114,922 \u00a0\u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-related\nexpenses 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(225,985 )\u00a0\u00a0225,985 \u00a0\u00a0\u00a0225,985 \u00a0\u00a0\u00a051,093 \u00a0\u00a0\u00a0174,892 \u00a0\u00a0\u00a00.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(22,610 )\u00a0\u00a022,610 \u00a0\u00a0\u00a022,610 \u00a0\u00a0\u00a07,144 \u00a0\u00a0\u00a015,466 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,627 )\u00a0\u00a075,627 \u00a0\u00a0\u00a075,627 \u00a0\u00a0\u00a016,453 \u00a0\u00a0\u00a059,174 \u00a0\u00a0\u00a00.29 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,230 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,150 \u00a0\u00a0\u00a0916 \u00a0\u00a0\u00a05,234 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,230 \u00a0\u00a0\u00a043,658 \u00a0\u00a0\u00a0(30,428 )\u00a0\u00a0(0.15 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,529,527 \u00a0\u00a0$1,495,743 \u00a0\u00a0$1,033,784 \u00a0\u00a0$968,358 \u00a0\u00a0$202,395 \u00a0\u00a0$765,100 \u00a0\u00a0$3.80 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "62e75998-5959-41c0-a06a-9bb5eaa87858": {"node_ids": ["bbf02833-fe40-4860-8460-e53f5df00670", "761957b0-439b-4652-9171-c3044e52f0b3", "09f08ef6-c5e1-4c95-a38b-eec72bacdff0", "ab03d49e-aaf6-4d97-b886-082f6ea837e0", "c7173bba-f621-4909-aec5-ac7521290be2", "fd6ab857-e118-457c-9cbd-ba95ac26a1d5", "be1bb707-3dbb-4c6c-9772-275a019d46f6"], "metadata": {"window": "Adjusted Non-GAAP % change vs.\n prior year \u00a0\u00a07.4 %\u00a0\u00a05.2 %\u00a0\u00a010.9 %\u00a0\u00a010.6 %\u00a0\u00a021.7 %\u00a0\u00a07.0 %\u00a0\u00a08.6 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.71% \u00a03.70%\nOperating expenses \u00a02.90% \u00a02.19%\nOperating income \u00a00.81% \u00a01.51%\n_______________________\n1Includes a $214.0 million opioid litigation accrual.\n 2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0", "original_text": "Adjusted Non-GAAP % change vs.\n", "page_label": "11", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a81bcfaa-f328-44f6-813d-f24531c85447": {"node_ids": ["36abdebd-05c0-4af3-823c-2772d35babde"], "metadata": {"window": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "Gains from antitrust litigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a02 \u00a0\u00a0\u00a0(2 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a0\u00a012,676 \u00a0\u00a0\u00a041,594 \u00a0\u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTurkey highly inflationary\nimpact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,455 \u00a0\u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114 )\u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a0\u00a032,727 \u00a0\u00a0\u00a0106,403 \u00a0\u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLitigation and opioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813 )\u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a0\u00a03,693 \u00a0\u00a0\u00a012,120 \u00a0\u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113 )\u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a0\u00a013,808 \u00a0\u00a0\u00a045,305 \u00a0\u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444 )\u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a0\u00a022,763 \u00a0\u00a0\u00a074,681 \u00a0\u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(2,182 )\u00a0\u00a0(3,244 )\u00a0\u00a01,062 \u00a0\u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$2,354,567\u00a0$1,422,439 \u00a0\u00a0$932,128\u00a0$875,494 \u00a0\u00a0$166,342 \u00a0\u00a0$715,357 \u00a0\u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "page_label": "12", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a64808f1-ce11-4767-afc4-6e88c2c164b5": {"node_ids": ["d63250a0-a804-40f4-a00e-e3b3edc4bbb1", "de2166dc-cf5e-4f9b-9baf-bc5b71618542", "5239d60e-7297-480c-ac45-91427851d131", "5e1f72e8-287f-4621-8640-7bcc5a846d21"], "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2024 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n  \nExpenses \u00a0Operating \n  \nIncome \u00a0Income \n  \nBefor e \n  \nIncome T axes\u00a0Income T ax \n  \nExpense \u00a0Net Income \n  \nAttributable \n  \nto Cencora \u00a0Dilut ed \n  \nEarnings \n  \nPer Shar e\u00a0\nGAAP \u00a0$5,006,835 \u00a0\u00a0$3,630,701 \u00a0\u00a0$1,376,134 \u00a0\u00a0$1,250,464 \u00a0\u00a0$226,251 \u00a0\u00a0$1,022,275 \u00a0\u00a0$5.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0(56,962 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,962 )\u00a0\u00a0(56,962 )\u00a0\u00a0(14,715 )\u00a0\u00a0(42,247 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(71,280 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,280 )\u00a0\u00a0(71,280 )\u00a0\u00a0(18,413 )\u00a0\u00a0(52,867 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly inflationary impact \u00a0\u00a040,279 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,279 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,129 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(330,523 )\u00a0\u00a0330,523 \u00a0\u00a0\u00a0330,523 \u00a0\u00a0\u00a085,357 \u00a0\u00a0\u00a0244,298 \u00a0\u00a0\u00a01.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Operating income \u00a00.88% \u00a01.47%\n_______________________\n1Includes tax expense relating to S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss (Income), Net.\n\u00a0", "page_label": "13", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "44dcd1ff-0364-46a7-bd0c-532862c300d1": {"node_ids": ["344f3c9e-c857-4ca1-af9e-5bb42e9988e1", "83a5d413-dfb1-4825-a3b4-befd27c3333c", "ca1450bb-9c9e-44b6-bd2a-44ca6393b899"], "metadata": {"window": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n prior year \u00a0\u00a09.8 %\u00a0\u00a06.6 %\u00a0\u00a015.2 %\u00a0\u00a015.6 %\u00a0\u00a027.1 %\u00a0\u00a011.9 %\u00a0\u00a014.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.56% \u00a03.50%\nOperating expenses \u00a02.58% \u00a02.13%\nOperating income \u00a00.98% \u00a01.36%\n_______________________\n1Includes a $214.0 million opioid litigation accrual, offset in part by a $92.2 million opioid settlement accrual reduction primarily\nas a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement\nagreements.\n 14", "original_text": "Litigation and opioid-related\nexpenses, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,068 )\u00a0\u00a0147,068 \u00a0\u00a0\u00a0147,068 \u00a0\u00a0\u00a039,065 \u00a0\u00a0\u00a0108,003 \u00a0\u00a0\u00a00.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(43,673 )\u00a0\u00a043,673 \u00a0\u00a0\u00a043,673 \u00a0\u00a0\u00a011,708 \u00a0\u00a0\u00a031,965 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(110,068 )\u00a0\u00a0110,068 \u00a0\u00a0\u00a0110,068 \u00a0\u00a0\u00a023,916 \u00a0\u00a0\u00a086,152 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on remeasurement of equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,431 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,372 \u00a0\u00a0\u00a0807 \u00a0\u00a0\u00a05,565 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform and discrete tax items 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(3,455 )\u00a0\u00a024,742 \u00a0\u00a0\u00a0(28,197 )\u00a0\u00a0(0.14 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,918,872 \u00a0\u00a0$2,999,369 \u00a0\u00a0$1,919,503 \u00a0\u00a0$1,808,031 \u00a0\u00a0$378,718 \u00a0\u00a0$1,426,507 \u00a0\u00a0$7.08 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP % change vs.\n", "page_label": "14", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fcd64c8f-38e7-4e84-9c4e-797c5956f95e": {"node_ids": ["07bfa497-0b82-4bf5-901a-d5ff6134bafd", "fccc8ee0-ab94-4244-8a72-a07038f24310", "6c434626-4aab-46a5-be8e-2d51619ce329", "dbd1f504-8904-479e-9f43-9317e563c650", "1d24d70b-2911-454c-b568-d2de6b5dfb58"], "metadata": {"window": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n 3The sum of the components does not equal the total due to rounding.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n CENC ORA, INC.\n", "original_text": "2Includes a tax benefit attributable to an adjustment of the S wiss valuation allowance (due to an increase in projected S wiss\nincome and D TA utilization), tax expense relating to 2020 S wiss tax reform, and the currency remeasurement of the related\ndeferred tax assets, the latter of which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9d424d89-7111-4b99-9ca1-4cedb48c0000": {"node_ids": ["323e347a-14d2-4fb4-885c-864b3222648e", "5885b961-6701-4602-9179-c63488e128ad", "b52a2e02-9571-400e-b9cf-4ea086eef033", "cb86db53-c9f2-48d3-a099-9179eaf88550"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n 2The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\u00a0\n 16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related deal\nand integration expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(80,109 )\u00a0\u00a080,109 \u00a0\u00a0\u00a080,109 \u00a0\u00a0\u00a018,714 \u00a0\u00a0\u00a061,395 \u00a0\u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,684 )\u00a0\u00a0113,684 \u00a0\u00a0\u00a0113,684 \u00a0\u00a0\u00a026,557 \u00a0\u00a0\u00a087,127 \u00a0\u00a0\u00a00.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,663 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,639 )\u00a0\u00a0(11,608 )\u00a0\u00a04,969 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0\u00a0$2,813,429 \u00a0\u00a0$1,665,826 \u00a0\u00a0$1,564,301 \u00a0\u00a0$297,921 \u00a0\u00a0$1,275,002 \u00a0\u00a0$6.21 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n_______________________\n1Tax expense relating to 2020 S wiss tax reform and the currency remeasurement of the related deferred tax assets, the latter of\nwhich is recorded within Other Loss, Net.\n", "page_label": "16", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "43aee5d8-c5c7-4b62-a8c8-604ff2579d97": {"node_ids": ["b1248432-5856-4eda-add8-cfc0e1dc19ed", "49509dfe-ea7f-4ec7-adca-1f7e9514116a", "8634038e-b6f3-454e-9237-ce0f1a06bb42", "4ab4ed94-55ac-465e-816e-a0fa4f05c5bb"], "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$61,292,897 \u00a0\u00a0$56,693,456 \u00a0\u00a08.1%\nInternational Healthcare Solutions \u00a0\u00a07,123,385 \u00a0\u00a0\u00a06,764,935 \u00a0\u00a05.3%\nIntersegment eliminations \u00a0\u00a0(1,975 )\u00a0\u00a0(1,186 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,414,307 \u00a0\u00a0$63,457,205 \u00a0\u00a07.8%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$841,064 \u00a0\u00a0$756,137 \u00a0\u00a011.2%\nInternational Healthcare Solutions \u00a0\u00a0192,720 \u00a0\u00a0\u00a0175,991 \u00a0\u00a09.5%\nTotal segment operating income \u00a0\u00a01,033,784 \u00a0\u00a0\u00a0932,128 \u00a0\u00a010.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a08,714 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a022,835 \u00a0\u00a0\u00a0(54,270 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(23,053 )\u00a0\u00a0(4,855 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(164,799 )\u00a0\u00a0(140,114 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(225,985 )\u00a0\u00a0(15,813 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(22,610 )\u00a0\u00a0(59,113 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(75,627 )\u00a0\u00a0(97,444 )\u00a0\u00a0\n17", "original_text": "CENC ORA, INC.\n", "page_label": "17", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6477e49d-e2e0-455b-b2eb-377bfe97098a": {"node_ids": ["13755b78-9a87-4904-a574-70c04906a7f5", "8abd9258-016c-4ec1-9a9d-7445abfd3ebe", "6c7b3d39-ee49-407a-afa7-c2f1e55f4956", "edd09976-3685-492d-92be-329add1ad645", "9b66b757-01b3-4f4e-bdd5-fce7d4b6eab2"], "metadata": {"window": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74 %\u00a0\u00a02.74 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.40 %\u00a0\u00a0\nOperating income \u00a0\u00a01.37 %\u00a0\u00a01.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.95 %\u00a0\u00a011.88 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.24 %\u00a0\u00a09.28 %\u00a0\u00a0\nOperating income \u00a0\u00a02.71 %\u00a0\u00a02.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.71 %\u00a0\u00a03.62 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.90 %\u00a0\u00a02.73 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a00.88 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.70 %\u00a0\u00a03.71 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a02.24 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.51 %\u00a0\u00a01.47 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Operating income \u00a0$553,259 \u00a0\u00a0$560,519 \u00a0\u00a0(1.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "18", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d75023b3-9659-451e-a937-7277b012911b": {"node_ids": ["d8234117-73cf-4f20-9e15-820e83dad97a", "a989f9e9-5479-4b59-b639-5d7495d49766", "5f67c9f5-ad18-4ba6-bf90-e459cad69656", "59aae726-591c-4939-b3a6-f027d846dbb8"], "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$126,476,699 \u00a0\u00a0$112,930,035 \u00a0\u00a012.0%\nInternational Healthcare Solutions \u00a0\u00a014,193,612 \u00a0\u00a0\u00a013,376,213 \u00a0\u00a06.1%\nIntersegment eliminations \u00a0\u00a0(3,171 )\u00a0\u00a0(2,211 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,667,140 \u00a0\u00a0$126,304,037 \u00a0\u00a011.4%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,539,188 \u00a0\u00a0$1,328,553 \u00a0\u00a015.9%\nInternational Healthcare Solutions \u00a0\u00a0380,315 \u00a0\u00a0\u00a0337,273 \u00a0\u00a012.8%\nTotal segment operating income \u00a0\u00a01,919,503 \u00a0\u00a0\u00a01,665,826 \u00a0\u00a015.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a056,962 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a071,280 \u00a0\u00a0\u00a0(79,320 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,279 )\u00a0\u00a0(8,439 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(330,523 )\u00a0\u00a0(211,992 )\u00a0\u00a0\nLitigation and opioid-related expenses, net \u00a0\u00a0(147,068 )\u00a0\u00a0(28,519 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(43,673 )\u00a0\u00a0(80,109 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(110,068 )\u00a0\u00a0(113,684 )\u00a0\u00a0\n19", "original_text": "CENC ORA, INC.\n", "page_label": "19", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9c9c8977-bbed-4d80-ba16-b8a7c5903325": {"node_ids": ["fb88628b-c38a-4a91-81d3-d269d60b5bae", "3d541ec1-f767-44a8-8bc3-4939535a7e6d", "7679600a-783f-40f7-8275-a94e8782dd0e", "adf1e957-9e22-47bd-9d43-e5d9b986f47f", "90bf1d69-2c23-450f-8244-1a0825974db4"], "metadata": {"window": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.60 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.35 %\u00a0\u00a01.42 %\u00a0\u00a0\nOperating income \u00a0\u00a01.22 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.76 %\u00a0\u00a011.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.08 %\u00a0\u00a09.01 %\u00a0\u00a0\nOperating income \u00a0\u00a02.68 %\u00a0\u00a02.52 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating income \u00a0\u00a00.98 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.50 %\u00a0\u00a03.55 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.13 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.36 %\u00a0\u00a01.32 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Operating income \u00a0$1,376,134 \u00a0\u00a0$1,193,662 \u00a0\u00a015.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a43e8e71-79fa-4b67-adb9-9940cbdf3796": {"node_ids": ["ea029605-e0f1-4560-93a6-c9727b3ead62", "eb0c7c81-0331-4337-ad99-2f36ae5ed01b"], "metadata": {"window": "CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a02024\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,068,858 \u00a0$2,592,051\nAccounts receivable, net \u00a022,642,880 \u00a0\u00a020,911,081\nInventories \u00a017,630,985 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,194,915 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0623,414\u00a0\u00a0526,069\nTotal current assets \u00a044,161,052 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,089,497 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a013,794,611 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0256,890 \u00a0\u00a0200,667\nOther long-term assets\u00a03,565,996\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets$63,868,046\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n21", "original_text": "CENC ORA, INC.\n", "page_label": "21", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5c21ab07-b6aa-4446-a340-ad76849162db": {"node_ids": ["f30083e6-7521-4056-8655-3ef7e4ea7a6f", "6603e679-dc64-4f96-9cf1-c2178a611e2a"], "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Six Months Ended Mar ch\n31,\n\u00a0\u00a02024 \u00a0\u00a0\u00a02023 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,024,213 \u00a0\u00a0$904,383 \u00a0\n22", "original_text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $46,320,774 \u00a0$45,836,037\nAccrued expenses and other \u00a02,371,885 \u00a0\u00a02,353,817\nShort-term debt\u00a01,069,152\u00a0\u00a0641,344\nTotal current liabilities \u00a049,761,811 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,180,306 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0315,559 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,701,735 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,719,545 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,962,068 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,227,022\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$63,868,046\u00a0$62,558,746\nCENC ORA, INC.\n", "page_label": "22", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "eba6faba-975d-4de3-87ed-925a72c0253f": {"node_ids": ["59d48b6e-9b4d-434e-bac2-03457f655ea8"], "metadata": {"window": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23", "original_text": "Adjustments to reconcile net income to net cash provided by operating activities \u00a0635,324 \u00a0\u00a0\u00a0527,840 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,682,145 )\u00a0\u00a0(861,202 )\nInventories \u00a0(119,023 )\u00a0\u00a0(1,413,515 )\nAccounts payable \u00a0497,670 \u00a0\u00a0\u00a02,391,172 \u00a0\nOther, net\u00a0(349,325 )\u00a0\u00a0(209,090 )\nNet cash provided by operating activities\u00a06,714 \u00a0\u00a0\u00a01,339,588 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(186,970 )\u00a0\u00a0(178,581 )\nCost of acquired companies, net of cash acquired 1 \u00a0(2,310 )\u00a0\u00a0(1,409,681 )\nNon-customer note receivable \u00a0(50,000 )\u00a0\u00a0\u2014 \u00a0\nOther, net\u00a06,993 \u00a0\u00a0\u00a0(11,633 )\nNet cash used in investing activities\u00a0(232,287 )\u00a0\u00a0(1,599,895 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt borrowings (repayments) \u00a0472,409 \u00a0\u00a0\u00a0(685,101 )\nPurchases of common stock 2 \u00a0(436,378 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a018,629 \u00a0\u00a0\u00a031,712 \u00a0\nCash dividends on common stock \u00a0(212,692 )\u00a0\u00a0(201,479 )\nEmployee tax withholdings related to restricted share vesting \u00a0(60,086 )\u00a0\u00a0(67,954 )\nOther, net\u00a0(10,381 )\u00a0\u00a0(3,355 )\nNet cash used in financing activities\u00a0(228,499 )\u00a0\u00a0(1,733,391 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a0(13,671 )\u00a0\u00a088,822 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nDecrease in cash, cash equivalents, and restricted cash \u00a0(467,743 )\u00a0\u00a0(1,904,876 )\n23", "page_label": "23", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "44648c52-62c2-495b-ae28-ed91b0616f28": {"node_ids": ["3b0b8ba9-8d8e-4369-a420-f3487e19c0a9", "41d5c42a-4114-4f32-8ad0-2ca7cda0db2f", "b6df7724-3802-455f-9bcd-b76e47bd6c39", "c62ee8d8-fee2-4bdb-9ef8-9390d874132a", "9e9b370f-b836-4913-b79c-34d778ed88be", "d8b5b899-ab43-4ef6-9ab8-6ae21a16ef00", "21862e34-08f6-48c9-a10b-6f494a57322f", "aba9120c-5bc8-45cd-8a19-950f98ce3834", "57dfe59e-c719-4d39-994e-4cb4e2eb0241", "ba07c8b6-9276-4e06-9da8-f1c5a9085293"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n 2Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 3The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0March 31, \n \n2024 \u00a0September 30, \n \n2023 \u00a0March 31, \n \n2023 \u00a0September 30, \n \n2022\nCash and cash equivalents \u00a0$2,068,858 \u00a0$2,592,051 \u00a0$1,539,406 \u00a0$3,388,189\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0151,446 \u00a0\u00a097,722 \u00a0\u00a087,740 \u00a0\u00a0144,980\nRestricted cash (included in Other Long-T erm Assets) \u00a0\u00a064,842\u00a0\u00a063,116\u00a0\u00a061,517\u00a0\u00a060,370\nCash, cash equivalents, and restricted cash \u00a0$2,285,146\u00a0$2,752,889\u00a0$1,688,663\u00a0$3,593,539\nSUPPLEMENT AL INFORMA TION REGARDING \n  \nNON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3$2,285,146 \u00a0\u00a0$1,688,663 \u00a0\n_______________________\n1Includes $1,406.3 million for the acquisition of PharmaLex in the six months ended March 31, 2023.\n", "page_label": "24", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2ce0d458-440b-40c1-bca9-19f491b0d2c5": {"node_ids": ["cf02d00d-77f9-4468-be64-8b0c3fe3bdfc", "c59de0b5-a5d8-4b2f-bb76-755c46f912bc", "7aaf5c77-2e30-48c3-a15a-f9cdd8b6d0bf", "9286bcf7-aa2c-4872-91b9-c2e4cd20e7ee", "079946bb-afd5-4114-a16c-5871d77241e5", "973eadac-3c08-40b9-a294-c359b57ef066", "0190ebf7-c3f1-4459-bb0e-3e712a7ace02", "dcb0063c-e567-4aa2-8d7f-7b3eb84814cd", "d0e25140-cdf1-43ec-bffd-178ad6461eb0", "976c79d1-5208-4664-aa22-8654951aeac5", "36e085af-f499-46a7-a672-16990caa79cb", "4eb862f7-9faf-403a-b1c5-ece9293fb333", "dfc477a0-e974-4586-9a95-1feb6b4d1c5e", "cbd661ce-34bc-44c3-98bb-0ac89dddef5d", "693cb39d-ab09-40a2-961d-72d7d90ae222", "0b71669a-cb97-4947-ac6c-21254b463822", "38fdead0-06d0-432b-b84a-dd3cb9e17eae", "e0a50645-4dd5-42a3-a960-d22954155cd1", "0b75493b-6412-46c6-842c-58d4c24eefe9", "0d266458-f544-40e0-88f8-95085fd759e0", "0c7ba644-d6a4-46ae-adbc-ba0a6c86bd0a", "fe610356-d1d6-4197-9288-224fd2d412b7", "47ab876c-fd77-45d2-b1dc-cc36e97eb9c9", "ca2f4900-cfe9-48be-a7a5-ef399fb96527", "422246ed-bd89-4bf8-9186-cb8167cbdc05", "b369f15b-f9ef-4ea3-8a01-4f9338cf481d", "5cc39121-672a-4d0d-9160-0c902b59d1f4", "af397ca0-fe10-48fe-961c-07711f7af423"], "metadata": {"window": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "gains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "page_label": "25", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ce2d6a07-8da0-4106-a61e-5a203941e598": {"node_ids": ["a7edf3ef-b6d2-48d7-9607-ecbb8579a1b0", "e4ce63b9-cfd3-459f-94fd-58fbddb6217e", "1a35a495-4424-4b0e-abfb-8fe5f9adfe0e", "30c97ff3-dffe-4419-87b2-c78b94d312ba", "841716eb-6c44-4c17-a8b5-fe4836f1892e", "6f297e84-29db-44e6-878e-6f01c9df4f17", "48b8e9f6-46ee-44f5-a52a-3f8ae6b6f2a9", "183541d7-b8ad-4ff1-87aa-25ace852edcf", "2948d9af-db39-412a-ae0e-89e8a953d8db", "e010476c-eba7-4e27-b570-efdd0602c146", "399c890a-ccb3-484e-be4d-4ae260f5144d", "6cb51f76-b49b-43fe-8b99-3d5ed8e6287b", "ebdaa66b-c6f0-46d3-bc72-238cf11687ab", "dcb49e9c-7305-485a-94ae-0aca7b156ec4", "2a853307-0011-4964-899d-3be5937effd7", "a957daa4-0cc7-4043-85a7-58fae9a3cca0"], "metadata": {"window": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the six months ended March 31, 2024, net cash provided by operating activities of $6.7 million plus $237.7\nmillion for the prepayment of a future obligation as permitted under our opioid settlement agreements was largely offset by\ncapital expenditures of $187.0 million and gains from antitrust litigation settlements of $57.0 million. ", "original_text": "financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "26", "file_name": "CEN-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 244126, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}